prostate-specific membrane antigen binding protein

专利摘要:
psma binding proteins with improved binding affinities and robust aggregation profiles are disclosed herein. multispecific binding proteins are also described comprising a psma binding protein according to the present description. pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
公开号:BR112019010604A2
申请号:R112019010604
申请日:2017-11-22
公开日:2019-12-17
发明作者:D Lemon Bryan；Wesche Holger；Guenot Jeanmarie；Baeuerle Patrick；Seto Pui；J Austin Richard；Dubridge Robert
申请人:Harpoon Therapeutics Inc；
IPC主号:

专利说明:

PROSTATE MEMBRANE ANTIGEN BINDING PROTEIN— SPECIFIC CROSS REFERENCE [001] This order claims the benefit of Provisional U.S. Order No. 62 / 426,086 filed on November 23, 2016, which is incorporated by reference into this full specification.
SEQUENCE LISTING [002] This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. This ASCII copy, created on November 22, 2017, is called 47517-707_601_SL.txt and is 148,650 bytes in size.
INCORPORATION BY REFERENCE [003] All publications, patents and patent applications mentioned in this specification are incorporated in that specification by reference to the same extent as each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference, and as if described in their entirety.
BACKGROUND OF THE INVENTION [004] The present disclosure provides a prostate specific membrane antigen-binding protein (PSMA) that can be used for the diagnosis and treatment of prostate conditions and other indications correlated with PSMA expression.
SUMMARY OF THE INVENTION [005] It is provided in this specification, in a
Petition 870190117813, of 11/14/2019, p. 6/156
2/133 modality, a prostate-specific membrane antigen-binding protein (PSMA), which comprises CDR1, CDR2 and CDR3 complementarity determining regions, in which:
(a) the sequence in amino acids from CDR1 is how presented in RFMISX1YX2MH (SEQ ID. No.: 1); (b) the sequence in amino acids from CDR2 is how presented in X ₃ INPAX ₄ X5TDYAEXgVKG (SEQ ID. NO: 2) ; and (c) the sequence in amino acids from CDR3 is how presented in DX ₇ YGY (ID. . SEQ. No. : 3). In some modalities, the protein in binding to the antigen of membrane
prostate-specific comprises the following formula: fl-rlf2-r2-f3-r3-f4, where, rl is the ID. SEQ. No.: 1; r2 is the ID. SEQ. No.: 2; and r3 is the ID. SEQ. No.: 3; and where fi, f ₂ , fs and Í4 are structural residues (framework) selected so that said protein is at least eighty percent identical to the amino acid sequence shown in the ID. SEQ. N °: 4. In some modalities, Xi is proline. In some embodiments, X ₂ is histidine. In some embodiments, X ₃ is aspartic acid. In some embodiments, X4 is lysine. In some modalities, X5 is glutamine. In some embodiments, Xg is tyrosine. In some modalities, X it's serine. In some embodiments, the prostate-specific membrane antigen-binding protein has a greater affinity for a human prostate-specific membrane antigen than that of a binding protein that has the sequence shown as ID. SEQ. N °: 4. In some modalities, Xi is proline. In some modalities, X5 is glutamine. In some embodiments, Xg is tyrosine. In some modalities, X4 is lysine and X it's serine. In some
Petition 870190117813, of 11/14/2019, p. 7/156
3/133 modalities, X2 is histidine, X3 is aspartic acid, X4 is lysine and X it's serine. In some embodiments, Xi is proline, X2 is histidine, X3 is aspartic acid and X it's serine. In some embodiments, X2 is histidine, X3 is aspartic acid, X5 is glutamine and X it's serine. In some embodiments, X2 is histidine, X3 is aspartic acid, Xs is tyrosine and X it's serine. In some embodiments, X2 is histidine and X it's serine. In some embodiments, X2 is histidine, X3 is aspartic acid and X it's serine. In some embodiments, the prostate-specific membrane antigen-binding protein has a greater affinity for a human prostate-specific membrane antigen than that of a binding protein that has the sequence shown in ID. SEQ. N °: 4. In some embodiments, the prostate-specific membrane antigen-binding protein still has a greater affinity for a Cynomolgus prostate-specific membrane antigen than that of a binding protein that has the sequence shown in ID . SEQ. N °: 4. In some modalities, rl comprises the ID. SEQ. No. 5, ID. SEQ. No. 6, or ID. SEQ. N °: 7. In some modalities, r2 comprises the ID. SEQ. No. 8, ID. SEQ. No. 9, ID. SEQ. No. 10, ID. SEQ. No. 11, ID. SEQ. No. 12, ID. SEQ. No. 13, or ID. SEQ. N °: 14. In some modalities, r3 comprises the ID. SEQ. N °: 15.
[006] Another embodiment of the invention provides a prostate-specific membrane antigen-binding protein comprising CDR1, CDR2 and CDR3, which comprises the sequence shown as ID. SEQ. No.: 4, in which one or more amino acid residues selected from amino acid positions 31, 33, 50, 55, 56, 62 and 97 are replaced. In some
Petition 870190117813, of 11/14/2019, p. 8/156
4/133 embodiments, the binding protein comprises one or more additional substitutions at amino acid positions other than positions 31, 33, 50, 55, 56, 62 and 97. In some embodiments, the binding protein comprises substitution at position 31. In some embodiments, the binding protein comprises substitution at position 33. In some embodiments, the binding protein comprises substitution at position 50. In some embodiments, the binding protein comprises substitution at position 55. In some embodiments, the binding protein comprises substitution at position 56. In some embodiments, the binding protein comprises substitution at position 62. In some embodiments, the binding protein comprises substitution at position 97. In some embodiments, the binding protein comprises substitutions at amino acid positions 55 and 97. In some embodiments, the antigen-binding protein specific prostate membrane antigen has a greater affinity for human prostate specific membrane antigen than that of a binding protein that has the sequence shown in ID. SEQ. N °: 4. In some embodiments, the binding protein comprises substitutions at amino acid positions 33 and 97. In some embodiments, the binding protein comprises substitutions at amino acid positions 33, 50 and 97. In some embodiments, the binding protein binding to the prostate-specific membrane antigen has a greater affinity for human prostate-specific membrane antigen than that of a binding protein that has the sequence shown as ID. SEQ. N °: 4. In some embodiments, the specific membrane antigen binding protein of
Petition 870190117813, of 11/14/2019, p. 9/156
5/133 prostate has a greater affinity for Cynomolgus prostate specific membrane antigen than that of a binding protein that has the sequence shown in the ID. SEQ. N °: 4. In some embodiments, the binding protein comprises substitutions at amino acid positions 31, 33, 50 and 97. In some embodiments, the binding protein comprises substitutions at amino acid positions 33, 50, 55 and 97. In in some embodiments, the binding protein comprises substitutions at amino acid positions 33, 50, 56 and 97. In some embodiments, it comprises substitutions at amino acid positions 33, 50, 62 and 97.
[007] An additional modality provides a prostate-specific membrane antigen-binding protein that comprises a CDR1, CDR2 and CDR3, wherein CDR1 comprises the sequence as shown is the ID. SEQ. N °: 16. One embodiment provides a prostate-specific membrane antigen binding protein that comprises a CDR1, CDR2 and CDR3, wherein CDR2 comprises the sequence as shown in ID. SEQ. No. 17. An additional embodiment provides a prostate-specific membrane antigen-binding protein that comprises a CDR1, CDR2 and CDR3, wherein CDR3 comprises the sequence as shown in ID. SEQ. N °: 18. In one embodiment, a prostate-specific membrane antigen binding protein is provided that comprises a sequence that is at least 80% identical to the sequence shown in ID. SEQ. N °: 4. In one embodiment, a prostate-specific membrane antigen binding protein is provided that comprises a CDR1, CDR2 and CDR3, where CDR1 has at least 80% identity for the ID. SEQ. N °: 16, CDR2 has at least 85% of
Petition 870190117813, of 11/14/2019, p. 10/156
6/133 identity for the ID. SEQ. N °: 17, and CDR3 has at least 80% identity for the ID. SEQ. N °: 18.
[008] Another embodiment provides a prostate-specific membrane antigen-binding protein that comprises a CDR1, CDR2 and CDR3, where CDR1 comprises the sequence shown in the ID. SEQ. No. 16, CDR2 comprises the sequence shown in the ID. SEQ. N °: 17, and CDR3 comprises the sequence shown in the ID. SEQ. N °: 18. In some embodiments, the prostate specific membrane antigen binding protein binds to one or both of the human prostate specific membrane antigen and Cynomolgus prostate specific membrane antigen. In some embodiments, the binding protein binds a human prostate specific membrane antigen and Cynomolgus prostate specific membrane antigen with comparable binding affinities. In some embodiments, the binding protein binds to a human prostate specific membrane antigen with a higher binding affinity than Cynomolgus prostate specific membrane antigen.
[009] Another embodiment provides a polynucleotide that encodes a PSMA-binding protein according to the present disclosure. An additional embodiment provides a vector comprising the polynucleotide that encodes a PSMA-binding protein according to the present disclosure. In another embodiment, a host cell is provided and transformed with the vector. In another embodiment, a pharmaceutical composition is provided which comprises (i) a PSMA-binding protein according to the present disclosure, the polynucleotide according to the present disclosure, the vector according to the present disclosure
Petition 870190117813, of 11/14/2019, p. 11/156
7/133 disclosure or the host cell according to the present disclosure, and (ii) a pharmaceutically acceptable carrier. Another embodiment provides a process for the production of a PSMA-binding protein according to the present disclosure, said process comprising cultivating a host transformed or transfected with a vector comprising a nucleic acid sequence that encodes a binding protein. to albumin-PSMA according to the present disclosure under conditions that allow expression of the PSMA-binding protein and recovery and purification of the protein produced from the culture. In one embodiment, a method is provided for treating or ameliorating a proliferative disease, a tumor disease, an inflammatory disease, an immune disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host disease or a host-versus-graft disease, which comprises administering the PSMA-binding protein according to the present disclosure, to an individual who needs it. In some modalities, the individual is human. In some embodiments, the method further comprises administering an agent in combination with the PSMA-binding protein according to the present disclosure.
[010] One embodiment provides a multispecific binding protein that comprises the PSMA binding protein according to the present disclosure. An additional embodiment provides an antibody comprising the PSMA-binding protein according to the present disclosure. In one embodiment, a multispecific antibody, a bispecific antibody, an sdAb, a variable heavy domain, a
Petition 870190117813, of 11/14/2019, p. 12/156
8/133 peptide or a linker, comprising the PSMA binding protein according to the present disclosure. In one embodiment, an antibody is provided that comprises the PSMA-binding protein according to the present disclosure, wherein said antibody is a single domain antibody. In some embodiments, the single domain antibody is derived from a variable region of the IgG heavy chain. An additional embodiment provides a multispecific binding protein or antibody that comprises the PSMA binding protein according to the present disclosure. In one embodiment, a method is provided for treating or ameliorating a proliferative disease, a tumor disease, an inflammatory disease, an immune disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host disease or a host-versus-graft disease, which comprises administering the multispecific antibody according to the present disclosure, to an individual who needs it. In an additional embodiment, a method for treating or ameliorating a prostate condition is provided, which comprises administering the multispecific antibody according to the present disclosure to an individual who needs it. Another embodiment provides a method for treating or ameliorating a condition of the prostate, which comprises administering the PSMA-binding protein according to any of the above embodiments to an individual who needs it. An additional embodiment provides a method for treating or ameliorating a condition of the prostate, which comprises administering the PSMA-binding protein according to the present disclosure, to a
Petition 870190117813, of 11/14/2019, p. 13/156
9/133 individual who needs it.
[011] In some embodiments, the prostate-specific membrane antigen-binding protein comprises any combination of the following: (i), where Xi is proline; (ii), where X ₂ is histidine; (iii), where X3 is aspartic acid; (iv) where X4 is lysine; (v), where X5 is glutamine; (vi), where Xg is tyrosine; and (vii), in which X it's serine. In some embodiments, the prostate-specific membrane antigen-binding protein of the above modality has a greater affinity for a human prostate-specific membrane antigen than that of a binding protein having the sequence shown as ID. SEQ. No.: 4. In some embodiments, binding to the prostate-specific membrane antigen comprises any combination of the following: (i), where Xi is proline; where X5 is glutamine; (ii), where Xg is tyrosine; where X4 is lysine and X it is serine; (iii), where X ₂ is histidine, X3 is aspartic acid, X4 is lysine and X it is serine; (iv), where Xi is proline, X ₂ is histidine, X3 is aspartic acid and X it is serine; (v), where X ₂ is histidine, X3 is aspartic acid, X5 is glutamine and X it is serine; (vi), where X ₂ is histidine, X3 is aspartic acid, X4 is lysine and X it is serine; (vii), where Xi is proline, X ₂ is histidine, X3 is aspartic acid and X it is serine; (viii), where X ₂ is histidine, X3 is aspartic acid, X5 is glutamine and X it is serine; (ix), where X ₂ is histidine, X3 is aspartic acid, Xg is tyrosine and X it is serine; and (x), where X ₂ is histidine, X3 is aspartic acid and X it's serine. In some cases, the prostate-specific membrane antigen-binding protein of the above modality has a greater affinity for a membrane-specific antigen of
Petition 870190117813, of 11/14/2019, p. 14/156
10/133 human prostate than that of a binding protein that has the sequence shown in ID. SEQ. N °: 4. In some cases, the prostate-specific membrane antigen-binding protein of the above modality still has a greater affinity for a Cynomolgus prostate-specific membrane antigen than that of a binding protein having the sequence displayed in the ID. SEQ. N °: 4. In some embodiments, the prostate-specific membrane antigen-binding protein comprises any combination of the following: (i) substitution at position 31; (ii) replacement in position 50; (iii) replacement in position 55; replacement in position 56; (iv) replacement in position 62; (v) replacement in position 97; (vi) substitutions in positions 55 and 97; (vii) substitutions in positions 33 and 97; (viii) substitutions in positions 33, 50
and 97; (ix) substitutions in positions 31, 33, 50 and ! 97; (x) substitutions in positions 33, 50, 55 and 97; (xi) substitutions in positions 33, 50, 56 and 97; and (xiii) substitutions in positions 33 , 50, 62 and 97 . In some cases,
the prostate specific membrane antigen binding protein of the above modality has a greater affinity for human prostate specific membrane antigen than that of a binding protein having the sequence shown in ID. SEQ. N °: 4. In some cases, the prostate-specific membrane antigen binding protein of the above modality still has a greater affinity for Cynomolgus prostate specific membrane antigen than that of a binding protein that has the sequence shown in the ID. SEQ. N °: 4.
[012] One modality provides a method for the treatment
Petition 870190117813, of 11/14/2019, p. 15/156
11/133 or improvement of prostate cancer, the method comprising administering the PSMA-binding protein which comprises CDR1, CDR2 and CDR3 complementarity determining regions, where (a) the amino acid sequence of CDR1 is as shown in RFMISX1YX2MH ( SEQ ID NO: 1); (b) the amino acid sequence of CDR2 is as shown in X3INPAX4X5TDYAEX6VKG (SEQ ID. NO: 2); and (c) the amino acid sequence of CDR3 is as presented in DX YGY (SEQ ID. NO: 3), to an individual who needs it.
[013] In some embodiments, the PSMA-binding protein is a single domain antibody. In some embodiments, said single domain antibody is part of a triespecific antibody.
BRIEF DESCRIPTION OF THE DRAWINGS [014] The new features of the invention are presented with particularity in the appended claims. A better understanding of the characteristics and advantages of the present invention will be obtained by reference to the following detailed description which presents illustrative modalities, in which the principles of the invention are used, and the accompanying drawings, of which:
[015] Figure 1 is a schematic representation of an triespecific antigen-binding protein targeting the exemplary PMSA, where the protein has a constant central element comprising a single-chain anti-CD3e (scFv) variable fragment and a variable region anti-HSA heavy chain; and a PMSA-binding domain which can be a VH, scFv, a non-Ig binder or ligand.
[016] Figures 2A-B compare the ability of exemplary PSMA-targeted proteins (molecules
Petition 870190117813, of 11/14/2019, p. 16/156
12/133
PST-directed TriTAC) with different affinities for CD3 to induce T cells to kill human prostate cancer cells. Figure 2A shows the death of different PMSA-directed TriTAC molecules in the LNCaP prostate cancer model. Figure 2B shows the death of different PMSA-directed TriTAC molecules in the 22Rvl prostate cancer model. Figure 2C shows EC50 values for TriTAC directed to PMSA in LNCaP and 22Rvl prostate cancer models.
[017] Figure 3 shows the serum concentration of TriTAC directed to PSMA C236 in Cynomolgus monkeys after i.v. administration (100 pg / kg) over three weeks.
[018] Figure 4 shows the serum concentration of TriTAC molecules directed to PSMA with different CD3 affinities in Cynomolgus monkeys after i.v. administration (100 pg / kg) over three weeks.
[019] Figures 5A — C show the ability of TriTAC molecules targeting PSMA with different affinities for PSMA to induce T cells to kill the human prostate cancer lineage cell LNCaP. Figure 5A shows the experiment carried out in the absence of human serum albumin with a BiTE directed to PSMA as a positive control. Figure 5B shows the experiment carried out in the presence of human serum albumin with a BiTE directed to PSMA as a positive control. Figure 5C shows EC50 values for TriTAC targeting PMSA in the presence or absence of HSA with a BiTE targeting PSMA as a positive control in LNCaP prostate cancer models.
[020] Figure 6 demonstrates the ability of TriTAC molecules targeting PSMA to inhibit tumor growth
Petition 870190117813, of 11/14/2019, p. 17/156
13/133 of human prostate cancer cells in a mouse xenograft experiment.
[021] Figures 7A-D illustrate the specificity of TriTAC molecules in cell death assays with target cell lines that express or not the target protein. Figure 7A shows the expression of EGFR and PSMA in LNCaP, KMS12BM and OVCAR8 cell lines. Figure 7B shows the death of LNCaP tumor cells by PSMA, EGFR, and negative control TriTACs. Figure 7C shows the killing of KMS12BM tumor cells by PSMA, EGFR, and negative control TriTACs. Figure 7D shows the death of OVCAR8 cells by PSMA, EGFR and TriTACs of negative control.
[022] Figures 8A — D depict the impact of pre-incubation at 37 ° C and freeze / thaw cycles on TriTAC activity. Figure 8A shows the activity of PSMA TriTAC C235 after pre-incubation at 37 ° C or freeze / thaw cycles. Figure 8B shows the activity of PSMA TriTAC C359 after pre-incubation at 37 ° C or freeze / thaw cycles. Figure 8C shows the activity of PSMA TriTAC C360 after pre-incubation at 37 ° C or freeze / thaw cycles. Figure 8D shows the activity of PSMA TriTAC C361 after pre-incubation at 37 ° C or freeze / thaw cycles.
[023] Figures 9A — B depict the activity of a TriTAC molecule targeting the PSMA of this disclosure in T cell-redirected death in T-dependent cell cytotoxicity (TDCC) assays. Figure 9A shows the impact of the TriTAC molecule targeting PSMA on the redirection of Cynomolgus peripheral blood mononuclear cells (PBMCs) from Cynomolgus monkey donor
Petition 870190117813, of 11/14/2019, p. 18/156
14/133
G322, in the death of LNCaP cells. Figure 9B shows the impact of the TriTAC molecule targeting PSMA on the redirection of Cynomolgus PBMCs, from monkey donor Cynomolgus D173, to kill MDAPCa2b cells.
[024] Figure 10 depicts the impact of a TriTAC molecule targeting the PSMA of this disclosure on the expression of CD25 and CD69 T cell activation markers.
[025] Figure 11 depicts the ability of a TriTAC molecule directed to the PSMA in this disclosure to stimulate proliferation of T cells in the presence of target cells that express PSMA.
[02 6] Figure 12 depicts death by a T cell redirected in LnCaP cells by the TriTAC molecule directed to the PSMA PSMA Z2 TriTAC (SEQ ID: No. 156).
DETAILED DESCRIPTION OF THE INVENTION [027] Although preferred embodiments of the present invention have been shown and described in this specification, it will be obvious to those skilled in the art that these modalities are provided by way of example only. Various variations, changes and substitutions will occur to those skilled in the art without departing from the invention. It should be understood that several alternatives to the modalities of the invention described in this specification can be used in the practice of the invention. It is desired that the following claims define the scope of the invention and that methods and structures within the scope of those claims and their equivalents are encompassed by them.
Some definitions [028] The terminology used in this specification is intended to describe only particular cases and is not intended to
Petition 870190117813, of 11/14/2019, p. 19/156
15/133 be limiting. As used in this specification, the singular forms one, o, one and a aim to also include the plural forms, unless the context clearly indicates otherwise. Furthermore, insofar as the terms including, includes, owns, owns, with, or variants of these are used in the detailed description and / or in the claims, these terms are intended to be inclusive in a similar way to the term it comprises.
[029] The term about or approximately means within an acceptable error range for the particular value, as determined by those skilled in the art, which will depend, in part, on how the value is measured or determined, for example, on the limitations measurement system. For example, about can mean within 1 or more than 1 standard deviation, by practicing at a certain value. When particular values are described in the application and in the claims, unless otherwise stated, the term about should be assumed to mean an acceptable error range for the particular value.
[030] The terms individual, patient or individual are used interchangeably. None of the terms requires or is limited to the situation characterized by the supervision (for example, constant or intermittent) of a health professional (for example, a doctor, a registered nurse, a nursing assistant, an assistant physician, a hospital servant or a nursing home employee).
[031] The term '' 'FR framework or residues (or regions) refer to residues in the variable domain other than the residues of the CDR or the hypervariable region, as defined in this specification. A consensus framework
Petition 870190117813, of 11/14/2019, p. 20/156
16/133 human is a framework that represents the amino acid residues that occur most commonly in a selection of human immunoglobulin VL or VH framework sequences.
[032] As used in this specification, the term variable region or variable domain refers to the fact that certain portions of the variable domains differ widely in sequence between antibodies and are used in the binding and specificity of each particular antibody by its particular antigen. However, variability is not distributed evenly across all variable domains of antibodies. It is concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions in both the light and heavy chain variable domains. The most highly conserved portions of variable domains are called the framework (FR). Each of the variable domains of native heavy and light chains comprises four FR regions, which largely adopt a β-blade configuration, connected by three CDRs, which form loops that connect and, in some cases, form part of the blade structure -β. The CDRs in each chain are held close together by the FR regions and, with the CDRs in the other chain, contribute to the formation of the antibody antigen binding site (see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition , National Institute of Health, Bethesda, Md. (1991)). The constant domains are not directly involved in the binding of an antibody to an antigen, but exhibit various effector functions, for example, participation of the antibody in anti-drug dependent cell toxicity. The terms residue numbering of the domain
Petition 870190117813, of 11/14/2019, p. 21/156
17/133 variable as in Kabat or numbering of the amino acid position as in Kabat, and variations thereof, refer to the numbering system used for variable domains of heavy chain or variable domains of light chain of the compilation of antibodies in Kabat et al., sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Using this numbering system, the actual linear amino acid sequence may contain fewer amino acids or additional amino acids that correspond to a shortening of, or insertion into, a variable domain FR or CDR. For example, a heavy chain variable domain may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (for example, residues 82a, 82b and 82c etc. according to Kabat) after residue 82 of the heavy chain FR. The numbering of Kabat residues can be determined for a certain antibody by aligning regions of homology of the antibody sequence with a standard Kabat numbered sequence. The CDRs in this disclosure are not intended to necessarily correspond to the Kabat numbering convention.
[033] As used in this specification, the term percentage (%) of amino acid sequence identity, with respect to a sequence, is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the sequence after alignment of the sequences and introduction of gaps, if necessary, to obtain the identity of maximum percentage sequence, and not considering any conservative substitutions as part of the identity of
Petition 870190117813, of 11/14/2019, p. 22/156
18/133 sequence. The alignment for purposes of determining the percent amino acid sequence identity can be obtained in various ways that are part of the skill in the art, for example, using publicly available computer software such as, for example, EMBOSS MATCHER, EMBOSS WATER, EMBOSS STRETCHER, EMBOSS NEEDLE, EMBOSS LALIGN, BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms necessary to obtain maximum alignment over the total length of the sequences being compared.
[034] As used in this specification, the term elimination half-life is used in its common sense, as described in Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 21-25 (Alfred Goodman Gilman, Louis S. Goodman and Alfred Gilman , eds., 6th Edition, 1980). Briefly, the term is intended to encompass a quantitative measure of the time course of drug elimination. The elimination of most drugs is exponential (that is, it accompanies first-order kinetics), as drug concentrations do not normally approach those necessary for the elimination process. The rate of an exponential process can be expressed by its speed constant, k, which expresses the fractional change per unit of time, or by its half-life, ti / 2 the time required for 50% of the end of the process. The units of these two constants are time ¹ and time, respectively. A first order velocity constant and the reaction half-life are simply related
Petition 870190117813, of 11/14/2019, p. 23/156
19/133 (k x ti / 2 = 0.693) and can be exchanged accordingly. Since first-order elimination kinetics dictates that a constant drug fraction is lost per unit of time, a graph of the drug concentration versus time log is linear at all times after the initial distribution phase (ie after absorption and drug distribution are complete). The drug elimination half-life can be accurately determined from such a graph.
[035] As used in this specification, the term binding affinity refers to the affinity of the proteins described in the disclosure to their binding targets, and is expressed numerically using Kd values. If two or more proteins are indicated to have comparable binding affinities for their binding targets, then the Kd values for binding the respective proteins to their binding targets are within ± 2 times between them. If two or more proteins are indicated to have comparable binding affinities for a single binding target, then the Kd values for binding the respective proteins to said single binding target are within ± 2 times between them. If a protein is indicated to bind to one or more targets with comparable binding affinities, then the Kd values for binding that protein to the two or more targets are within ± 2 times between them. In general, a higher Kd value corresponds to a weaker bond. In some embodiments, Kd is measured by a radiolabeled antigen (RIA) binding assay or surface plasmon resonance assays using a BIAcore ™ -2000 or BIAcore ™ -3000 apparatus (BIAcore, Inc., Piscataway, NJ) . In certain
Petition 870190117813, of 11/14/2019, p. 24/156
20/133 modalities, an on-rate or association fee or association fee or kon and an off-rate or dissociation fee or dissociation or koff rate are also determined with the surface plasmon resonance technique using a BIAcore device ™ -2000 or BIAcore ™ -3000 (BIAcore, Inc., Piscataway, NJ). In additional modalities, Kd, kon and koff are measured using OCTET® Systems (Pall Life Sciences). In an exemplary method for measuring binding affinity using OCTET® Systems, the ligand, for example, human PSMA or biotinylated Cynomolgus, is immobilized on the tip surface of the OCTET® streptavidin capillary sensor, whose streptavidin tips are then activated according to the manufacturer's instructions using about 20-50 pg / ml of human PSMA protein or Cynomolgus. A PBS / Casein solution is also introduced as a blocking agent. For measurements of association kinetics, PSMA-binding protein variants are introduced at a concentration ranging from about 10 pg / ml to about 1,000 pg / ml. Complete dissociation is observed in the case of the negative control, assay buffer without binding proteins. The kinetic parameters of the binding reactions are then determined using an appropriate tool, for example, ForteBio software.
[036] PSMA-binding proteins, pharmaceutical compositions, as well as nucleic acids, recombinant expression vectors and host cells for the production of these PSMA-binding proteins are described in this specification. Methods of using the PSMA-binding proteins disclosed in the prevention and / or treatment of diseases, conditions and disorders are also provided. Proteins
Petition 870190117813, of 11/14/2019, p. 25/156
21/133 connection to PSMA are able to specifically connect to PSMA. In some embodiments, PSMA-binding proteins include additional domains, for example, a CD3-binding domain.
Prostate-specific membrane antigen (PSMA) and its role in prostate conditions [037] Protein-binding proteins to the prostate-specific membrane antigen are contemplated in this specification. Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, acid-N-acetyl-a-linked dipeptidase I [NAALAdase (NLD) I], or folate hydrolase, is a 750-residue type II transmembrane glycoprotein which is highly expressed in prostate cancer cells and in the solid non-prostate tumor neovasculature and expressed at lower levels in other tissues, including healthy prostate, kidney, liver, small intestine, salivary gland, duodenal mucosa, proximal renal tubules and brain. PSMA is a member of a superfamily of zinc-dependent exopeptidases, which include carboxypeptidases with a mononuclear zinc active site (eg, carboxypeptidase A) and carboxy- and aminopeptidases with a binuclear zinc active site (eg, carboxypeptidase G2 ( CPG2), peptidases T and V (PepT and PepV), aminopeptidase from Streptomyces griseus (Sgap) and aminopeptidase from Aeromonas proteolytica (AAP)]. In addition to a region of limited homology with these soluble zinc-dependent exopeptidases, single domain (eg, AAP) or double domain (eg, CPG2), the entire PSMA sequence is homologous to at least four other human proteins: NLDL (expressed in the ileum; 35%
Petition 870190117813, of 11/14/2019, p. 26/156
22/133 identity), NLD2 (expressed in the ovary, testis and brain; 67% identity), transferrin receptor (TfR) 1 (TfRl; expressed in most cell types; 26% identity), and TfR2 (expressed predominantly in the liver; 28% identity).
[038] The PSMA crystal structure has been shown to comprise a symmetrical dimer with each polypeptide chain that contains three domains analogous to the three TfR1 domains: a protease domain, an apical domain and a helical domain. A large cavity (approximately 1,100 Â2) at the interface between the three domains includes a binuclear zinc site and predominantly polar residues (66% of 70 residues). The observation of two zinc ions and the conservation of many of the cavity-forming residues among orthologists and PSMA counterparts identify the cavity as the likely substrate binding site.
[039] PSMA expression typically increases with prostate disease progression and metastasis. PSMA expression is increased in prostate cancer, especially in poorly differentiated, metastatic and refractory hormone carcinomas. PSMA is also expressed in capillary vessel endothelial cells in peritumoral and endotumoral areas of certain malignancies, including renal cell carcinomas and colon carcinomas, but not in blood vessels of normal tissues. In addition, there are reports that PSMA is related to tumor angiogenesis. PSMA has been shown to be expressed on tumor-associated neovasculature endothelial cells in carcinomas of the colon, breast, bladder, pancreas, kidney and melanoma.
[040] In addition to its role as a tumor marker, PSMA
Petition 870190117813, of 11/14/2019, p. 27/156
23/133 contains a binuclear zinc site and is active as a glutamate carboxypeptidase, catalyzing the enzymatic dividing of a- or γ-linked glutamates from peptides or small molecules. Its substrates include ροϊί-γglutamate folates, which are essential nutrients, and the polyγ-glutamate form of the anti-cancer drug methotrexate, when then divage makes it less effective. The enzymatic activity of PSMA can be exploited for the design of prodrugs, in which an inactive glutamate form of the drug is selectively cleaved and thus activated only in cells that express PSMA. PSMA also deactivates and inactivates the abundant neuropeptide N-acetyl-l-aspartyl-l-glutamate (α-NAAG), which is an inhibitor of the NMDA ionotropic receptor and an agonist of the type II metabotropic glutamate receptor subtype 3. A breakdown of regulation of glutamatergic neurotransmission by α-NAAG is implicated in schizophrenia, seizure disorders, Alzheimer's disease, Huntington's disease and amyotrophic lateral sclerosis. Thus, PSMA inhibition potentially confers neuroprotection both by reducing glutamate and increasing α-NAAG. For example, the subnanomolar acid 2 (phosphonomethyl) pentanedioic inhibitor has been shown to provide neuroprotection in cell culture and / or animal models of ischemia, diabetic neuropathy, drug abuse, chronic pain and amyotrophic lateral sclerosis.
[041] Prostate cancer is the most prevalent type of cancer and one of the leading causes of cancer death in American men. The number of men diagnosed with prostate cancer has been growing steadily as a result of the growing population of older men, as well as by
Petition 870190117813, of 11/14/2019, p. 28/156
24/133 greater awareness of the disease leading to its earlier diagnosis. The lifetime risk for men who develop prostate cancer is about 1 in 5 for Caucasians, 1 in 6 for African Americans. High-risk groups are represented by those with a positive family history of prostate cancer or African-Americans. Over the course of their lives, more than two-thirds of men diagnosed with prostate cancer die from the disease. In addition, many patients who do not succumb to prostate cancer require continuous treatment to improve symptoms such as pain, bleeding and urinary obstruction. Thus, prostate cancer also represents an important cause of suffering and increased spending on medical care. When prostate cancer is located and the patient's life expectancy is 10 years or more, radical prostatectomy offers the best chance for eradicating the disease. Historically, the disadvantage of this procedure is that most cancers have spread beyond the limits of the operation at the time they are detected. Patients with large, high-grade tumors are less likely to be successfully treated by radical prostatectomy. Radiotherapy has also been widely used as an alternative to radical prostatectomy. Patients generally treated by radiotherapy are those older and less healthy and those with higher grade tumors, clinically more advanced. Particularly preferred procedures are external beam therapy, which involves three-dimensional confocal radiotherapy, in which the radiation field is designed to adapt to the volume of treated tissue; interstitial radiotherapy, in which seeds of
Petition 870190117813, of 11/14/2019, p. 29/156
25/133 radioactive compounds are implanted using ultrasound guidance; and a combination of external beam therapy and interstitial radiation therapy. For the treatment of patients with locally advanced disease, hormonal therapy, before or after radical prostatectomy or radiation therapy, has been used. Hormone therapy is the main form of treatment for men with disseminated prostate cancer. Orchidectomy reduces serum testosterone concentrations, while treatment with estrogen is similarly beneficial. Estrogen diethylstilbestrol is another useful hormonal therapy that has the disadvantage of causing cardiovascular toxicity. When gonadotropin-releasing hormone agonists are administered, testosterone concentrations are ultimately reduced. Flutamide and other non-steroidal antiandrogen agents block the binding of testosterone to its intracellular receptors. As a result, it blocks the effect of testosterone, increasing serum testosterone concentrations and allowing patients to remain potent - a significant problem after radical prostatectomy and radiation treatments. Cytotoxic chemotherapy is largely ineffective in treating prostate cancer. Its toxicity makes this therapy unsuitable for elderly patients. In addition, prostate cancer is relatively resistant to cytotoxic agents. Relapse or more advanced disease is also treated with antiandrogen therapy. Unfortunately, almost all tumors become hormone-resistant and progress quickly in the absence of any effective therapy. Consequently, there is a need for effective therapies for breast cancer.
Petition 870190117813, of 11/14/2019, p. 30/156
26/133 prostate glands that are not excessively toxic to a patient's normal tissues, and that are effective in the selective elimination of prostate cancer cells. The present disclosure provides, in certain embodiments, PSMA-binding proteins that are useful in the treatment of prostate cancer. In additional embodiments, the disclosure provides a method of treating prostate cancer by immunotherapy using the PSMA-binding proteins described in this specification.
[042] Prostate cancer is also difficult to diagnose, as the method of evaluating prostate-specific membrane antigen is associated with many false positives. Consequently, in some embodiments, the present disclosure provides an improved method of detecting prostate cancer using the PSMA-binding proteins described in this specification.
PSMA-binding proteins [043] In this specification, binding proteins, for example, antibodies or anti-PSMA antibody variants, which bind to a PSMA protein are provided in that specification. The PSMA protein, in some modalities, is a multimer. The term PSMA protein multimer, as used in this specification, is a protein complex of at least two PSMA proteins or fragments thereof. PSMA protein multimers can be composed of various combinations of full-length PSMA proteins (for example, SEQ ID. No.: 20), recombinant soluble PSMA (rsPSMA, for example, amino acids 44-750 of SEQ ID. N °: 20) and fragments of those mentioned above that form multimers (that is, that retain the protein domain
Petition 870190117813, of 11/14/2019, p. 31/156
27/133 necessary for the formation of higher order dimers and / or multimers of PSMA). In some embodiments, at least one of the PSMA proteins that make up the multimer is a recombinant soluble PSMA polypeptide (rsPSMA). In some embodiments, PSMA protein multimers are dimers, for example, those formed by recombinant soluble PSMA protein. In some embodiments, rsPSMA is a homodimer Without attaching to a particular theory, it is believed that the PSMA protein multimers mentioned in this specification assume a native conformation and preferably have that conformation. PSMA proteins, in certain embodiments, are non-covalently linked together to form the PSMA protein multimer. For example, the PSMA protein has been found to non-covalently associate to form dimers under non-denaturing conditions. PSMA protein multimers can, and preferably do, retain PSMA activities. The activity of a PSMA protein is, in certain embodiments, an enzyme activity, for example, folate hydrolase activity, NAALADase activity, dipeptidyl peptidase IV activity and γ-glutamyl hydrolase activity. Methods for testing the activity of PSMA multimers are known in the field (for example, reviewed by O'Keefe et al, in: Prostate Cancer: Biology, Genetics, and the New Therapeutics, L.W.
K. Chung, W.B. Isaacs and J.W. Simons (eds.) Humana Press, Totowa, N.J., 2000, pages 307-326).
[044] In some embodiments, the binding proteins of the present disclosure that bind to a PSMA protein or a PSMA protein multimer modulate the enzymatic activity of the PSMA protein or the PSMA protein multimer. In some
Petition 870190117813, of 11/14/2019, p. 32/156
28/133 modalities, the PSMA-binding protein inhibits at least one enzyme activity, for example, NAALADase activity, folate hydrolase activity, dipeptidyl dipeptidase IV activity, γ-glutamyl hydrolase activity or combinations thereof. In other embodiments, the PSMA-binding protein increases at least one enzyme activity, for example, NAALADase activity, folate hydrolase activity, dipeptidyl dipeptidase IV activity, γ-glutamyl hydrolase activity, or combinations thereof.
[045] As used in this specification, the term antibody variants refers to the variants and derivatives of an antibody described in this specification. In certain embodiments, amino acid sequence variants of the anti-PSMA antibodies described in this specification are contemplated. For example, in certain embodiments, amino acid sequence variants of anti-PSMA antibodies described in that specification are contemplated to increase the binding affinity and / or other biological properties of the antibodies. Exemplary methods for the preparation of amino acid variants include, without limitation, the introduction of appropriate modifications to the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions of, and / or insertions in and / or substitutions of residues within the antibody's amino acid sequences.
[046] Any combination of deletion, insertion and substitution can be done to arrive at the final construction, as long as the final construction has the desired characteristics, for example, antigen binding. In certain
Petition 870190117813, of 11/14/2019, p. 33/156
29/133 embodiments, antibody variants are provided that have one or more amino acid substitutions. Sites of interest for substitution mutagenesis include CDRs and framework regions. Examples of such substitutions are described below. Amino acid substitutions can be introduced into an antibody of interest and the products evaluated for a desired activity, for example, retained / increased antigen binding, decreased immunogenicity or anti-dependent cell mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) increased. Both conservative and non-conservative amino acid substitutions are contemplated for the preparation of antibody variants.
[047] In another example of a substitution to create a variant anti-PSMA antibody, one or more residues from the hypervariable region of a parental antibody are replaced. In general, variants are then selected based on improvements in desired properties, compared to a parent antibody, for example, increased affinity, reduced affinity, reduced immunogenicity, increased pH binding dependency. For example, a variant antibody with matured affinity can be generated, for example, using affinity maturation techniques based on phage display, such as those described in this specification and known in the field.
[048] Substitutions can be made in hypervariable regions (HVR) of a parental anti-PSMA antibody to generate variants and the variants are then selected based on binding affinity, that is, by affinity maturation. In some types of affinity maturation,
Petition 870190117813, of 11/14/2019, p. 34/156
30/133 diversity is introduced in the variable genes chosen for maturation by any of several methods (for example, PCR error-prone, chain shuffling or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then evaluated to identify any antibody variants with the desired affinity. Another method for introducing diversity involves HVR-directed approaches, in which several HVR residues (for example, 4-6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scan mutagenesis or modeling. Substitutions can be at one, two, three, four, or more sites within a parental antibody sequence.
[049] In some embodiments, the PSMA-binding protein described in that specification is a single domain antibody, for example, a heavy chain (VH) variable domain, a camelid-derived sdAb variable domain (VHH) , ligand or small molecule entity specific for PSMA. In some embodiments, the PSMA-binding domain of the PSMA-binding protein described in that specification is any domain that binds to PSMA including, without limitation, domains of a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody , a humanized antibody. In certain embodiments, the PSMA-binding protein is a single domain antibody. In other embodiments, the PSMA-binding protein is a peptide. In additional embodiments, the PSMA-binding protein is a small molecule.
[050] Generally, it should be noted that the term
Petition 870190117813, of 11/14/2019, p. 35/156
31/133 single domain antibody, as used in this specification in its broadest sense, is not limited to a specific biological source or a specific preparation method. For example, in some embodiments, the single domain antibodies of the disclosure are obtained: (1) by isolating the VHH domain from a naturally occurring heavy chain antibody; (2) by expression of a nucleotide sequence that encodes a naturally occurring VHH domain; (3) by humanizing a naturally occurring VHH domain or by expressing a nucleic acid encoding that humanized VHH domain; (4) by camelization of a naturally occurring VH domain of any animal species and, in particular, of a mammal species, for example, of a human being, or by expression of a nucleic acid encoding that camelized VH domain; (5) by camelization of a domain or Dab antibody, or by expression of a nucleic acid encoding that camelized VH domain; (6) by using synthetic or semi-synthetic techniques for the preparation of polypeptide proteins or other amino acid sequences; (7) by preparing a nucleic acid encoding a single domain antibody using techniques for nucleic acid synthesis known in the field, followed by expression of the nucleic acid thus obtained; and / or (8) by any combination of one or more of those mentioned above.
[051] In one embodiment, a single domain antibody corresponds to the VHH domains of naturally occurring heavy chain antibodies directed against PSMA. As further described in this specification, these VHH sequences can generally be generated or obtained by immunizing
Petition 870190117813, of 11/14/2019, p. 36/156
32/133 a species of camelid with PSMA (that is, in order to evoke an immune response and / or heavy chain antibodies directed against PSMA), by obtaining an appropriate biological sample of said camelid (for example, a sample of blood, serum sample or B cell sample), and by generating VHH sequences directed against PSMA, from said sample, using any suitable technique known in the field.
[052] In another embodiment, these naturally occurring VHH domains against PSMA are obtained from naive libraries of camelid VHH sequences, for example, by evaluating that library using PSMA, or at least part, fragment, antigenic determinant or epitope, using one or more evaluation techniques known in the field. Such libraries and techniques are described, for example, in WO 99/37681, WO 01/90190, WO 03/025020 and WO 03/035694. Alternatively, enhanced synthetic or semi-synthetic libraries derived from naive VHH libraries are used, for example, VHH libraries obtained from naive VHH libraries by techniques such as, for example, random mutagenesis and / or CDR shuffling such as, for example, described in WO 00/43507.
[053] In an additional embodiment, yet another technique for obtaining VHH sequences directed against PSMA, involves adequate immunization of a transgenic mammal that is capable of expressing heavy chain antibodies (that is, in order to evoke an immune response and / or heavy chain antibodies directed against PSMA), obtaining an appropriate biological sample from said transgenic mammal (for example, a blood sample, serum sample or sample
Petition 870190117813, of 11/14/2019, p. 37/156
33/133 of B cells), and then the generation of VHH sequences directed against PSMA, from said sample, using any suitable technique known in the field. For example, for this purpose, rats or mice expressing the heavy chain antibody and the additional methods and techniques described in WO 02/085945 and WO 04/049794 can be used.
[054] In some embodiments, a single domain PSMA antibody, as described in that specification, comprises single domain antibody with an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring VHH domain, but which has been humanized, that is, by replacing one or more amino acid residues in the amino acid sequence of said naturally occurring VHH sequence (and in particular, in the framework sequences) with one or more of the amino acid residues that occur in the corresponding position (or positions) in a VH domain of a conventional human 4-chain antibody (for example, as indicated above). This can be done in a way known in the field, which will be evident to those skilled in the art, for example, based on the additional description in this specification. Again, it should be noted that these single-domain, humanized anti-PSMA antibodies from the disclosure are obtained in any way known to you (i.e., as indicated under points (1) - (8) above) and are therefore not strictly limited to the polypeptides that were obtained using a polypeptide that comprises a naturally occurring VHH domain as a starting material In some additional embodiments, a single domain PSMA antibody, as described in that specification,
Petition 870190117813, of 11/14/2019, p. 38/156
34/133 comprises a single domain antibody with an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring VH domain, but that has been camelized, that is, by replacing one or more amino acid residues in the amino acid sequence of a naturally occurring VH domain of a conventional 4-chain antibody by one or more of the amino acid residues occurring at the corresponding position (or positions) in a VHH domain of a heavy chain antibody. These camelization substitutions are preferably inserted at the amino acid positions that form and / or are present at the VHVL interface, and / or in the so-called unmistakable residues of Camelidae (see, for example, WO 94/04678 and Davies and Riechmann (1994 and 1996) ). Preferably, the VH sequence that is used as a starting material or starting point for the generation or design of the camelized single domain is preferably a mammalian VH sequence, more preferably a human VH sequence, for example example, a VH3 sequence. However, it should be noted that these camelized anti-PSMA single domain antibodies of the disclosure, in certain embodiments, are obtained by any suitable form known in the field (i.e., as indicated under (1) - (8) above) and, therefore, they are not strictly limited to the polypeptides that have been obtained using a polypeptide that comprises a naturally occurring VH domain as a starting material. For example, as further described in this specification, both humanization and camelization are accomplished by providing a nucleotide sequence that encodes a naturally occurring VHH or VH domain,
Petition 870190117813, of 11/14/2019, p. 39/156
35/133 respectively, and then changing one or more codons in said nucleotide sequence in such a way that the new nucleotide sequence encodes a humanized or camelized single domain antibody, respectively. That nucleic acid can then be expressed in order to provide the desired anti-PSMA single domain antibody of the disclosure. Alternatively, in other embodiments, based on the amino acid sequence of a naturally occurring VHH or VH domain, respectively, the amino acid sequence of the desired humanized or camelized anti-PSMA single domain antibody from the disclosure, respectively, is designed and then synthesized again using known techniques for peptide synthesis. In some embodiments, based on the amino acid sequence or nucleotide sequence of a naturally occurring VHH domain or VH domain, respectively, a nucleotide sequence encoding the desired humanized or camelized antiPSMA single domain antibody of the disclosure, respectively, is designed and then synthesized again using known techniques for nucleic acid synthesis, and then the nucleic acid so obtained is expressed using known expression techniques, in order to provide the desired anti-PSMA single domain antibody of the disclosure.
[055] Other methods and techniques suitable for obtaining the single-domain anti-PSMA antibody of the disclosure and / or nucleic acids encoding it, starting from naturally occurring VH sequences or VHH sequences, for example, comprise the combination of one or more parts of one or more naturally occurring VH sequences (for example, one or more framework (FR) sequences and / or
Petition 870190117813, of 11/14/2019, p. 40/156
36/133 complementarity determining region (CDR) sequences, one or more parts of one or more naturally occurring VHH sequences (for example, one or more FR sequences or CDR sequences), and / or one or more sequences synthetic or semi-synthetic, suitably, to provide a single domain anti-PSMA antibody of the disclosure or a nucleotide or nucleic acid sequence encoding the same.
[056] It is contemplated that, in some modalities, the PSMA-binding protein is reasonably small and has a maximum of 25 kD, a maximum of 20 kD, a maximum of 15 kD or a maximum of 10 kD in some modalities. In certain cases, the PSMA-binding protein is 5 kD or less, if it is a peptide or small molecule entity.
[057] In some embodiments, the PSMA-binding protein is a specific anti-PSMA antibody comprising variable heavy chain (CDR) complementarity determining regions, CDR1, a heavy chain variable CDR2, a heavy chain variable CDR3, a Light chain variable CDR1, light chain variable CDR2 and light chain variable CDR3. In some embodiments, the PSMA-binding protein comprises any domain that binds to PSMA including, without limitation, domains of a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, or fragments binding to antigens such as single domain antibodies (sdAb), Fab, Fab ', F (ab) 2 and Fv fragments, fragments composed of one or more CDRs, single chain antibodies (for example, single chain Fv fragments ( scFv)), Fv fragments stabilized with
Petition 870190117813, of 11/14/2019, p. 41/156
37/133 disulfide (dsFv), heteroconjugate antibodies (e.g., bispecific antibodies), pFv fragments, heavy chain monomers or dimers, light chain monomers or dimers, and dimers consisting of a heavy chain and a light chain. In some cases, it is beneficial that the PSMA-binding domain is derived from the same species in which the PSMA-binding protein described in this specification will ultimately be used. For example, for use in humans, it may be beneficial that the PSMA-binding domain of the PSMA-binding protein comprises human or humanized residues from the antigen-binding domain of an antibody or antibody fragment. In some embodiments, the PSMA binding protein is a specific antiPSMA binding protein comprising a heavy chain variable CDR1, a heavy chain variable CDR2 and a heavy chain variable CDR3. In some embodiments, the PSMA binding protein is a single domain anti-PSMA antibody comprising a heavy chain variable CDR1, a heavy chain variable CDR2 and a heavy chain variable CDR3.
[058] In some embodiments, the PSMA-binding protein of the present disclosure is a polypeptide comprising an amino acid sequence that is composed of four framework regions / sequences (fl-f4) interrupted by three complementarity determining regions / sequences, such as represented by the formula: f1-rl-f2-r2-f3-r3-f4, where rl, r2 and r3 are complementarity determining regions CDR1, CDR2 and CDR3, respectively, and fl, f2, f3 and f4 are structural residues. The structural residues of the PSMA-binding protein of the present disclosure comprise, for example, 75,
Petition 870190117813, of 11/14/2019, p. 42/156
38/133
76, 77, 78, 79, 80, 81 amino acid residues, and complementarity determining regions comprise, for example, 30, 31, 32, 33, 34, 35, 36 amino acid residues. In some embodiments, the PSMA-binding protein comprises an amino acid sequence as shown in the ID. SEQ. No. 4 comprising structural residues and CDR1, a CDR2, and a CDR3, where (a) CDR1 comprises the amino acid sequence as shown in the ID. SEQ. N °: 16 or a variant that has one, two, three or four amino acid substitutions in the ID. SEQ. No. 16, (b) CDR2 comprises a sequence as shown in the ID. SEQ. N °: 17 or a variant that has one, two, three or four amino acid substitutions in the ID. SEQ. No. 17, and (c) CDR3 comprises a sequence as shown in the ID. SEQ. N °: 18 or a variant that has one, two, three or four amino acid substitutions in the ID. SEQ. N °: 18.
[059] In some embodiments, the PSMA-binding protein comprises an amino acid sequence as shown in the ID. SEQ. No. 19 comprising structural residues and CDR1, a CDR2, and a CDR3, where (a) CDR1 comprises the amino acid sequence as shown in the ID. SEQ. N °: 16 or a variant that has one, two, three or four amino acid substitutions in the ID. SEQ. No. 16, (b) CDR2 comprises a sequence as shown in the ID. SEQ. N °: 17 or a variant that has one, two, three or four amino acid substitutions in the ID. SEQ. No. 17, and (c) CDR3 comprises a sequence as shown in the ID. SEQ. N °: 18 or a variant that has one, two, three or four amino acid substitutions in the ID. SEQ. N °: 18.
Petition 870190117813, of 11/14/2019, p. 43/156
39/133 [060] In embodiments in which the PSR-binding protein CDR1 comprises the amino acid sequence as shown in the ID. SEQ. N °: 16 or a variant that has one, two, three or four amino acid substitutions in the ID. SEQ. No. 16, these substitutions include, for example, proline, histidine. In embodiments in which the PSMA-binding protein CDR2 comprises the amino acid sequence as shown in the ID. SEQ. N °: 17 or a variant that has one, two, three or four amino acid substitutions in the ID. SEQ. No. 17, these substitutions include, for example, aspartic acid, lysine, glutamine, tyrosine.
[061] In modalities in which the PSR-binding protein CDR3 comprises the amino acid sequence as shown in the ID. SEQ. N °: 18 or a variant that has one, two, three or four amino acid substitutions in the ID. SEQ. No. 18, these substitutions include, for example, serine.
[062] In some embodiments, the PSMA-binding protein of the present disclosure comprises the following formula: f1-rl-f2-r2-f3-r3-f4, where ri, r2 and r3 are determining regions of complementarity CDR1, CDR2 and CDR3, respectively, and fl, f2, f3 and f4 are structural residues, and where ri comprises the ID. SEQ. No. 5, ID. SEQ. No. 6, or ID. SEQ. No.: 7, r2 comprises the ID. SEQ. No. 8, ID. SEQ. No. 9, ID. SEQ. No. 10, ID. SEQ. No. 11, ID. SEQ. No. 12, ID. SEQ. No. 13, or ID. SEQ. N °: 14, and r3 comprises the ID. SEQ. N °: 15. In some embodiments, the PSMA-binding protein of the present disclosure is a single domain antibody comprising the
Petition 870190117813, of 11/14/2019, p. 44/156
40/133 following formula: f1-rl-f2-r2-f3-r3-f4, where rl, r2 and r3 are complementarity determining regions CDR1, CDR2 and CDR3, respectively, and fl, f2, f3 and f4 are residues structural, and where rl is the ID. SEQ. No. 5, ID. SEQ. No. 6, or ID. SEQ. N °: 7, r2 is the ID. SEQ. No. 8, ID. SEQ. No. 9, ID. SEQ. No. 10, ID. SEQ. No. 11, ID. SEQ. No. 12, ID. SEQ. No. 13, or ID. SEQ. N °: 14, and r3 is the ID. SEQ. N °: 15.
[063] In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. N °:
(RFMISX1YX2MH), (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No.: 2 (X ₃ INPAX4X ₅ TDYAEX6VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. NO: 3 (DX7YGY). In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No.: 1 (RFMISX1YX2MH), (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No. 17, and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °: 18. In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No. 16, (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. N °:
(X3INPAX4X5TDYAEX6VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °: 18. In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. N °: 16, (b) the sequence
Petition 870190117813, of 11/14/2019, p. 45/156
41/133 of CDR2 amino acids is as shown in ID. SEQ. N °:
17, and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. No. 3 (DX YGY). In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No.: 1 (RFMISX1YX2MH), (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No.: 2 (X3INPAX4X5TDYAEX6VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °:
18. In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No.: 1 (RFMISX1YX2MH), (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No. 17, and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. No. 3 (DX YGY). In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No. 16, (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No.: 2 (X3INPAX4X5TDYAEX6VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. No. 3 (DX YGY).
[064] In some embodiments, amino acid residues Xi, X2, X3, X4, Xs, Xs and X7 are independently selected from glutamic acid, proline, serine, histidine, threonine, aspartic acid, glycine, lysine, threonine, glutamine and tyrosine. In some embodiments, Xi is proline. In some embodiments, X2 is histidine. In some embodiments, X3 is aspartic acid. In some embodiments, X4 is lysine. In some modalities, X5 is glutamine. In some modalities,
Petition 870190117813, of 11/14/2019, p. 46/156
42/133
Xg is tyrosine. In some modalities, X it's serine. The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1, CDR2 and CDR3 in which Xi is glutamic acid, X2 is histidine, X3 is aspartic acid, X4 is glycine, X5 is threonine, Xg is serine and X it's serine.
[065] In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No.: 1 (RFMISX1YX2MH), (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No.: 2 (X3INPAX4X5TDYAEX6VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °: 3 (DX7YGY), where Xi is proline. In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No.: 1 (RFMISX1YX2MH), (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No.: 2 (X3INPAX4X5TDYAEX6VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °: 3 (DX YGY), where X5 is glutamine. In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No.: 1 (RFMISX1YX2MH), (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No.: 2 (X3INPAX4X5TDYAEX6VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °: 3 (DX7YGY), where Xg is tyrosine. In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. N °: 1 (RFMISX1YX2MH), (b) a
Petition 870190117813, of 11/14/2019, p. 47/156
43/133 CDR2 amino acid sequence is as shown in ID. SEQ. No.: 2 (X3INPAX4X5TDYAEX6VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °: 3 (DX7YGY), where X4 is lysine and X it's serine. In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No.: 1 (RFMISX1YX2MH), (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. NO: 2 (X3INPAX ₄ X5TDYAEX ₆ VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °: 3 (DX YGY), where X ₂ is histidine, X3 is aspartic acid, X4 is lysine and X7 is serine. In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No.: 1 (RFMISXiYX ₂ MH), (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No.: 2 (X3INPAX4X5TDYAEX6VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °: 3 (DX7YGY), where Xi is proline, X ₂ is histidine, X3 is aspartic acid and X7 is serine. In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No.: 1 (RFMISXiYX ₂ MH), (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No.: 2 (X3INPAX4X5TDYAEX6VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °: 3 (DX7YGY), where X ₂ is histidine, X ₃ is aspartic acid, X5 is glutamine and X7 is serine. In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. N °: 1 (RFMISXiYX ₂ MH),
Petition 870190117813, of 11/14/2019, p. 48/156
44/133 (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No. 2 (X ₃ INPAX ₄ X5TDYAEXgVKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °: 3 (DX YGY), where X2 is histidine, X3 is aspartic acid, Xg is tyrosine and X it's serine. In some embodiments, the PSMA-binding protein comprises a CDR1, CDR2 and CDR3, where (a) the amino acid sequence of CDR1 is as shown in ID. SEQ. No.: 1 (RFMISX1YX2MH), (b) the amino acid sequence of CDR2 is as shown in ID. SEQ. No.: 2 (X3INPAX4X5TDYAEX6VKG), and (c) the amino acid sequence of CDR3 is as shown in ID. SEQ. N °: 3 (DX YGY), where X2 is histidine, X3 is aspartic acid and X it's serine.
[066] The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1 CDR2 and CDR3 in which Xi is glutamic acid, X2 is histidine, X3 is threonine, X4 is glycine, X5 is threonine, Xg is serine and X it's serine. The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1 CDR2 and CDR3 in which Xi is glutamic acid, X2 is histidine, X3 is threonine, X4 is glycine, X5 is threonine, Xg is serine and X it's serine. The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1 CDR2 and CDR3 in which Xi is glutamic acid, X2 is serine, X3 is threonine, X4 is lysine, X5 is threonine, Xg is serine and X it's serine. The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1 CDR2 and CDR3 in which Xi is proline, X2 is serine, X3 is threonine, X4 is glycine, X5 is threonine, Xg is serine and X is glycine. The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1, CDR2 and
Petition 870190117813, of 11/14/2019, p. 49/156
45/133
CDR3 in which Xi is glutamic acid, X ₂ is serine, X3 is threonine X4 is glycine, X5 is glutamine, Xg is serine and X is glycine. The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1, CDR2 and CDR3 in which Xi is glutamic acid, X ₂ is serine, X3 is threonine X4 is glycine, X5 is threonine, Xg is tyrosine and X is glycine. The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1, CDR2 and CDR3 in which Xi is glutamic acid, X ₂ is histidine, X3 is aspartic acid, X4 is lysine, X5 is threonine, Xg is serine and X it's serine. The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1 CDR2 and CDR3 in which Xi is proline, X ₂ is histidine, X3 is aspartic acid, X4 is glycine, X5 is threonine, Xg is serine and X it's serine. The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1 CDR2 and CDR3 in which Xi is glutamic acid, X ₂ is histidine, X3 is aspartic acid, X4 is glutamine, X5 is threonine, Xg is serine and X it's serine. The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1, CDR2 and CDR3 in which Xi is glutamic acid X ₂ is histidine, X3 is aspartic acid, X4 is glycine, X5 is threonine, Xg is tyrosine and X it's serine. The PSMA-binding protein of the present disclosure may, in some embodiments, comprise sequences of CDR1, CDR2 and CDR3 in which X ₂ is histidine and X it's serine. Exemplary framework strings are revealed as ID. SEQ. No. 165-168.
[067] In some embodiments, the prostate-specific membrane antigen-binding protein comprises any combination of the following: (i), where Xi is proline;
Petition 870190117813, of 11/14/2019, p. 50/156
46/133 (ii), where X2 is histidine; (iii), where X3 is aspartic acid; (iv) where X4 is lysine; (v), where X5 is glutamine; (vi), where Xg is tyrosine; and (vii), in which X it's serine. In some embodiments, the prostate-specific membrane antigen-binding protein of the above modality has a greater affinity for a human prostate-specific membrane antigen than that of a binding protein having the sequence shown as ID. SEQ. No.: 4. In some embodiments, binding to the prostate-specific membrane antigen comprises any combination of the following: (i), where Xi is proline; where X5 is glutamine; (ii), where Xg is tyrosine; where X4 is lysine and X it is serine; (iii), where X2 is histidine, X3 is aspartic acid, X4 is lysine and X it is serine; (iv), where Xi is proline, X2 is histidine, X3 is aspartic acid and X it is serine; (v), where X2 is histidine, X3 is aspartic acid, X5 is glutamine and X it is serine; (vi), where X2 is histidine, X3 is aspartic acid, X4 is lysine and X it is serine; (vii), where Xi is proline, X2 is histidine, X3 is aspartic acid and X it is serine; (viii), where X2 is histidine, X3 is aspartic acid, X5 is glutamine and X it is serine; (ix), where X2 is histidine, X3 is aspartic acid, Xg is tyrosine and X it is serine; and (x), where X2 is histidine, X3 is aspartic acid and X it's serine.
[068] In some embodiments, the PSMA-binding protein has an amino acid sequence as shown in the ID. SEQ. N °: 4. In some embodiments, the PSMA-binding protein has an amino acid sequence as shown in the ID. SEQ. No.: 4 where one or more amino acid positions are replaced. In some embodiments, one or more of amino acid positions 19, 86, 87 and 106 of the ID.
Petition 870190117813, of 11/14/2019, p. 51/156
47/133
SEQ. N °: 4 are replaced. Exemplary substitutions at amino acid positions 19, 86, 87 and 106 include, without limitation, T19R, K86R, P87A and Q106L. In some embodiments, one or more of the amino acid positions 31, 33, 50, 55, 56, 62 and 97 of the ID. SEQ. N °: 4 are replaced. In some embodiments, the amino acid position 31 of the ID. SEQ. No. 4 is replaced as E31P. In some embodiments, the amino acid position 33 of the ID. SEQ. No. 4 is replaced as S33H. In some embodiments, the amino acid position 50 of the ID. SEQ. No: 4 is replaced as T50D. In some embodiments, the amino acid position 55 of the ID. SEQ. No. 4 is replaced as G55K. In some embodiments, the amino acid position 5 6 of the ID. SEQ. No. 4 is replaced as T56Q. In some embodiments, the amino acid position 62 of the ID. SEQ. No. 4 is replaced as S62Y. In some embodiments, the amino acid position 97 of the ID. SEQ. No. 4 is replaced as G97S. In some embodiments, the amino acid position 33 of the ID. SEQ. No. 4 is replaced as S33H. In some modalities, the replacement of the ID. SEQ. No. 4 at position 31 is combined with substitutions at positions 50 and 97. In some embodiments, amino acid positions 31, 50 and 97 of the ID. SEQ. N °: 4 are respectively replaced as E31P, T50D and G97S. In some modalities, the replacement of the ID. SEQ. No. 4 at position 33 is combined with substitutions at position 97. In some embodiments, amino acid positions 33 and 97 of ID. SEQ. N °: 4 are respectively replaced as S33H and G97S. In some modalities, the replacement of the ID. SEQ. No. 4 in position 33 is combined with substitutions in positions 50 and 97. In some embodiments, the positions of
Petition 870190117813, of 11/14/2019, p. 52/156
48/133 amino acid 33, 50 and 97 of ID. SEQ. N °: 4 are respectively replaced as S33H, T50D and G97S. In some modalities, the replacement of the ID. SEQ. No. 4 at position 33 is combined with substitutions at positions 50, 55 and 97. In some embodiments, amino acid positions 33, 50, 55 and 97 of the ID. SEQ. N °: 4 are respectively replaced as S33H, T50D, G55K and G97S. In some modalities, the replacement of the ID. SEQ. No. 4 at position 33 is combined with substitutions at positions 31, 50 and 97. In some embodiments, amino acid positions 31, 33, 50 and 97 of the ID. SEQ. N °: 4 are respectively replaced as E31P, S33H, T50D and G97S. In some modalities, the replacement of the ID. SEQ. No. 4 at position 33 is combined with substitutions at positions 50, 56 and 97. In some embodiments, amino acid positions 33, 50, 56 and 97 of the ID. SEQ. N °: 4 are respectively replaced as S33H, T50D, T56Q and G97S. In some modalities, the replacement of the ID. SEQ. No. 4 at position 33 is combined with substitutions at positions 50, 62 and 97. In some embodiments, amino acid positions 33, 50, 62 and 97 of the ID. SEQ. N °: 4 are respectively replaced as S33H, T50D, S62Y and G97S.
[069] In some embodiments, the PSMA-binding protein has an amino acid sequence as shown in the ID. SEQ. N °: 19. In some embodiments, the PSMA-binding protein has an amino acid sequence as shown in the ID. SEQ. No. 19, where one or more amino acid positions are replaced. In some embodiments, one or more of the amino acid positions 31, 33, 50, 55, 56, 62 and 97 of the ID. SEQ. N °: 19 are replaced. In some
Petition 870190117813, of 11/14/2019, p. 53/156
49/133 modalities, the position of amino acid 31 of the ID. SEQ. No. 4 is replaced as E31P. In some embodiments, the amino acid position 33 of the ID. SEQ. No. 19 is replaced as S33H. In some embodiments, the amino acid position 50 of the ID. SEQ. N °: 19 is replaced as T50D. In some embodiments, the amino acid position 55 of the ID. SEQ. N °: 19 is replaced as G55K. In some embodiments, the amino acid position 5 6 of the ID. SEQ. N °: 19 is replaced as T56Q. In some embodiments, the amino acid position 62 of the ID. SEQ. N °: 19 is replaced as S62Y. In some embodiments, the amino acid position 97 of the ID. SEQ. N °: 19 is replaced as G97S. In some embodiments, the amino acid position 33 of the ID. SEQ. No. 19 is replaced as S33H. In some modalities, the replacement of the ID. SEQ. No. 19 at position 31 is combined with substitutions at positions 50 and 97. In some embodiments, amino acid positions 31, 50 and 97 of the ID. SEQ. N °: 19 are respectively replaced as E31P, T50D and G97S. In some modalities, the replacement of the ID. SEQ. No. 19 at position 33 is combined with substitutions at position 97. In some embodiments, amino acid positions 33 and 97 of ID. SEQ. N °: 19 are replaced, respectively, as S33H and G97S. In some modalities, the replacement of the ID. SEQ. No. 19 at position 33 is combined with substitutions at positions 50 and 97. In some embodiments, amino acid positions 33, 50 and 97 of the ID. SEQ. N °: 19 are respectively replaced as S33H, T50D and G97S. In some modalities, the replacement of the ID. SEQ. No. 19 at position 33 is combined with substitutions at positions 50, 55 and 97. In some embodiments, amino acid positions 33,
Petition 870190117813, of 11/14/2019, p. 54/156
50/133
50, 55 and 97 of the ID. SEQ. N °: 19 are respectively replaced as S33H, T50D, G55K and G97S. In some modalities, the replacement of the ID. SEQ. No. 19 at position 33 is combined with substitutions at positions 31, 50 and 97. In some embodiments, amino acid positions 31, 33, 50 and 97 of the ID. SEQ. N °: 19 are respectively replaced as E31P, S33H, T50D and G97S. In some modalities, the replacement of the ID. SEQ. No. 19 at position 33 is combined with substitutions at positions 50, 56 and 97. In some embodiments, amino acid positions 33, 50, 56 and 97 of the ID. SEQ. N °: 19 are respectively replaced as S33H, T50D, T56Q and G97S. In some modalities, the replacement of the ID. SEQ. No. 4 at position 33 is combined with substitutions at positions 50, 62 and 97. In some embodiments, amino acid positions 33, 50, 62 and 97 of the ID. SEQ. N °: 4 are respectively replaced as S33H, T50D, S62Y and G97S.
[070] In some embodiments, the prostate-specific membrane antigen-binding protein comprises any combination of the following: (i) substitution at position 31; (ii) replacement in position 50; (iii) replacement in position 55; replacement in position 56; (iv) replacement in position 62; (v) replacement in position 97; (vi) substitutions in positions 55 and 97; (vii) substitutions in positions 33 and 97; (viii) substitutions in positions 33, 50 and 97; (ix) substitutions in positions 31, 33, 50 and 97; (x) substitutions in positions 33, 50, 55 and 97; (xi) substitutions in positions 33, 50, 56 and 97; and (xiii) substitutions in positions 33, 50, 62 and 97.
[071] In some embodiments, the protein binding to
Petition 870190117813, of 11/14/2019, p. 55/156
51/133
PSMA is cross-react with human and Cynomolgus PSMA. In some embodiments, the PSMA-binding protein is specific for human PSMA. In various embodiments, the PSMA-binding protein of the present disclosure is at least about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81% , about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91% , about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the amino acid sequence displayed in the ID. SEQ. N °: 4.
[072] In various embodiments, the PSMA-binding protein of the present disclosure is at least about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about of 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to the amino acid sequence shown in the ID. SEQ. N °: 19.
[073] In several embodiments, a region determining the complementarity of the PSMA-binding protein of the present disclosure is at least about 80%, about 81%, about 82%, about 83%, about 84%, about about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the amino acid sequence shown in the ID. SEQ. N °: 16.
Petition 870190117813, of 11/14/2019, p. 56/156
52/133 [074] In several embodiments, a complementary determining region of the PSMA-binding protein of the present disclosure is at least about 75%, about 76%, about 77%, about 78%, about 79 %, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89 %, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99 % or about 100% identical to the amino acid sequence shown in the ID. SEQ. N °: 17.
[075] In various embodiments, a region determining the complementarity of the PSMA-binding protein of the present disclosure is at least about 85%, about 86%, about 87%, about 88%, about 89%, about about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the amino acid sequence shown in the ID. SEQ. N °: 18.
Humanization and affinity maturation [076] In the design of binding proteins for therapeutic applications, it is desirable to create proteins that, for example, modulate a target's functional activity, and / or enhanced binding proteins such as binding proteins with greater specificity and / or affinity and / or binding proteins that are more bioavailable, or stable or soluble, in particular, in cellular or tissue environments.
[077] The PSMA binding proteins described in the present disclosure exhibit increased binding affinities for the target binding domain, which is PSMA. THE
Petition 870190117813, of 11/14/2019, p. 57/156
The present disclosure identifies amino acid substitutions in the complementarity determining regions (CDRs) of the PSMA-binding proteins described in that specification that lead to greater binding affinity for one or both of human and cyano PSMA. In some embodiments, the PSMA-binding protein is an antibody. In certain embodiments, the PSMA-binding protein is a humanized antibody. Generally, a humanized antibody comprises one or more variable domains in which CDRs or portions of CDRs are derived from a non-human antibody, and framework regions or portions of framework regions are derived from human antibody sequences. Optionally, a humanized antibody also comprises at least a portion of a human constant region. In some embodiments, selected structural residues are replaced with corresponding residues of a non-human antibody (for example, the antibody from which CDRs are derived), for example, to restore or increase the specificity, affinity, or pH dependence of the antibody. Human framework regions that can be used for humanization include, without limitation, framework regions selected using a best fit method (for example, Sims et al J. Immunol. 151: 2,296, 1993); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of variable regions of light or heavy chain (for example, Carter et al. Proc. Natl. Acad. Sci. USA, 89: 4,285, 1992; and Presta et al ., J. Immunol., 151: 2.623, 1993); mature human framework regions (somatically mutated) or framework regions of the human germ line (for example, Almagro and Fransson, Front. Biosci. 13: 1.619-1.633, 2008); and regions
Petition 870190117813, of 11/14/2019, p. 58/156
54/133 frameworks derived from the evaluation of framework libraries (for example, Baca et al., J. Biol. Chem. 272: 10.67810.684, 1997; and Rosok et al., J. Biol. Chem. 271: 22.61122.618 , 1996)). Thus, in one aspect, the PSMA-binding protein comprises a humanized or human antibody or an antibody fragment. In one embodiment, the humanized or human anti-PSMA binding protein comprises one or more (for example, all three) of the light chain complementarity determining region 1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2) and light chain complementarity determining region 3 (LC CDR3) of a humanized or human anti-PSMA binding domain described in that specification, and / or one or more (for example, all three) of the complementarity determining region heavy chain 1 (HC CDR1), heavy chain 2 complementarity determining region (HC CDR2) and heavy chain 3 complementarity determining region (HC CDR3) of a humanized or human anti-PSMA binding domain described in that specification, for example, a humanized or human anti-PSMA binding domain comprising one or more, for example, all three, LC CDRs and one or more, for example, all three, HC CDRs. In some embodiments, the humanized or human anti-PSMA binding domain comprises a PSMA specific humanized or human light chain variable region, wherein the PSMA specific light chain variable region comprises human or non-human light chain CDRs in a human light chain framework region. In certain cases, the light chain framework region is an À light chain framework (lambda). In other cases, the framework region of
Petition 870190117813, of 11/14/2019, p. 59/156
55/133 light chain is a κ (kappa) light chain framework. In some embodiments, the humanized or human anti-PSMA binding domain comprises a PSMA specific humanized or human heavy chain variable region, wherein the PSMA specific heavy chain variable region comprises human or non-human heavy chain CDRs in a human heavy chain framework region. In certain cases, the complementary determining regions of the heavy chain and / or the light chain are derived from anti-PSMA antibodies known as, for example, 7E11, EPR6253, 107.1A4, GCP-05, EP3253, BV9, SP29, human PSMA / FOLH1 antibody / NAALADase I.
[078] The PSMA binding proteins of the present disclosure are, in some embodiments, of affinity matured to increase their binding affinity for the target binding domain. When it is desired to increase the affinity of the PSMA binding proteins of the disclosure, for example, anti-PSMA antibodies that contain one or more of the CDRs mentioned above, those antibodies with increased affinity can be obtained by various affinity maturation protocols including, without limitation, maintenance of CDRs, chain shuffling, use of E. coli mutation strains, DNA shuffling, phage and sexual presentation. The exemplary methods of affinity maturation above are discussed by Vaughan et al. (Nature Biotechnology, 16, 535-539, 1998). Thus, in addition to the PSMA-binding protein variants discussed in the preceding sections, the disclosure provides additional sequence variants that increase the affinity of the binding protein to its target, that is, PSMA. In certain modalities, these
Petition 870190117813, of 11/14/2019, p. 60/156
56/133 sequence variants comprise one or more semiconservative or conservative substitutions within the PSMA binding protein sequences and these substitutions preferably do not significantly affect the desired activity of the binding protein. Substitutions can be naturally occurring or can be introduced, for example, using mutagenesis (for example, Hutchinson et al., 1978, J. Biol. Chem. 253: 6,551). For example, the amino acids glycine, alanine, valine, leucine and isoleucine can often be substituted for each other (amino acids that have aliphatic side chains). Of these possible substitutions, typically glycine and alanine are used to replace each other, as they have relatively short side chains, and valine, leucine and isoleucine are used to replace each other, as they have larger aliphatic side chains that are hydrophobic. . Other amino acids that can be frequently substituted among them include, without limitation: phenylalanine, tyrosine and tryptophan (amino acids that have aromatic side chains); lysine, arginine and histidine (amino acids that have basic side chains); aspartate and glutamate (amino acids that have acidic side chains); asparagine and glutamine (amino acids that have amide side chains); and cysteine and methionine (amino acids that have sulfur-containing side chains).
[079] In some embodiments, PSMA-binding proteins are isolated by evaluating combinatorial libraries, for example, by generating presentation phage libraries and evaluating those libraries for antibodies that
Petition 870190117813, of 11/14/2019, p. 61/156
57/133 have the desired connection characteristics. In addition, the binding affinity of the PSMA-binding protein to its binding target can be selected to target a specific elimination half-life in a particular albumin-PSMA-binding protein. Thus, in some embodiments, the PSMA-binding protein has a high binding affinity for its binding target. In other embodiments, the PSMA-binding protein has a medium binding affinity for its binding target. In still other embodiments, the PSMA-binding protein has a low or marginal binding affinity for its binding target. Exemplary binding affinities include Kd of 10 nM or less (high), between 10 nM and 100 nM (average) and more than 100 nM (low). The affinity for binding to PSMA can be determined, for example, by the ability of the binding protein itself or its PSMA binding domain to bind to the coated PSMA on an assay plate; displayed on the surface of a microbial cell; in solution; etc. The binding activity of the protein of the present disclosure to PSMA can also be tested by immobilizing the ligand (e.g., PSMA) or said binding protein itself or its PSMA binding domain, to a globule, substrate, cell, etc. In some embodiments, the binding between the PSMA-binding protein itself, or its PSMA-binding domain, and a target ligand (for example, PSMA) is determined, for example, by a binding kinetics assay. The binding kinetics test, in certain modalities, is performed using an OCTET® system. In these modalities, a first step involves the immobilization of a ligand (for example, biotinylated PSMA) on the surface
Petition 870190117813, of 11/14/2019, p. 62/156
58/133 of a biosensor (for example, a streptavidin biosensor) at an optimal charge density, followed by a wash with an assay buffer to remove unbound ligands, which is followed by association of the analyte, that is, the analyte itself PSMA-binding protein or its PSMA-binding domain with the ligand, which is followed by exposure of the biosensor to a buffer that does not contain the analyte, thereby resulting in dissociation of the PSMA-binding protein itself or its binding to the PSMA of the ligand. Suitable blocking agents, for example, BSA, Barrel, Tween-20, PEG, gelatin, are used to block non-specific binding sites on the biosensor. Binding kinetics data is subsequently analyzed using appropriate software (eg, ForteBio's Octet software) to determine the association and dissociation rate constants for binding interaction between the PSMA binding protein itself or its binding domain PSMA and a binder.
[080] In certain embodiments, the PSMA-binding protein disclosed in that specification binds to human PSMA with a human Kd (hKd). In certain embodiments, the PSMA-binding protein disclosed in that specification binds to Cynomolgus PSMA with a kino of cino (cKd). In certain embodiments, the PSMA-binding protein disclosed in that specification binds Cynomolgus PSMA with a kino of cino (cKd) and human PSMA with a human Kd (hKd). In some embodiments, hKd and cKd range from about 0.1 nM to about 500 nM. In some embodiments, hKd and cKd range from about 0.1 nM to about 450 nM. In some modalities, hKd and cKd vary
Petition 870190117813, of 11/14/2019, p. 63/156
59/133 from about 0.1 nM to about 400 nM. In some embodiments, hKd and cKd range from about 0.1 nM to about 350 nM. In some embodiments, hKd and cKd range from about 0.1 nM to about 300 nM. In some embodiments, hKd and cKd range from about 0.1 nM to about 250 nM. In some embodiments, hKd and cKd range from about 0.1 nM to about 200 nM. In some embodiments, hKd and cKd range from about 0.1 nM to about 150 nM. In some embodiments, hKd and cKd range from about 0.1 nM to about 100 nM. In some embodiments, hKd and cKd range from about 0.1 nM to about 90 nM. In some embodiments, hKd and cKd range from about 0.2 nM to about 80 nM. In some embodiments, hKd and cKd range from about 0.3 nM to about 70 nM. In some embodiments, hKd and cKd range from about 0.4 nM to about 50 nM. In some embodiments, hKd and cKd range from about 0.5 nM to about 30 nM. In some embodiments, hKd and cKd range from about 0.6 nM to about 10 nM. In some embodiments, hKd and cKd range from about 0.7 nM to about 8 nM. In some embodiments, hKd and cKd range from about 0.8 nM to about 6 nM. In some embodiments, hKd and cKd range from about 0.9 nM to about 4 nM. In some embodiments, hKd and cKd range from about 1 nM to about 2 nM. In some embodiments, the PSMA-binding protein binds to human and Cynomolgus PSMA with comparable binding affinity (Kd).
[081] In some embodiments, the PSMA-binding protein of the present disclosure comprises the sequence as shown in the ID. SEQ. N °: 4 and has an hKd of about
Petition 870190117813, of 11/14/2019, p. 64/156
60/133 from 10 nM to about 20 nM. In some embodiments, the PSMA-binding protein of the present disclosure comprises a mutation from glutamic acid to proline at amino acid position 31 of the ID. SEQ. No. 4 and has an hKd of about 5 nM to about 10 nM. In some embodiments, the PSMA-binding protein of the present disclosure comprises a mutation of threonine to glutamine at amino acid position 56 of the ID. SEQ. No.: 4 and has an hKd of about 1 nM to about 7 nM. In some embodiments, the PSMA-binding protein of the present disclosure comprises a mutation from glycine to lysine at amino acid position 55 of the ID. SEQ. No.: 4 and has an hKd of about 0.5 nM to about 5 nM. In some embodiments, the PSMA-binding protein of the present disclosure comprises a mutation from serine to histidine at amino acid position 33, from threonine to aspartic acid at amino acid position 50 and substitution of glycine to serine at amino acid position 97 of ID. SEQ. No. 4 and has an hKd of about 5 nM to about 10 nM. In some embodiments, the PSMA-binding protein of the present disclosure comprises a mutation from serine to histidine at amino acid position 33 and substitution of glycine to serine at amino acid position 97 of ID. SEQ. N °: 4 and has an hKd of about 0.05 nM to about 2 nM. Thus, in various embodiments, PSMA-binding proteins that comprise one or more substitutions compared to the sequence as shown in the ID. SEQ. No. 4 have binding affinities for human PSMA that are 1.5 times to about 300 times greater than that of a protein comprising the ID sequence. SEQ. N °: 4, without any substitution. For example, binding affinity is about
Petition 870190117813, of 11/14/2019, p. 65/156
61/133
1.5 times up to about 3 times higher when replacing (or replacing) the ID. SEQ. N °: 4 comprises E31P; about 2 times to about 15 times greater when replacing (or replacing) the ID. SEQ. No. 4 comprises T56Q; about 3 times to about 30 times greater when replacing (or replacing) the ID. SEQ. N °: 4 comprises G55K; about 2 times to about 3 times greater when replacing (or replacing) the ID. SEQ. No. 4 comprises S33H T50D G97S; and about 5 times to about 300 times greater when replacing (or replacing) the ID. SEQ. No. 4 comprises S33H G97S. In some embodiments, (one or more) amino acid substitutions of ID. SEQ. No. 4, as described above, leads to increased binding affinity for both human and Cynomolgus PSMA, for example, a PSMA-binding protein of the present disclosure comprising amino acid substitutions S33H and G97S in ID. SEQ. No. 4 shows increased affinity for human and Cynomolgus PSMA compared to a protein comprising the ID sequence. SEQ. N °: 4 without any replacement. A further example of such an increase in double affinity is seen in the case of a PSMA-binding protein comprising amino acid substitutions S33H, T50D and G97S in ID. SEQ. NO: 4. In some embodiments, any one of the PSMA binding proteins mentioned above (e.g., single domain anti-PSMA antibodies of ^the SEQ IDs 21-32..) Are peptide affinity tag to facilitate purification. In some embodiments, the peptide affinity tag consists of six consecutive histidine residues, also called 6his (SEQ ID. N °: 33).
Petition 870190117813, of 11/14/2019, p. 66/156
62/133 [082] The binding affinity of PSMA binding proteins, for example, a single domain anti-PSMA antibody of the present disclosure, can also be described in relative terms or compared to the binding affinity of a second protein binding agent that also specifically binds to PSMA (for example, a second single domain anti-PSMA antibody that is PSMA-specific, which can be referred to in this specification as a second PSMA-specific antibody. In some embodiments, the second antibody PSMA-specific is any of the embodiments of the PSMA binding protein described in this specification, for example, the binding proteins defined by the IDS. SEQ. ^Nos 21-32. Accordingly, certain embodiments of the present disclosure relate to a anti-PSMA single domain antibody that binds to human PSMA and / or Cynomolgus PSMA with greater affinity than the binding protein of ID SEQ. 4, or with a Kd that is less than the Kd of the ID binding protein. SEQ. No.: 4. In addition, additional embodiments of the present disclosure relate to an anti-PSMA single domain antibody that binds to human PSMA and / or Cynomolgus PSMA with greater affinity than the ID binding protein. SEQ. No. 19, or with a Kd that is less than the Kd of the ID binding protein. SEQ. N °: 19.
CD3-binding domain [083] The specificity of the T cell response is mediated by antigen recognition (displayed in the context of a major histocompatibility complex, MHC) by the T cell receptor complex. As part of the T cell receptor complex, CD3 is a protein complex that
Petition 870190117813, of 11/14/2019, p. 67/156
63/133 includes a CD3y chain (gamma), a CD36 chain (delta) and two CD3e chains (epsilon), which are present on the cell surface. CD3 associates with the α (alpha) and β (beta) chains of the T cell receptor (TCR) and also CD3 ζ (zeta) together to understand the T cell receptor complex. For example, by immobilized anti-CD3 antibodies, it leads to T cell activation similar to T cell receptor engagement, but regardless of its typical clone specificity.
[084] In one aspect, a multispecific protein comprising a PSMA-binding protein according to the present disclosure is described in that specification. In some embodiments, the multispecific protein still comprises a domain that specifically binds to CD3. In some embodiments, the multispecific protein still comprises a domain that specifically binds to Οϋ3γ. In some embodiments, the multispecific protein still comprises a domain that specifically binds to CD3. In some embodiments, the multispecific protein still comprises a domain that specifically binds to CD3e.
[085] In additional embodiments, the multispecific protein still comprises a domain that specifically binds to the T cell receptor (TCR). In some embodiments, the multispecific protein still comprises a domain that specifically binds to the α chain of the TCR. In some embodiments, the multispecific protein still comprises a domain that specifically binds to the β chain of the TCR.
[086] In some embodiments, the multispecific protein
Petition 870190117813, of 11/14/2019, p. 68/156
64/133 further comprises a domain that specifically binds to a bulky serum protein, for example, human serum albumin (HSA). In some embodiments, the HSA-binding domain comprises a sequence selected from the group consisting of the ID. SEQ. No: 123-146.
[087] In some embodiments, the multispecific protein is a tryma specific antigen-binding protein that targets PSMA, also referred to in this specification as a TriTAC molecule targeting PSMA or tries specific for PSMA or triespecific molecule.
[088] In certain embodiments, the CD3-binding domain of the multispecific protein comprising a PSMA-binding protein described in this specification not only exhibits potent CD3-binding affinities with human CD3, but also exhibits excellent cross-reactivity with the respective monkey CD3 proteins Cynomolgus. In some cases, the CD3-binding domain of multispecific proteins cross-reacts with Cynomolgus monkey CD3.
[089] In some embodiments, the CD3-binding domain of the multispecific protein comprising a PSMA-binding protein described in that specification can be any domain that binds to CD3 including, without limitation, domains of a monoclonal antibody, an antibody polyclonal, recombinant antibody, human antibody, humanized antibody, or antigen-binding fragments of CD3-binding antibodies, for example, single domain antibodies (sdAb), Fab, Fab ', F (ab) 2 fragments and Fv, fragments composed of one or more CDRs, single chain antibodies (for example, single chain Fv fragments
Petition 870190117813, of 11/14/2019, p. 69/156
65/133 (scFv)), disulfide stabilized Fv fragments (dsFv), heteroconjugate antibodies (for example, bispecific antibodies), pFv fragments, heavy chain monomers or dimers, light chain monomers or dimers, and dimers consisting of a heavy chain and a light chain. In some cases, it is beneficial that the CD3-binding domain is derived from the same species in which the multispecific protein comprising a single PSMA-binding protein described in this specification in which it will ultimately be used. For example, for use in humans, it may be beneficial that the CD3-binding domain of the multispecific protein comprising a PSMA-binding protein described in that specification comprises human or humanized residues from the PSMA-binding domain of an antibody or fragment of antibody.
[090] Thus, in one aspect, the CD3-binding domain of the multispecific protein comprising a PSMA-binding protein comprises a humanized or human antibody or an antibody fragment, or a murine antibody or antibody fragment. In one embodiment, the humanized or human anti-CD3 binding domain comprises one or more (for example, all three) complementary light chain determining regions, light chain complementarity determining region 1 (LC CDR1), complementarity determining region light chain 2 (LC CDR2) and light chain 3 complementarity determining region (LC CDR3) of a humanized or human anti-CD3 binding domain described in that specification, and / or one or more (for example, all three ) complementary determinant regions of heavy chain,
Petition 870190117813, of 11/14/2019, p. 70/156
66/133 heavy chain complementarity determining region 1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2) and heavy chain complementarity determining region 3 (HC CDR3) of a humanized or human anti-CD3 binding domain described in that specification, for example, a humanized or human anti-CD3 binding domain comprising one or more, for example, all three, LC CDRs and one or more, for example, all three, HC CDRs.
[091] In some embodiments, the humanized or human anti-CD3 binding domain comprises a CD3 specific humanized or human light chain variable region, where the CD3 specific light chain variable region comprises human or non-human light chain CDRs in a human light chain framework region. In certain cases, the light chain framework region is an À light chain framework (lambda). In other cases, the light chain framework region is a κ (kappa) light chain framework.
[092] In some embodiments, the humanized or human antiCD3 binding domain comprises a CD3 specific humanized or human heavy chain variable region, wherein the CD3 specific heavy chain variable region comprises human or non-human heavy chain CDRs in a human heavy chain framework region.
[093] In certain cases, complementary determining regions of the heavy chain and / or light chain are derived from anti-CD3 antibodies known, for example, muromonab-CD3 (OKT3), otelixizumab (TRX4), teplizumab (MGA031), visilizumab (Nuvion), SP34, TR-66 or X35-3, VIT3, BMA030 (BW264 / 56), CLB-T3 / 3, CRIS7, YTH12.5,
Petition 870190117813, of 11/14/2019, p. 71/156
67/133
Fill-409, CLB — T3.4.2, TR-66, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3 / RW2-8C8, T3 / RW2-4B6, 0KT3D, MT301, SMC2, F101.01, UCHT-1 and WT-31.
[094] In one embodiment, the anti-CD3 binding domain is a single chain variable fragment (scFv) comprising a light chain and a heavy chain of an amino acid sequence provided in that specification. As used in this specification, the term single chain variable fragment or scFv refers to an antibody fragment comprising a light chain variable region and at least one antibody fragment comprising a heavy chain variable region, where the variable regions of the light and heavy chain are connected contiguously by means of a short flexible polypeptide linker, capable of being expressed as a single polypeptide chain, and in which scFv retains the specificity of the intact antibody from which it is derived. In one embodiment, the anti-CD3 binding domain comprises: a variable region of the light chain comprising an amino acid sequence that has at least one, two or three modifications (for example, substitutions), but at most 30, 20 or 10 modifications (for example, substitutions) of an amino acid sequence of a variable region of the light chain provided in that specification, or a sequence with 95-99% identity with a sequence of amino acids provided in that specification; and / or a variable region of the heavy chain comprising an amino acid sequence that has at least one, two or three modifications (for example, substitutions), but a maximum of 30, 20 or 10 modifications (for example, substitutions) of a sequence amino acids from a variable region of the chain
Petition 870190117813, of 11/14/2019, p. 72/156
68/133 heavy weight provided in that specification, or a 95-99% identity sequence for an amino acid sequence provided in that specification. In one embodiment, the humanized or human anti-CD3 binding domain is a scFv, and a light chain variable region comprising an amino acid sequence described in that specification is attached to a heavy chain variable region comprising an amino acid sequence described in this specification, through an scFv linker. The variable region of the light chain and variable region of the heavy chain of an scFv can be, for example, in any of the following orientations: variable region of the light chain-linker of scFv-variable region of the heavy chain or variable region of the heavy chainlinker of scFv-variable region of the light chain.
[095] In some cases, scFvs that bind to CD3 are prepared according to known methods. For example, scFv molecules can be produced by ligating VH and VL regions together using flexible polypeptide linkers. The scFv molecules comprise an scFv linker (for example, a Ser-Gly linker) with an optimized length and / or amino acid composition. Consequently, in some embodiments, the length of the scFv linker is such that the VH or VL domain can associate intermolecularly with the other variable domain to form the CD3 binding site. In certain modalities, these scFv linkers are short, that is, they consist of 0,
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 waste in amino acids. Thus, in certain cas the, the linkers in scFv consist of about in 12 or any less waste in
Petition 870190117813, of 11/14/2019, p. 73/156
69/133 amino acids. In the case of 0 amino acid residues, ο scFv linker is a peptide bond. In some embodiments, these scFv linkers consist of about 3 to about 15, for example, 8, 9 or 10 contiguous amino acid residues. Regarding the amino acid composition of the scFv linkers, peptides are selected that provide flexibility, do not interfere with variable domains, as well as allow inter-chain folding to place the two variable domains together to form a functional CD3 binding site. For example, scFv binders that comprise glycine and serine residues generally provide protease resistance. In some embodiments, linkers in an scFv comprise glycine and serine residues. The amino acid sequence of scFv linkers can be optimized, for example, by phage display methods, to increase binding to CD3 and the production yield of scFv. Examples of suitable peptide scFv linkers for binding a light chain variable domain and a heavy chain variable domain in an scFv include, without limitation, (GS) _n (SEQ ID NO: 157), (GGS) _n (SEQ ID NO: 158), (GGGS) _n (SEQ ID NO: 159), (GGSG) _n (SEQ ID NO: 160), (GGSGG) _n ( SEQ ID NO: 161) or (GGGGS) _n (SEQ ID NO: 162), where n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 In one embodiment, the scFv linker can be (GGGGS) 4 (SEQ ID NO: 163) or (GGGGS) s (SEQ ID NO: 164). Variation in the linker's length can retain or increase activity, giving rise to superior effectiveness in activity studies.
[096] In some embodiments, the CD3 binding domain of the PSMA-specific antigen binding protein for PSMA
Petition 870190117813, of 11/14/2019, p. 74/156
70/133 has an affinity for CD3 in cells that express CD3 with a Kd of 1,000 nM or less, 500 nM or less, 200 nM or less, 100 nM or less, 80 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.5 nM or less. In some embodiments, the CDMA-binding domain of the PSMA-specific antigen-binding protein has an affinity for CD3e, γ or δ with a Kd of 1,000 nM or less, 500 nM or less, 200 nM or less, 100 nM or less, 80 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.5 nM or less. In additional embodiments, the CD3-binding domain of the PSMA-specific antigen-binding protein has low affinity for CD3, that is, about 100 nM or greater.
[097] The affinity for binding to CD3 can be determined, for example, by the ability of the PSMA-specific antigen-binding protein itself or its CD3-binding domain to bind to CD3 coated on an assay plate; displayed on the surface of a microbial cell; in solution; etc. The binding activity of the PSMA-specific antigen-binding protein itself or its CD3-binding domain of the present disclosure can be tested by immobilizing the ligand (e.g., CD3) or the PSMA-specific antigen-binding protein itself of its binding domain to CD3, to a globule, substrate, cell, etc. Agents can be added in an appropriate buffer and the binding partners incubated for a period of time at a certain temperature. After washing to remove unbound material, the bound protein can be released with, for example, SDS,
Petition 870190117813, of 11/14/2019, p. 75/156
71/133 buffers with a high pH and the like, and analyzed, for example, by surface plasmon resonance (SPR).
[098] In some embodiments, the CD3-binding domains described in that specification comprise a polypeptide that has a sequence described in Table 7 (SEQ ID. N °: 34-88) and its sequences. In some embodiments, the CD3-binding domain comprises a polypeptide that has at least 70% -95% or more homology to a sequence described in Table 7 (SEQ ID. NO: 34-122). In some embodiments, the CD3-binding domain comprises a polypeptide that has at least 70%, 75%, 80%, 85%, 90%, 95% or more homology to a sequence described in Table 7 (SEQ ID. No.: 34-122). In some embodiments, the CD3-binding domain has a sequence that comprises at least a portion of a sequence described in Table 7 (SEQ ID. NO: 34-122). In some embodiments, the CD3-binding domain comprises a polypeptide comprising one or more of the sequences described in Table 7 (SEQ ID NO: 34-122).
[099] In certain embodiments, the CD3-binding domain comprises a scFv with a heavy chain CDR1 comprising the ID. SEQ. No. 49, and 56-67. In certain embodiments, the CD3-binding domain comprises a scFv with a heavy chain CDR2 comprising the ID. SEQ. No. 50, and 68-77. In certain embodiments, the CD3-binding domain comprises a scFv with a heavy chain CDR3 comprising the ID. SEQ. No. 51, and 78-87. In certain embodiments, the CD3-binding domain comprises a scFv with a light chain CDR1 comprising the ID. SEQ. No. 53, and 88-100. In certain modalities, the domain of connection to the
Petition 870190117813, of 11/14/2019, p. 76/156
72/133
CD3 comprises a scFv with a light chain CDR2 comprising the ID. SEQ. No. 54, and 101-113. In certain embodiments, the CD3-binding domain comprises a scFv with a light chain CDR3 comprising the ID. SEQ. No. 55, and 114-120.
[100] The affinity to bind to CD3 can be determined, for example, by the ability of the multispecific protein that comprises a PSMA-binding protein itself or its CD3-binding domain to bind to CD3 coated on an assay plate; displayed on the surface of a microbial cell; in solution; etc. The multispecific protein binding activity comprising a PSMA-binding protein itself or its CD3-binding domain according to the present disclosure to CD3 can be tested by immobilizing the ligand (for example, CD3) or said multispecific protein itself or its CD3 binding domain, a globule, substrate, cell etc. The binding activity of the multispecific protein comprising a PSMA-binding protein itself or its CD3-binding domain to bind to CD3 can be determined by immobilizing the ligand (for example, CD3) or said multispecific protein itself or its binding domain to PSMA, a globule, substrate, cell etc. In some embodiments, the link between the multispecific protein comprising a PSMA-binding protein and a target ligand (e.g., CD3) is determined, for example, by a binding kinetics assay. The binding kinetics test, in certain modalities, is performed using an OCTET® system. In these modalities, a first stage comprises the immobilization of
Petition 870190117813, of 11/14/2019, p. 77/156
73/133 a binder (for example, biotinylated CD3) on the surface of a biosensor (for example, a streptavidin biosensor) at an optimal charge density, followed by washing with an assay buffer to remove unbound binders; which is followed by association of the analyte, for example, the multispecific protein comprising a PSMA-binding protein with the linker; which is followed by exposure of the biosensor to a buffer that does not contain the analyte, thereby resulting in the dissociation of the multispecific protein comprising a PSMA binding protein from the ligand. Suitable blocking agents, for example, BSA, Barrel, Tween-20, PEG, gelatin, are used to block non-specific binding sites on the biosensor during the kinetics test. Binding kinetics data is subsequently analyzed using appropriate software (eg, ForteBio Octet software) to determine the association and dissociation rate constants for binding interaction between the multispecific protein comprising a PSMA binding protein and a binder.
[101] In one aspect, the specific PSMA-targeted proteins comprise a domain (A) that specifically binds to CD3, a domain (B) that specifically binds to human serum albumin (HSA) and a domain (C) that specifically links to PSMA. The three domains in specific proteins that target PSMA are arranged in any order. Thus, it is contemplated that the domain orders of the specific proteins targeted to PSMA are:
H ₂ N- (A) - (B) - (C) -COOH,
Petition 870190117813, of 11/14/2019, p. 78/156
74/133
H ₂ N- (A) - (C) - (B) -COOH,
H ₂ N- (B) - (A) - (C) -COOH, H ₂ N- (B) - (C) - (A) -COOH, H ₂ N- (C) - (B) - (A ) -COOH, or H ₂ N- (C) - (A) - (B) -COOH.
[102] In some embodiments, the specific proteins targeting PSMA have a domain order of H ₂ N- (A) - (B) - (C) -COOH. In some embodiments, the specific proteins targeting PSMA have a domain order of H ₂ N- (A) - (C) - (B) -COOH. In some embodiments, the specific proteins targeted to PSMA have a domain order of H ₂ N- (B) - (A) - (C) -COOH. In some embodiments, the specific proteins targeted to PSMA have a domain order of H ₂ N (B) - (C) - (A) -COOH. In some embodiments, the specific proteins targeted to PSMA have a domain order of H ₂ N- (C) - (B) - (A) -COOH. In some embodiments, the specific proteins targeted to PSMA have an H ₂ N- (C) - (A) - (B) -COOH domain order.
[103] In some embodiments, the specific proteins targeting PSMA have the HSA-binding domain as the middle domain, so the domain order is H ₂ N- (A) - (B) - (C) - COOH or H ₂ N- (C) - (B) - (A) -COOH. It is contemplated that in these modalities in which the HSA-binding domain is the middle domain, the CD3 and PSMA-binding domains receive additional flexibility to connect to their respective targets.
[104] In some embodiments, the specific PSMA-directed proteins described in this specification include a polypeptide that has
Petition 870190117813, of 11/14/2019, p. 79/156
75/133 is a sequence described in Table 10 (SEQ ID. No.: 147156) and subsequences thereof. In some embodiments, the triespecific antigen-binding protein comprises a polypeptide that has at least 70% -95% or more homology to a sequence described in Table 10 (SEQ ID: No. 147-156). In some embodiments, the triespecific antigen-binding protein comprises a polypeptide that has at least 70%, 75%, 80%, 85%, 90%, 95% or more of homology to a sequence described in Table 10 (ID. DE SEQ No. 1470-156). In some embodiments, the triespecific antigen-binding protein has a sequence that comprises at least a portion of a sequence described in Table 10 (SEQ ID NO: 147-156). In some embodiments, the PSMA-specific antigen-binding protein comprises a polypeptide comprising one or more of the sequences described in Table 10 (SEQ ID NO: 147-156). In additional embodiments, the PSMA-specific antigen-binding protein comprises one or more CDRs as described in the sequences in Table 10 (SEQ ID NO: 147-156).
[105] The specific PSMA-directed proteins described in this specification are designed to specifically target cells that express PSMA by recruiting cytotoxic T cells. This increases the effectiveness compared to ADCC (antibody-dependent cell-mediated cytotoxicity), which is the use of full-length antibodies directed to a single antigen and is not able to directly recruit cytotoxic T cells. In contrast, by engaging CD3 molecules specifically expressed in these cells, proteins
Petition 870190117813, of 11/14/2019, p. 80/156
76/133 tries specific to PSMA can cross-link cytotoxic T cells with cells that express PSMA in a highly specific way, thereby directing the cytotoxic potential of the T cell towards the target cell. The specific PSMA-directed proteins described in this specification engage cytotoxic T cells by binding to the CD3 proteins expressed on the surface, which form part of the TCR. The simultaneous binding of several PSMA-specific antigen-binding proteins to CD3 and PSMA expressed on the surface of particular cells causes T cell activation and mediates subsequent lysis of the cell expressing PSMA in particular. Thus, it is contemplated that specific proteins targeting PSMA exhibit potent, specific and efficient target cell death. In some embodiments, the specific PSMA-directed proteins described in this specification stimulate target cell death by cytotoxic T cells to eliminate pathogenic cells (for example, tumor cells that express PSMA). In some of these modalities, cells are selectively eliminated, thereby reducing the potential for toxic side effects.
[106] The PSMA-directed trypecific proteins described in this specification give additional therapeutic advantages over traditional monoclonal antibodies and other minor bispecific molecules. Generally, the effectiveness of recombinant protein pharmaceutical products depends, in large part, on the intrinsic pharmacokinetics of the protein itself. One of these benefits here is that the specific PSMA-directed proteins described in this specification
Petition 870190117813, of 11/14/2019, p. 81/156
77/133 have an extended pharmacokinetic elimination half-life because they have a half-life extension domain, such as a specific domain for HSA. In this regard, the specific PSMA-directed proteins described in this specification have an extended serum elimination half-life of about two, three, about five, about seven, about 10, about 12 or about 14 days , in some modalities. This contrasts with other binding proteins, such as BiTE or DART molecules, which have relatively much shorter elimination half-lives. For example, the bispecific scFv-scFv fusion molecule CD19 x CD3 BiTE requires drug release by continuous intravenous (i.v.) infusion due to its short elimination half-life. The longer intrinsic half-lives of the tried specific proteins targeting PSMA address this issue, thereby allowing increased therapeutic potential, such as low-dose pharmaceutical formulations, decreased periodic administration and / or new pharmaceutical compositions.
[107] The specific PSMA-directed proteins described in this specification also have an optimal size for increased tissue penetration and tissue distribution. Large sizes limit or prevent the penetration or distribution of the protein in the target tissues. The specific PSMA-directed proteins described in this specification prevent this by having a small size that allows for increased tissue penetration and distribution. Consequently, the specific PSMA-directed proteins described in this specification, in some modalities, have a size of about 50 kD
Petition 870190117813, of 11/14/2019, p. 82/156
78/133 to about 80 kD, about 50 kD to about 75 kD, about 50 kD to about 70 kD or about 50 kD to about 65 kD. In this way, the size of the specific proteins targeted to PSMA is advantageous in relation to IgG antibodies that are around 150 kD and the biTE diabody molecules
and DART, what have about 55 kD, but don't have half life extendedtherefore, they are debugged quickly through kidney. [108] In modalities additional, the proteins
the specific PSMA-directed features described in this specification have an optimum size for increased tissue penetration and distribution. In these modalities, the specific proteins targeting PSMA are built to be as small as possible while retaining specificity for their targets. Consequently, in these modalities, the specific PSMA-directed proteins described in this specification have a size of about 20 kD to about 40 kD or about 25 kD to about 35 kD to about 40 kD, up to about 45 kD, up to about 50 kD, up to about 55 kD, up to about 60 kD, up to about 65 kD. In some embodiments, the specific PSMA-directed proteins described in this specification have a size of about 50 kD, 49, kD, 48 kD, 47 kD, 46 kD, 45 kD, 44 kD, 43 kD, 42 kD, 41 kD , 40 kD, about 39 kD, about 38 kD, about 37 kD, about 36 kD, about 35 kD, about 34 kD, about 33 kD, about 32 kD, about 31 kD, about about 30 kD, about 29 kD, about 28 kD, about 27 kD, about 26 kD, about 25 kD, about 24 kD, about 23 kD, about 22 kD, about 21 kD or about
Petition 870190117813, of 11/14/2019, p. 83/156
79/133 of 20 kD. An exemplary approach to small size is through the use of single domain antibody (sdAb) fragments for each of the domains. For example, a particular PSMA-specific antigen-binding protein has an anti-CD3 sdAb, anti-HSA sdAb and a PSMA sdAb. This reduces the size of the exemplary PSMA-specific antigen-binding protein to below 40 kD. Thus, in some embodiments, the domains of the specific PSMA-directed proteins are all single domain antibody (sdAb) fragments. In other embodiments, the specific PSMA-directed proteins described in this specification comprise small molecule entity binders (SME) for HSA and / or PSMA. SME binders are small molecules with an average of about 500 to 2,000 Da in size and are attached to the specific proteins targeted to PSMA by known methods, for example, binding or conjugation of sortase. In such cases, one of the domains of the PSMA-specific antigen-binding protein is a sortase recognition sequence, for example, LPETG (SEQ ID. NO: 57). To attach an SME binder to the PSMA-specific antigen-binding protein with a sortase recognition sequence, the protein is incubated with a sortase and an SME binder, and thus the sortase attaches the SME binder to the recognition. Known SME binders include MIP-1072 and MIP-1095 which bind to the prostate specific membrane antigen (PSMA). In still other modalities, the PSMA-bound domain of specific PSMA-directed proteins described in this specification includes a peptide
Petition 870190117813, of 11/14/2019, p. 84/156
80/133 knottin for connection to PSMA. Knott ins are disulfide stabilized peptides with a cistern knot framework and have average sizes of about 3.5 kD. Knott ins have been contemplated for binding to certain tumor molecules, such as PSMA. In additional embodiments, the PSMA-binding domain of specific PSMA-directed proteins described in this specification includes a natural PSMA ligand.
[109] Another feature of the specific PSMA-directed proteins described in this specification is that they are of a unique polypeptide design with flexible binding of their domains. This allows for easy production and manufacture of the specific proteins targeted to PSMA, as they can be encoded by a single cDNA molecule to be easily incorporated into a vector. In addition, as the specific PSMA-directed proteins described in this specification are a single monomeric polypeptide chain, there are no issues related to chain matching or the need for dimerization. It is contemplated that the specific PSMA-directed proteins described in this specification have a reduced tendency to aggregate, unlike other reported molecules, for example, bispecific proteins with Fc-gamma immunoglobulin domains.
[110] In the specific PSMA-directed proteins described in this specification, the domains are linked by internal linkers LI and L2, where LI binds the first and second domains of the specific proteins targeting PSMA and L2 binds the second and third domains
Petition 870190117813, of 11/14/2019, p. 85/156
81/133 of the specific proteins targeting PSMA. LI and L2 linkers have an optimized length and / or composition of amino acids. In some embodiments, the LI and L2 linkers are of the same length and amino acid composition. In other modalities, LI and L2 are different. In certain embodiments, the internal linkers LI and / or L2 are short, that is, they consist of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues. Thus, in certain cases, the internal linkers consist of about 12 or less amino acid residues. In the case of 0 amino acid residues, the internal linker is a peptide bond. In certain embodiments, the internal linkers LI and / or L2 are long, that is, they consist of 15, 20 or 25 amino acid residues. In some embodiments, these internal linkers consist of about 3 to about 15, for example, 8, 9 or 10 contiguous amino acid residues. In relation to the amino acid composition of the internal linkers LI and L2, peptides are selected with properties that give flexibility to the specific proteins targeted to PSMA, do not interfere with the binding domains, as well as resist protease dividing. For example, residues of glycine and serine generally provide resistance to protease. Examples of suitable internal linkers for binding domains in the specific proteins targeted to PSMA include, without limitation, (GS) _n (SEQ ID NO: 157), (GGS) _n (SEQ ID NO: 158 ), (GGGS) _n (SEQ ID NO: 159), (GGSG) _n (SEQ ID NO: 160), (GGSGG) _n (SEQ ID NO: 161) or (GGGGS) _n (SEQ ID. N °: 162), where n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In one embodiment, the internal linker LI and / or L2 is
Petition 870190117813, of 11/14/2019, p. 86/156
82/133 (GGGGS) 4 (SEQ ID NO: 163) or (GGGGS) 3 (SEQ ID NO: 164).
Modifications to the PSMA-binding protein [111] The PSMA-binding proteins described in this specification include derivatives or analogues in which (i) an amino acid is replaced with an amino acid residue that is not encoded by the genetic code, (ii) the mature polypeptide is fused with another compound, for example, polyethylene glycol, or (iii) additional amino acids are fused to the protein, for example, as a leader or secretory sequence or a sequence to block an immunogenic domain and / or for purification of the protein.
[112] Typical modifications include, without limitation, acetylation, acylation, ADP-ribosylation, amidation, covalent adhesion of flavin, covalent adhesion of a heme portion, covalent adhesion of a nucleotide or nucleotide derivative, covalent adhesion of a lipid or derivative of lipid, phosphatidylinositol covalent adhesion, crosslinking, cyclization, disulfide bond formation, demethylation, covalent crosslinking formation, cystine formation, pyroglutamate formation, formulation, carboxylation range, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation myristylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfatization, RNA-mediated addition of transferring amino acids to proteins such as arginylation and ubiquitination.
[113] Modifications are made anywhere in the PSMA-binding proteins described in that specification, including in the peptide framework, in the chains
Petition 870190117813, of 11/14/2019, p. 87/156
83/133 side of amino acids and at the amino or carboxyl termini. Certain common peptide modifications that are useful for modifying PSMA-binding proteins include glycosylation, lipid adhesion, sulfatization, gamma carboxylation of glutamic acid residues, hydroxylation, blocking of the amino or carboxyl group on a polypeptide, or both, by a covalent modification, and ADP-ribosylation.
Polynucleotides encoding PSMA-binding proteins [114] Polynucleotide molecules encoding a PSMA-binding protein are also provided in some embodiments as described in that specification. In some embodiments, polynucleotide molecules are provided as a DNA construct. In other embodiments, the polynucleotide molecules are provided as a messenger RNA transcript.
[115] Polynucleotide molecules are constructed by known methods, for example, by combining the genes encoding the anti-PSMA binding protein, operably linked to a suitable promoter and, optionally, a suitable transcription terminator, and expressing it a in bacteria or another appropriate expression system, for example, CHO cells.
[116] In some embodiments, the polynucleotide is inserted into a vector, preferably an expression vector, which represents an additional modality. This recombinant vector can be constructed according to known methods. Vectors of particular interest include plasmids, phagemids, phage derivatives, viruses (e.g., retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, lentiviruses and the like) and cosmids.
Petition 870190117813, of 11/14/2019, p. 88/156
84/133 [117] Various expression vector / host systems can be used to contain and express the polynucleotide encoding the described PSMA-binding protein polypeptide. Examples of expression vectors for expression in E. coli are pSKK (Le Gall et al., J. Immunol. Methods. (2004) 285 (1): 111-27), pcDNA5 (Invitrogen) for expression in mammalian cells, PICHIAPINK ™ Yeast Expression Systems (Invitrogen), Baculovirus Expression System BACUVANCE ™ (GenScript).
[118] Thus, the albumin-binding proteins PSMA as described in this specification, in some embodiments, are produced by introducing a vector that encodes the protein as described above into a host cell and culturing said host cell under conditions under which protein domains are expressed, can be isolated and, optionally, further purified.
Production of PSMA-binding proteins [119] In this specification, in some embodiments, a process for producing a PSMA-binding protein is revealed. In some embodiments, the process comprises culturing a host transformed or transfected with a vector comprising a nucleic acid sequence that encodes a PSMA-binding protein under conditions that allow expression of the PSMA-binding protein and recovery and purification of the protein produced from the culture.
[120] In an additional modality, a process is provided to improve one or more properties, for example, affinity, stability,
Petition 870190117813, of 11/14/2019, p. 89/156
85/133 thermal tolerance, cross-reactivity, etc., of PSMA binding proteins and / or multispecific binding proteins comprising a PSMA binding protein described in that specification, compared with a reference binding compound. In some embodiments, several single substitution libraries are provided, each corresponding to a different domain, or amino acid segment, of the PSMA binding protein or reference binding compound, so that each member of the unique substitution library codes only a single amino acid change in its corresponding domain, or amino acid segment. This typically allows all potential substitutions at a large protein or protein-binding site to be probed with a few small libraries. In some embodiments, the various domains form or cover a contiguous amino acid sequence of the PSMA-binding protein or a reference binding compound. Nucleotide sequences from different single substitution libraries overlap with nucleotide sequences from at least one other single substitution library. In some embodiments, several single replacement libraries are designed, so that each member overlaps with each member of each single replacement library that encodes an adjacent domain.
[121] The binding compounds expressed from these single substitution libraries are selected separately to obtain a subset of variants in each library that have properties at least as good as those of the reference binding compound and whose
Petition 870190117813, of 11/14/2019, p. 90/156
86/133 resulting library is reduced in size. Generally, the number of nucleic acids encoding the selected set of binding compounds is less than the number of nucleic acids encoding members of the original single substitution library. These properties include, without limitation, affinity for a target compound, stability to various conditions such as, for example, heat, high or low pH, enzymatic degradation, cross-reactivity to other proteins and the like. The compounds selected from each single substitution library are referred to in this specification interchangeably as pre-candidate compounds or pre-candidate proteins. Nucleic acid sequences that encode the pre-candidate compounds from the separate single substitution libraries are then scrambled in a PCR to generate a scrambled library, using PCR-based gene scrambling techniques.
[122] An exemplary evaluation process workflow is described in this specification. Pre-candidate compound libraries are generated from single substitution libraries and selected for binding to the target protein (or proteins), and then the pre-candidate libraries are shuffled to produce a nucleic acid library that encodes candidate compounds that, in turn, they are cloned into a convenient expression vector, for example, a phagemid expression system. Candidate compounds that express phage then undergo one or more rounds of selection to improve the desired properties, for example, binding affinity to a target molecule. Target molecules
Petition 870190117813, of 11/14/2019, p. 91/156
87/133 can be adsorbed or otherwise attached to a surface of a well or other reaction vessel, or the target molecules can be derivatized with a binding moiety, for example, biotin which, after incubation with binding compounds candidates, can be captured with a complementary portion, for example, streptavidin, attached to blood cells, for example, magnetic blood cells, for washing. In exemplary selection regimes, candidate binding compounds undergo a washing step so that only candidate compounds with very low dissociation rates from a target molecule are selected. Exemplary washing times for these modalities are about 10 minutes, about 15 minutes, about 20 minutes, about 20 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours; or, in other modalities, about 24 hours; or, in other modalities, about 48 hours; or, in other modalities, about 72 hours. Clones isolated after selection are amplified and subjected to an additional selection cycle or analyzed, for example, by sequencing and by producing comparative measurements of binding affinity, for example, by ELISA, surface plasmon resonance (SPR), interferometry bi-layer (e.g., OCTET® system, Pall Life Sciences, ForteBio, Menlo Park, CA) or the like.
[123] In some embodiments, the above process is implemented to identify one or more PSMA-binding proteins with increased binding affinity,
Petition 870190117813, of 11/14/2019, p. 92/156
88/133 increased cross-reactivity for a selected set of binding targets, compared to that of a reference PSMA binding protein. In some embodiments, the reference binding protein is a protein that has the amino acid sequence as shown in the ID. SEQ. N °: 4. In some embodiments, the reference binding protein is a protein that has the amino acid sequence as shown in the ID. SEQ. N °: 19. In certain embodiments, single-substitution libraries are prepared by varying codons in the VH region of the reference PSMA-binding protein, including codons in framework regions and in CDRs. In another embodiment, the locations where codons are varied comprise the CDRs of the reference PSMA binding protein heavy chain, or a subset of those CDRs, for example, exclusively CDR1, exclusively CDR2, exclusively CDR3, or pairs thereof. In another modality, the locations where codons are varied occur exclusively in framework regions. In some modalities, a library comprises single codon changes exclusively from a reference PSMA-binding protein exclusively in VH numbering framework regions in the range 10 to 111. In another embodiment, the locations where codons are varied comprise the CDR3s of the heavy chain of the reference PSMA-binding protein, or a subset of those CDR3s. In another modality, the number of locations where codons from regions encoding VH are varied is in the range of 10 to 111, so that up to 80 locations are in the framework region. After preparing the single replacement library, as described above, the following steps are performed: (a)
Petition 870190117813, of 11/14/2019, p. 93/156
89/133 expressing separately each member of each unique substitution library as a pre-candidate protein; (b) selection of members of each single substitution library that encode pre-candidate proteins that bind to a binding partner that may or may not differ from the original binding target [e.g., a desired cross-reaction target (or targets) ]; (c) shuffling selected library members in a PCR to produce a shuffled combinatorial library; (d) expression of shuffled library members as candidate PSMA-binding proteins; and (e) selecting members of the library shuffled one or more times for candidate PSMA-binding proteins that bind to the original binding partner, and potentially (f) additional selection of candidate proteins for binding to the target (or targets) of desired cross-reaction thereby providing a PSMA-binding protein encoded by the nucleic acid with increased cross-reactivity for one or more substances with respect to the reference PSMA-binding protein, without loss of affinity for the original ligand. In additional modalities, the method can be implemented to obtain a PSMA-binding protein with decreased reactivity for a substance (or substances) or compound (or compounds) or epitope (or epitopes) that cross-react selected by substituting the step (f) with the following step: depletion of candidate binding compounds one or more times from the subset of candidate PSMA binding proteins that bind to the unwanted compound that cross-reacts.
Pharmaceutical compositions [124] Also, in some modalities, are provided
Petition 870190117813, of 11/14/2019, p. 94/156
90/133 pharmaceutical compositions comprising a PSMA binding protein described in that specification, a vector comprising the polynucleotide encoding the polypeptide of the PSMA binding proteins or a host cell transformed by that vector and at least one pharmaceutically acceptable carrier. The term pharmaceutically acceptable carrier includes, without limitation, any carrier that does not interfere with the effectiveness of the biological activity of the ingredients and that is not toxic to the patient to whom it is administered. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, for example, oil / water emulsions, various types of wetting agents, sterile solutions, etc. These carriers can be formulated by conventional methods and can be administered to the individual in an appropriate dose. Preferably, the compositions are sterile. Such compositions can also contain adjuvants such as, for example, preservative agents, emulsifying agents and dispersing agents. The prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents.
[125] In some embodiments of the pharmaceutical compositions, the PSMA-binding protein described in this specification is encapsulated in nanoparticles. In some embodiments, nanoparticles are fullerenes, liquid crystals, liposomes, quantum dots, superparamagnetic nanoparticles, dendrimers or nanobonds. In other embodiments of the pharmaceutical compositions, the PSMA-binding protein is attached to
Petition 870190117813, of 11/14/2019, p. 95/156
91/133 liposomes. In some cases, the PSMA-binding protein is conjugated to the surface of liposomes. In some cases, the PSMA-binding protein is encapsulated within a liposome shell. In some cases, the liposome is a cationic liposome.
[126] The PSMA-binding proteins described in this specification are contemplated for use as a medicine. Administration is carried out in different ways, for example, by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration. In some embodiments, the route of administration depends on the type of therapy and the type of compound contained in the pharmaceutical composition. The dosage regimen will be determined by the attending physician and other clinical factors. Dosages for any patient depend on many factors, including size, body surface area, age, sex of the patient, the particular compound to be administered, the time and route of administration, the type of therapy, general health and others drugs that are being administered concurrently. An effective dose refers to the amounts of the active ingredient that are sufficient to affect the course and severity of the disease, leading to a reduction or remission of this pathology, and can be determined using known methods.
Treatment methods [127] Also provided in this specification, in some modalities, methods and uses for stimulating the immune system of an individual in need, which include the administration of a PSMA-binding protein or a multispecific binding protein that
Petition 870190117813, of 11/14/2019, p. 96/156
92/133 comprises the PSMA-binding protein described in that specification. In some cases, the administration of a PSMA-binding protein described in that specification induces and / or sustains cytotoxicity to a cell that expresses a target antigen. In some cases, the cell that expresses a target antigen is a cancer or tumor cell, a cell infected by a virus, a cell infected by a bacterium, an autoreactive T or B cell, damaged red blood cells, arterial plaques or tissue fibrotic.
[128] Also included in this specification are methods and uses for treating a disease, disorder or condition associated with a target antigen, which include administering to an individual who needs a PSMA-binding protein or a multispecific binding comprising PSMA binding protein described in that specification. Diseases, disorders or conditions associated with a target antigen include, without limitation, viral infection, bacterial infection, autoimmune disease, transplant rejection, atherosclerosis or fibrosis. In other embodiments, the disease, disorder or condition associated with a target antigen is a proliferative disease, a tumor disease, an inflammatory disease, an immune disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, an parasitic reaction, a graft-versus-host disease or a host-versus-graft disease. In one embodiment, the disease, disorder, or condition associated with a target antigen is cancer. In one case, cancer is a hematological cancer. In another case, cancer is prostate cancer.
Petition 870190117813, of 11/14/2019, p. 97/156
93/133 [129] In some modalities, prostate cancer is an advanced stage prostate cancer. In some modalities, prostate cancer is resistant to drugs. In some modalities, prostate cancer is resistant to antiandrogen drugs. In some modalities, prostate cancer is metastatic. In some modalities, prostate cancer is metastatic and drug resistant (for example, resistant to antiandrogen drugs). In some modalities, prostate cancer is resistant to castration. In some modalities, prostate cancer is
metastatic and resistant castration. In some modalities, O cancer of prostate is resistant to enzalutamide. In some modalities, cancer of the prostate it's tough The enzalutamide and abiraterone In some modalities, O cancer of prostate is resistant to enzalutamide, abiraterone and bicalutamide. In some
modalities, prostate cancer is resistant to docetaxel. In some of these modalities, prostate cancer is resistant to enzalutamide, abiraterone, bicalutamide and docetaxel.
[130] In some embodiments, administration of a single-domain anti-PSMA antibody described in that specification or a specific PSMA-directed protein described in that specification inhibits the growth of prostate cancer cells; inhibits the migration of prostate cancer cells; inhibits invasion of prostate cancer cells; improves symptoms of prostate cancer; reduces the size of a prostate cancer tumor; reduces the number of prostate cancer tumors; reduces the number of prostate cancer cells; induces
Petition 870190117813, of 11/14/2019, p. 98/156
94/133 necrosis of prostate cancer cells, pyroptosis, oncosis, apoptosis, autophagy, or other cell death; or enhances the therapeutic effects of a compound selected from the group consisting of enzalutamide, abiraterone, docetaxel, bicalutamide, and any combinations thereof.
[131] In some embodiments, the method comprises inhibiting the growth of prostate cancer cells by administering a single domain anti-PSMA antibody described in that specification or a specific PSMA-directed protein described in that specification. In some embodiments, the method comprises inhibiting the migration of prostate cancer cells by administering a single domain anti-PSMA antibody described in that specification or a specific PSMA-directed protein described in that specification. In some embodiments, the method comprises inhibiting prostate cancer cell invasion by administering a single domain anti-PSMA antibody described in that specification or a specific PSMA-directed protein described in that specification. In some embodiments, the method comprises ameliorating the symptoms of prostate cancer by administering a single domain anti-PSMA antibody described in that specification or a specific PSMA-directed protein described in that specification. In some embodiments, the method comprises reducing the size of a prostate cancer tumor by administering a single domain anti-PSMA antibody described in that specification or a specific PSMA-directed protein described in that specification. In
Petition 870190117813, of 11/14/2019, p. 99/156
95/133 In some modalities, the method comprises reducing the number of prostate cancer tumors by administering a single domain anti-PSMA antibody described in that specification or a specific PSMA-directed protein described in that specification. In some embodiments, the method comprises reducing the number of prostate cancer cells by administering a single-domain anti-PSMA antibody described in that specification or a specific PSMA-directed protein described in that specification. In some modalities, the method comprises inducing necrosis of prostate cancer cells, pyroptosis, oncosis, apoptosis, autophagy, or other cell death by administering a specific PSMA-directed protein described in this specification.
[132] As used in this specification, in some modalities, the term treatment or that treats or treats refers to therapeutic treatment in which the objective is to slow down (alleviate) an unwanted physiological condition, disorder or disease, or to obtain clinical results beneficial or desired. For the purposes described in this specification, beneficial or desired clinical results include, without limitation, symptom relief; decrease in the extent of the condition, disorder or disease; stabilization (that is, it does not worsen) the state of the condition, disorder or disease; delay the onset or slow down the progression of the condition, disorder or disease; improvement of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or improvement of the condition, disorder or disease.
Petition 870190117813, of 11/14/2019, p. 100/156
96/133
Treatment includes developing a clinically significant response, without excessive levels of side effects. Treatment also includes prolonging survival when compared to expected survival if you do not receive treatment. In other modalities, treatment or that treats or treats refers to prophylactic measures, in which the objective is to delay the onset or reduce the severity of an unwanted physiological condition, disorder or disease, such as, for example, in a person predisposed to a disease ( for example, an individual who carries the genetic marker for a disease such as breast cancer).
[133] In some embodiments of the methods described in that specification, the PSMA-binding proteins or a multispecific binding protein comprising the PSMA-binding protein described in that specification are administered in combination with an agent for the treatment of the disease, particular disorder or condition. Agents include, but are not limited to, therapies involving antibodies, small molecules (eg chemotherapy), hormones (steroidal, peptide and the like), radiotherapy (γ-rays, X-rays and / or the targeted release of radioisotopes, microwaves, radiation) UV and the like), gene therapies (for example, antisense, retroviral therapy and the like) and other immunotherapies. In some embodiments, the PSMA-binding protein or a multispecific binding protein comprising the PSMA-binding protein described in that specification is administered in combination with antidiarrheal agents, antiemetic agents, analgesics, opioids and / or non-steroidal anti-inflammatory agents . In
Petition 870190117813, of 11/14/2019, p. 101/156
In some embodiments, PSMA-binding proteins or a multispecific binding protein comprising a PSMA-binding protein as described in that specification are administered before, during or after surgery. According to another embodiment of the invention, kits for detecting prostate cancer are provided for diagnosis, prognosis or monitoring. The kits include the aforementioned PSMA-binding proteins (for example, labeled anti-PSMA single domain antibodies or antigen-binding fragments thereof), and one or more compounds for detection of the marker. In some embodiments, the marker is selected from the group consisting of a fluorescent marker, an enzyme marker, a radioactive marker, an active nuclear magnetic resonance marker, a luminescent marker and a chromophore marker.
[134] An additional embodiment provides one or more of the binding proteins described above, for example, single-domain anti-PSMA antibodies or antigen-binding fragments thereof, packaged in lyophilized form, or packaged in an aqueous medium. In another aspect of the disclosure, methods are provided for detecting the presence of PSMA, or a cell that expresses PSMA, in a sample. These methods include contacting the sample with any of the aforementioned PSMA-binding proteins (for example, single-domain anti-PSMA antibodies or antigen-binding fragments thereof) that specifically bind to an extracellular domain of PSMA, for one sufficient time to allow the formation of a complex between the antibody or antigen-binding fragment of this and PSMA, and detection of the PSMA-antibody complex or PSMA-fragment of
Petition 870190117813, of 11/14/2019, p. 102/156
98/133 binding to the antigen. In some embodiments, the presence of a complex in the sample is indicative of the presence in the sample of PSMA or a cell that expresses PSMA. In another aspect, the disclosure provides other methods for diagnosing a PSMA-mediated disease in an individual. These methods include administering to an individual suspected of having or previously diagnosed with a PSMA-mediated disease of an amount of any of the above-mentioned PSMA-binding proteins (for example, single-domain anti-PSMA antibodies or fragments of binding to the PSMA) antigen) that specifically bind to an extracellular domain of the prostate-specific membrane antigen. The method also includes allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and detecting the formation of the PSMA-antibody complex or the PSMA-antibody fragment-binding complex to the target epitope. The presence of a complex in the individual suspected of having or previously diagnosed with prostate cancer is indicative of the presence of a disease mediated by PSMA.
[135] In certain methods, PSMA-mediated disease is prostate cancer. In other modalities, PSMA-mediated disease is non-prostate cancer, such as those selected from the group consisting of bladder cancer, including transitional cell carcinoma; pancreatic cancer, including pancreatic duct carcinoma; lung cancer, including non-small cell lung carcinoma; kidney cancer, including conventional kidney cell carcinoma; sarcoma, including soft tissue sarcoma; breast cancer, including breast carcinoma; cancer of
Petition 870190117813, of 11/14/2019, p. 103/156
99/133 brain, including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer, including colonic carcinoma; testicular cancer, including testicular embryonic carcinoma; and melanoma, including malignant melanoma.
[136] In some embodiments of the aforementioned methods, PSMA-binding proteins (for example, anti-PSMA single domain antibodies or antigen-binding fragments thereof) are labeled. In other embodiments of the methods cited above, a second antibody is administered to detect the first antibody or antigen-binding fragment thereof. In an additional aspect of the disclosure, methods are provided for assessing the prognosis of an individual with a PSMA-mediated disease. Such methods include administering to an individual suspected of having or previously diagnosed with a PSMA-mediated disease of an effective amount of any of the above-mentioned PSMA-binding proteins (for example, anti-PSMA single domain antibodies or binding fragments to their antigen), allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and detection of the formation of the complex at the target epitope. The amount of the complex in the individual suspected of having or previously diagnosed with a PSMA-mediated disease is indicative of the prognosis.
[137] In another aspect of the disclosure, methods are provided for assessing the effectiveness of a treatment for an individual with a PSMA-mediated disease. These methods include administering to an individual who has or was previously diagnosed with a PSMA-mediated disease of a
Petition 870190117813, of 11/14/2019, p. 104/156
100/133 effective amount of any of the aforementioned PSMA-binding proteins, for example, single-domain anti-PSMA antibodies or antigen-binding fragments thereof, allowing the formation of a complex between the antibody or antigen-binding fragment of this and PSMA, and detection of complex formation to the target epitope. The amount of the complex in the individual suspected of having or previously diagnosed with a PSMA-mediated disease is indicative of the effectiveness of the treatment. In certain embodiments, the disease mediated by PSMA is prostate cancer. In other modalities, PSMA-mediated disease is non-prostate cancer. In those modalities, non-prostate cancer is preferably selected from the group consisting of bladder cancer, including transitional cell carcinoma; pancreatic cancer, including pancreatic duct carcinoma; lung cancer, including non-small cell lung carcinoma; kidney cancer, including conventional kidney cell carcinoma; sarcoma, including soft tissue sarcoma; breast cancer, including breast carcinoma; brain cancer, including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer, including colonic carcinoma; testicular cancer, including testicular embryonic carcinoma; and melanoma, including malignant melanoma. In still other embodiments, the antibody or antigen-binding fragment thereof is labeled. In additional embodiments, a second antibody is administered to detect the first antibody or antigen-binding fragment thereof.
[138] In accordance with yet another aspect of the disclosure, methods are provided for inhibiting the growth of a cell
Petition 870190117813, of 11/14/2019, p. 105/156
101/133 which expresses PSMA. These methods include contacting a cell that expresses PSMA with an amount of at least one of the antibodies or antigen-binding fragments of those mentioned above that specifically binds to an extracellular domain of PSMA effective to inhibit the growth of the cell that expresses PSMA.
EXAMPLES [139] The examples below further illustrate the described modalities, without limiting the scope of the invention. Example 1: Generation of single anti-PSMA domain antibody variants with equivalent or enhanced binding properties to a parental single anti-PSMA domain antibody
Characterization of parental anti-PSMA phage [140] The specific binding of parental anti-PSMA phage to a PSMA antigen was determined (Table 1)
Single-substituted PSMA sdAb phage libraries selected in cyan PSMA [141] A single substitution library was provided for each of the three CDR domains. Single replacement libraries were linked to Cynomolgus PSMA and then washed in buffer for 30 minutes. Phages switched on at 0 and 30 minutes were rescued and counted. Phages selected using a 30-minute wash in the buffer were used to create two independent phage combinatorial libraries. Combinatorial anti-PSMA libraries [142] Cynomolgus' PSMA was used as the selection target for three rounds of selection. The wells were washed for 2 to 4 hours after combinatory phage binding from two independent libraries for three rounds of selection.
Petition 870190117813, of 11/14/2019, p. 106/156
102/133
PCRed inserts from the third round of selection were subcloned into the p34 expression vector. Ninety-six clones were chosen, DNA was purified, sequenced and transfected in Expi293 cells.
Single-substituted PSMA sdAb phage libraries selected in huPSMA [143] A single substitution library was provided for each of the three CDR domains. Single replacement libraries were linked to human PSMA and then washed in buffer containing 30 pg / ml h of PSMA-Fc for 24 hours. Phages switched on at 0 and 24 hours were rescued and counted. Phages selected using competitive 24-hour washing were used to create a combinatorial phage library.
Combinatorial anti-PSMA libraries [144] Human PSMA was used as the target of selection for three rounds of selection. The wells were washed in buffer containing 30 pg / ml - 850 pg / ml of human PSMA-Fc for 24 - 96 hours after combinatorial phage binding for three rounds of selection. PCRed inserts from the third round of selection were subcloned into the p34 expression vector. 96 clones were chosen, DNA was purified, sequenced and transfected in Expi293 cells.
Measurement of binding affinity [145] Supernatants were used to estimate Kd, kon and koff (or kdis) to human and Cynomolgus PSMA using the OCTET® system. Several clones were selected for further characterization (Table 1), based on their binding affinities, and constant in the association and dissociation rate for interaction with human PSMA, compared with
Petition 870190117813, of 11/14/2019, p. 107/156
103/133 the parental sdAb, as well as profiles of robust production, aggregation and stability. Parental sdAb is listed as Anti-PSMA wt sdAb.6his in Table 1.
Table 1: Binding affinity (Kd) of various PSMA binding proteins to human PSMA.
Kd (hFc. Flag.hPSMA) kon (1 / Ms) kdis (1 / s) Anti-PSMA wt sdAb.6his 15.0 nM 8.77E + 05 1.32E-02 anti-PSMA E31P sdAb.6his 9.5 nM 3.83E + 05 3.66E-03 anti-PSMA T56Q sdAb.6his 5.6 nM 8.22E + 05 4.61E-03 anti-PSMA G55K sdAb.6his 4.5 nM 5.5 6E + 0 5 2.48E-03 anti-PSMA S33HT50D G97SsdAb.6his 6.7 nM 8.00E + 05 5.38E-03 anti-PSMA S33HG97SsdAb.6his 0.21 nM 9.36E + 05 1.97E-05
Example 2: Methods for evaluating the binding and cytotoxic activities of exemplary PSMA-targeting antigen-binding molecules to exemplary PSMA
Protein production [146] Sequences of triespecific molecules were cloned into the mammalian expression vector pcDNA 3.4 (Invitrogen), preceded by a leader sequence and followed by a Histidine Tag 6x (SEQ ID. NO: 33). Expi293F cells (Life Technologies A14527) were kept in suspension in Optimum Growth Vials (Thomson) between 0.2 to 8 x le6 cells / ml in Expi293 medium. Purified plasmid DNA was transfected into Expi293 cells according to the Expi293 Expression System Kit protocols (Life Technologies, A14635), and maintained for 4-6 days post-transfection. Conditioned medium was partially purified
Petition 870190117813, of 11/14/2019, p. 108/156
104/133 by affinity chromatography and desalination. Triespecific proteins were subsequently polished by ion exchange or, alternatively, concentrated with Amicon Ultra centrifugal filtration units (EMD Millipore), applied to the Superdex 200 size exclusion medium (GE Healthcare) and resolved in a neutral buffer containing excipients. The pooling of the fractions and the final purity were evaluated by SDS-PAGE and analytical SEC.
Affinity measurements [147] The affinities of all binding domain molecules were measured by bi-layer inferometry using an Octet instrument.
[148] PSMA affinities were measured by loading human PSMA-Fc protein (100 nM) onto anti-human IgG Fc biosensors for 120 seconds, followed by a 60-second baseline, and then associations were measured by incubation of the tip of the sensor in a series of dilutions of the molecules triespecificas for 180 seconds, followed by dissociation for 50 seconds. Affinities for EGFR and CD3 were measured by loading human EGFR-Fc protein or human CD3-Flag-Fc protein, respectively (100 nM) onto anti-human IgG Fc biosensors for 120 seconds, followed by a 60-second baseline , and then the associations were measured by incubating the sensor tip in a series of dilutions of the triespecific molecules for 180 seconds, followed by dissociation for 300 seconds. Affinities for human serum albumin (HSA) were measured by loading biotinylated albumin onto streptavidin biosensors, and then following the same kinetic parameters used for CD3 affinity measurements. Every
Petition 870190117813, of 11/14/2019, p. 109/156
105/133 steps were performed at 30 ° C in barracks 0.25% in phosphate buffered saline.
Cytotoxicity assays [149] A human T cell-dependent cell cytotoxicity (TDCC) assay was used to measure the ability of T cell engagers, including triespecific molecules, to target T cells to kill tumor cells (Nazarian et al 2015. J. Biomol, Screen. 20: 519-27). In this assay, T cells and target cells from the cancer cell line are mixed together in a 10: 1 ratio on a 384-well plate, and varying amounts of T-cell engagement are added. After 48 hours, T cells are washed away leaving target cells that have not been killed by T cells attached to the plate. To quantify the remaining viable cells, the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) is used. In some cases, the target cells are genetically modified to express luciferase. In these cases, the viability of the target cells is assessed by evaluating a luminescent luciferase assay with STEADYGLO® reagent (Promega), in which the viability is directly proportional to the amount of luciferase activity.
Stability assays [150] The stability of triespecific binding proteins was evaluated at low concentrations in the presence of non-human primate serum. TriTACs were diluted to 33 pg / ml in Cynomolgus serum (BioReclamationIVT) and incubated for 2 at 37 ° C or subjected to five freeze / thaw cycles. After treatment, the samples were evaluated in
Petition 870190117813, of 11/14/2019, p. 110/156
106/133 cytotoxicity (TDCC) and its remaining activity was compared with untreated stock solutions.
Xenograft assays [151] The in vivo efficacy of triespecific binding proteins was evaluated in xenograft experiments (Crown Bioscience, Taicang). NOD / SCID mice deficient in the common gamma chain (NCG, Model Animal Research Center of Nanjing University) were inoculated on day 0 with a mixture of 5e6 human 22Rvl prostate cancer cells and 5e6 resting human T cells, which were isolated from a healthy human donor. The mice were randomized into three groups, and treated with vehicle, 0.5 mg / kg PSMA TriTAC C324 or 0.5 mg / kg PSMA BiTE. The treatments were administered daily for 10 days by means of an i.v. bolus injection. The animals were checked daily for morbidity and mortality. Tumor volumes were determined twice a week with a caliper. The study was completed after 30 days.
PK assays [152] The purpose of this study was to evaluate the pharmacokinetics of single dose triespecific binding proteins after intravenous injection. Two experimentally virgin Cynomolgus monkeys per group (1 male and 1 female) received compound by means of a slow bolus IV injection administered over approximately 1 minute. After administration of the dose, observations were made on the side of the cage once a day and body weights were recorded weekly. Blood samples were collected and processed to serum for pharmacokinetic analysis for 21 days post dose administration.
Petition 870190117813, of 11/14/2019, p. 111/156
107/133 [153] Test article concentrations were determined from monkey serum with an electroluminescent reading (Meso Scale Diagnostics, Rockville). 96-well plates with immobilized recombinant CD3 were used to capture the analyte. Detection was performed with recombinant PSMA, marked with sulfo, in an MSD reader according to the manufacturer's instructions.
Example 3: Evaluation of the impact of CD3 affinity on the properties of exemplary tries specific PSMA molecules [154] Try specific molecules directed to PSMA with distinct CD3 binding domains were studied to demonstrate the effects of altering affinity for CD3. A triespecific molecule targeting the exemplary PSMA is illustrated in Figure 1. Table 2 lists the affinity of each molecule for the three binding partners (PSMA, CD3, HSA). Affinities were measured by bi-layer interferometry using an Octet instrument (Pall Forté Bio). Reduced affinity for CD3 leads to a loss in potency in terms of T-cell-mediated cellular toxicity (Figures 2A-C). The pharmacokinetic properties of these triespecific molecules have been evaluated in Cynomolgus monkeys. Molecules with high CD3 affinity such as TriTAC C236 have a terminal half-life of approximately 90 h (Figure 3). Despite the altered ability to bind CD3 to T cells, the terminal half-life of two molecules with different CD3 affinities shown in Figure 4 is very similar. However, the reduced affinity for CD3 appears to lead to a greater volume of distribution, which is consistent with reduced sequestration of the molecule triespecifica by
Petition 870190117813, of 11/14/2019, p. 112/156
108/133 T cells. There were no adverse clinical observations or changes in body weight observed during the study period.
Table 2: Binding affinities for human and
Cynomolgus.
Anti-PSMA K _D value (nM) K _{D value} Anti-albumin (nM) K _{D value} Anti-CD3e (nM)Human Cino Cino / human proportion pHSA CSA Cino / Human Ratio Human Cino Cino / human ratio ToolHigh affinity TriTAC- C236 16, 3 0 0 22.7 25, 4 1, 1 6, 0 4.7 0.8 TriTAC CD3 high affinity - C324 17, 9 0 0 9, 8 9, 7 1 7.4 5, 8 0.8 TriTAC CD3 medium affinity C339 13, 6 0 0 8.8 8.3 0, 9 40, 6 33, 6 0, 8 TriTAC CD3 low affinity C325 15, 3 0 0 10, 1 9, 7 1 217 160 0.7
Example 4: Evaluation of the impact of PSMA affinity on the properties of exemplary PSMA-targeted molecules [155] PSMA-targeted molecules with distinct PSMA binding domains have been studied to demonstrate the effects of altered PSMA affinity. Table 3 lists the affinity of each molecule for the three binding partners (PSMA, CD3, HSA). Reduced PSMA affinity leads to a loss in potency in terms of T-cell-mediated cellular toxicity (Figures 5A-C).
Table 3: Binding affinities for human and
Petition 870190117813, of 11/14/2019, p. 113/156
109/133
Cynomolgus.
Anti-PSMA K _D value (nM) K _{D value} Anti-albumin (nM) K _{D value} Anti-CD3e (nM) Huma-at the Cin o Ratio cino / human pHSTHE CSA Ratio cino / human Huma-at the Cino Cino / human ratio PSMATriTAC (p8) C362 22.0 0 at 6, 6 6, 6 1.0 8.3 4.3 0.52 PSMATriTAC (HDS) C363 3, 7 540 146 7, 6 8.4 1, 1 8.0 5, 2 0.65 PSMATriTAC(HTS) -C364 0.15 663 4423 8.4 8, 6 1.0 7.7 3, 8 0.49
Example 5: In vivo efficacy of exemplary PSMA targeting specific molecules [156] The exemplary PSMA targeting specific molecule C324 was assessed for its ability to inhibit tumor growth in mice. For this experiment, immunocompromised mice reconstituted with human T cells were subcutaneously inoculated with human prostate tumor cells expressing PSMA (22Rvl) and treated daily for 10 days with 0.5 mg / kg of molecules directed to PSMA BiTE or TriTAC. Tumor growth was measured for 30 days. Throughout the evolution of the experiment, the triespecific molecule was able to inhibit tumor growth with an efficiency comparable to a BiTE molecule (Figure 6).
Example 6: Specificity of specimen specific PSMA-directed molecules [157] In order to assess the specificity of PST-directed TriTAC molecules, their ability to induce T cells to kill tumor cells was tested with cells
Petition 870190117813, of 11/14/2019, p. 114/156
110/133 tumors that are negative for PSMA (Figure 7A). A TriTAC molecule targeting EGFR served as a positive control, a TriTAC molecule targeting GFP as a negative control. All three TriTACs with different PSMA-binding domains showed the expected activity against the PSMA-positive cell line LNCaP (Figure 7B), but did not reach EC50s in the PSMA-negative tumor cell lines KMS12BM and OVCAR8 (Figures 7C and 7D). EC50s are summarized in Table 4. At very high TriTAC concentrations (> 1 nM), some death outside the limited target cell could be observed for TriTACs C362 and C363, while C364 did not show significant cell death under any of the conditions tested.
Table 4: Cell death activity of TriTAC molecules with antigen-positive and antigen-negative tumor cell lines (EC50 [M]).
TriTAC LNCaP KMS12BM OVCAR8 PSMA p8 TriTAC C362 13, 0 > 10,000 > 10,000 PSMA HDS TriTAC C363 6, 2 > 10,000 > 10,000 PSMA HTS TriTAC C364 0.8 > 10,000 > 10,000 EGFR TriTAC C131 9, 4 > 10,000 6 GFP TriTAC C > 10,000 > 10,000 > 10,000
Example 7: Protein stress and stability tests [158] Four specific PSMA-directed molecules were incubated for 48 h in low-concentration Cynomolgus serum (33.3 pg / ml) or subjected to five freeze / thaw cycles in serum of Cynomolgus. After treatment, the bioactivity of the TriTAC molecules was evaluated in cell death assays and compared to non-stressed samples (positive control, Figure 8A-D). All molecules maintained most of their cell death activity. TriTAC C362 was the most
Petition 870190117813, of 11/14/2019, p. 115/156
111/133 resistant to stress and did not appear to lose any activity under the conditions tested here.
Example 8: Xenograft tumor model [159] An attempted specific protein targeting the exemplary PSMA is evaluated in a xenograft model.
[160] Males from immunodeficient NCG mice are inoculated subcutaneously with 5 x 10 ⁶ 22Rvl cells on their right dorsal flank. When the tumors reach 100 to 200 mm ³ , the animals are allocated to 3 treatment groups. Groups 2 and 3 (8 animals each) are injected intraperitoneally with 1.5 x 10 ⁷ activated human T cells. Three days later, Group 3 animals are subsequently treated with a total of 9 50 pg intravenous doses of the tryma specific PSMA-specific antigen binding protein (qdx9d). Groups 1 and 2 are treated with vehicle only. Body weight and tumor volume are determined for 30 days. Tumor growth in mice treated with the PSMA-specific antigen-binding protein is expected to be significantly reduced compared to tumor growth in the respective vehicle-treated control group.
Example 9: Proof-of-bias clinical trial protocol for administering an exemplary PSMA antigen-binding protein to exemplary prostate cancer patients [161] This is a Phase I / II clinical trial for studying the protein binding tries specific PSMA antigen of Example 1 as a treatment for prostate cancer.
[162] Final results of the study:
[163] Primers: Maximum tolerated protein dose
Petition 870190117813, of 11/14/2019, p. 116/156
112/133 PSMA-specific attempts from previous examples [164] Secondary: Determine whether the in vitro response of PSMA-specific proteins from previous examples is associated with clinical response
Phase I
[165] The dose maximum tolerated (BAT) it will be determined at section of1.1 Phase IThe dose of the experiment.maximum tolerated (BAT) it will be determined at section of1.2 Phase I of the experiment.Patients who fill the criteria in
eligibility will be included in the experiment for specific proteins targeted to the PSMA from the previous examples.
1.3 The aim is to identify the highest dose of specific proteins targeted to PSMA from previous examples that can be safely administered without severe or unmanageable side effects in participants. The dose given will depend on the number of participants who were included in the study before and how well the dose was tolerated. Not all participants will receive the same dose.
Phase II [166] 2.1 A subsequent Phase II section will be dealt with in BAT with the aim of determining whether therapy with therapy with the specific PSMA-directed proteins in the previous examples results in a response rate of at least 20%.
Primary end result for Phase II - Determine whether the PSMA-targeted protein therapy of the previous examples results in at least 20% of patients obtaining a clinical response (explosive response, minor response, partial response or complete response).
Petition 870190117813, of 11/14/2019, p. 117/156
113/133
Eligibility:
[167] Aggressive prostate cancer newly diagnosed histologically confirmed according to the current World Health Organization classification, 2001-2007
Final disease stage.
Treatment with docetaxel and prednisone (+/- surgery).
Age 18 years
Karnofsky performance status> 50% or ECOG performance status 0-2
Life expectancy> 6 weeks
Example 10: Activity of an exemplary PSMA antigen-binding protein (PSMA-directed TriTAC molecule) in redirected T cell death assays using a panel of cell lines expressing PSMA and T cells from different donors [168] This study was carried out to demonstrate that the activity of the exemplary PSMA-specific antigen-binding protein is not limited to LNCaP cells or a single cell donor.
[169] Redirected T cell death assays were performed using T cells from four different donors and prostate cancer cell lines expressing human PSMA VCaP, LNCaP, MDAPCa2b and 22Rvl. With one exception, the PSMA-specific antigen-binding protein was able to drive the death of these cancer cell lines using T cells from all donors with EC50 values from 0.2 to 1.5 pM, as shown in Table 5. With the prostate cancer cell line 22 Rvl and Donor 24, little to no death was observed (data not shown). Donor 24 also only resulted in approximately 50% death
Petition 870190117813, of 11/14/2019, p. 118/156
114/133 of the MDAPCa2b cell line, while T cells from the other 3 donors resulted in almost complete death of that cell line (data not shown). Control trials demonstrated that death by the PSMA-specific antigen-binding protein for PSMA was PSMA-specific. No deaths were observed when cells expressing PSMA were treated with a specific control protein directed to green fluorescent protein (GFP) instead of PSMA (data not shown). Similarly, the PSMA-specific antigen-binding protein was inactive with cell lines that lack expression of PSMA, NCI1563 and HCT116, also shown in Table 5.
Table 5: ECso values from TDCC assays with six human cancer cell lines and four different T cell donors.
Cell line TDCC ECso values (M) Donor 2 4 Donor 8144 Donor 72 Donor 41 LNCaP 1.5E-12 2.2E-13 3.6E-13 4.3E-13 MDAPCa2b 4.8E-12 4.1E-13 4.9E-13 6.5E-13 VCaP 6.4E-13 1.6E-13 2, OE-13 3.5E-13 22Rvl at 7.2E-13 1.4E-12 1.3E-12 HCT116 > 1, OE-8 > 1, OE-8 > 1, OE-8 > 1, OE-8 NCI-1563 > 1, OE-8 > 1, OE-8 > 1, OE-8 > 1, OE-8
Example 11: Stimulation of cytokine expression by an exemplary tries specific PSMA antigen-binding protein (PSMA-directed TriTAC molecule) in redirected T cell death assays [170] This study was performed to demonstrate T cell activation by the protein of binding to the exemplary PSMA-specific antigen during redirected T cell death assays by measuring cytokine secretion in the assay medium by activated T cells.
Petition 870190117813, of 11/14/2019, p. 119/156
115/133 [171] Conditioned media collected from redirected T cell death assays, as described above in Example 9, were analyzed for expression of the cytokines TNFa and IFNy. Cytokines were measured using AlphaLISA assays (Perkin-Elmer). The addition of a titration of the PSMA antigen-binding protein to T cells from four different donors and four cell lines expressing PSMA, LNCaP, VCaP, MDAPCa2b and 22Rvl, resulted in increased levels of TNFa. The results for the levels of TNFα expression and IFNy expression in the conditioned media are shown in Tables 6 and 7, respectively. The EC50 values for the expression induced by the PSMA antigen-binding protein of these cytokines ranged from 3 to 15 pM. Increased cytokine levels were not seen with a specific control protein directed to GFP. Similarly, when the assays were performed with two cell lines that are expression of PSMA, HCT116 and NCIH1563, PSMA HTS TriTAC also did not increase the expression of TNFa or IFNy.
Table 6: EC50 values for TNFα expression in means of TDCC assays of tryma specific antigen binding protein for PSMA with six human cancer cell lines and T cells from four different donors.
Cell line Donor 24 Donor 8144 Donor41 Donor 72 LNCaP 4.9E-12 2.8E-12 4, OE-12 3.2E-12 VCaP 3.2E-12 2.9E-12 2.9E-12 2.9E-12 MDAPCa2b 2.1E-11 4, OE-12 5.5E-12 3.6E-12 22Rvl 8.9E-12 2.5E-12 4, OE-12 3.3E-12 HCT116 > lE-8 > lE-8 > lE-8 > lE-8 NCI-H1563 > lE-8 > lE-8 > lE-8 > lE-8
Table 7: EC50 values for IFNy expression in media
Petition 870190117813, of 11/14/2019, p. 120/156
116/133 antigen-binding protein TDCC assays tries specific for PSMA with six human cancer cell lines and T cells from four different donors.
Cell line Donor 2 4 Donor 8144 Donor 41 Donor 72 LNCaP 4.2E-12 4.2E-12 4.2E-12 2.8E-12 VCaP 5.1E-12 1.5E-11 3.4E-12 4.9E-12 MDAPCa2b 1.5E-11 5.8E-12 9.7E-12 3.5E-12 22Rvl 7.8E-12 3, OE-12 9.1E-12 3, OE-12 HCT116 > lE-8 > lE-8 > lE-8 > lE-8 NCI-H1563 > lE-8 > lE-8 > lE-8 > lE-8
Example 12: Activity of an exemplary PSMA-specific antigen-binding protein (PSMA-directed TriTAC) in the redirected T cell death (TDCC) assay using T cells from Cynomolgus monkeys [172] This study was conducted to test the ability of exemplary PSMA-specific antigen-binding protein to direct T cells of Cynomolgus monkeys to kill cell lines expressing PSMA.
[173] TDCC assays were set up using peripheral blood mononuclear cells (PBMCs) from Cynomolgus monkeys. Chino PBMCs were added to the LNCaP cells in a 10: 1 ratio. It was observed that the tryma-specific antigen binding protein for PSMA redirected the death of LNCaP by the cyan PBMCs with an ECso value of 11 pM. The result is shown in Figure 9A. To confirm these results, a second cell line was used, MDAPCa2b, and PBMCs from a second donor Cynomolgus monkey were tested. The redirected death of the target cells was observed with an ECso value of 2.2 pM. The result is shown in Figure 9B. Death was specific to the anti-PMSA arm of the antigen-binding protein
Petition 870190117813, of 11/14/2019, p. 121/156
117/133 tries specific for PSMA, insofar as death was not observed with a triespecific protein targeting negative control GFP. These data demonstrate that the PSMA-specific antigen-binding protein can target Cynomolgus T cells to kill target cells that express human PSMA.
Example 13: Expression of T cell activation markers in T cell death assays redirected with an exemplary PSMA-specific antigen-binding protein (PSMA-directed TriTAC molecule) [174] This study was conducted to assess whether T cells were activated when the exemplary PSMA-specific antigen-binding protein directed T cells to kill target cells.
[175] The assays were set up using conditions for the redirected T cell death assays described in the example above. T cell activation was assessed by measuring the expression of CD25 and CD69 on the surface of T cells using flow cytometry. The PSMA-specific antigen-binding protein was added to a 10: 1 mixture of purified human T cells and the VCaP prostate cancer cell line. Upon the addition of increasing amounts of the PSMA-specific antigen-binding protein, increased expression of CD69 and expression of CD25 were observed, as shown in Figure 10. The ECso value was 0.3 pM for CD69 and 0.2 pM for CD25. A specific GFP-directed protein was included in these assays as a negative control, and little or no increase in CD69 or CD25 expression is seen with the specific GFP-directed protein, also shown in Figure
Petition 870190117813, of 11/14/2019, p. 122/156
118/133
10.
Example 14: Stimulation of T cell proliferation by an exemplary PSMA-specific antigen-binding protein (PSMA-directed TriTAC molecule) in the presence of PSMA-expressing target cells [176] This study was used as an additional method to demonstrate that the exemplary PSMA-specific antigen-binding protein was able to activate T cells when it redirects them to kill target cells.
[177] T cell proliferation assays were set up using the conditions of the redirected T cell death assay using LNCaP as target cells, as described above, and measuring the number of T cells present in 72 hours. The exemplary tryma-specific antigen-binding protein for PSMA stimulated proliferation with an EC value of 0.5 pM. As a negative control, a specific GFP-directed protein was included in the assay, and no increased proliferation was observed with that protein. The results for the T cell proliferation assay are illustrated in Figure 11.
Example 15: Death by T cell redirected from LNCaP cells by exemplary PSMA-specific antigen-binding proteins (PSMA Z2-directed TriTAC molecule) [178] This study was carried out to test the ability of a PSMA-specific antigen-binding protein example, which has the sequence as presented in the IDS. SEQ. ^Nos: 156 to redirect T-cells to kill the cell line LNCaP.
[179] In TDCC assays, configured as described in the examples above, the PSMA Z2 TriTAC protein (SEQ ID. NO:
Petition 870190117813, of 11/14/2019, p. 123/156
119/133
156) directed death with an EC50 value of 0.8 pM, as shown in Figure 12.
Table 8
IDS. SEQ. N ^os Sequence ID. SEQ. N °: 1 RFMISX1YX2MH ID. SEQ. N °: 2 X3INPAX4X5TDYAEX6VKG ID. SEQ. N °: 3 DX7YGY ID. SEQ. N °: 4 EVQLVESGGGLVQPGGSLTLSCAASRFMISEYSMHWVRQAPGKGLEWVSTINPAGTTDYAESVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCDGYGYRGQGTQVTVSS ID. SEQ. No. 5 RFMISEYHMH ID. SEQ. No. 6 RFMISPYSMH ID. SEQ. No. 7 RFMISPYHMH ID. SEQ. No. 8 DINPAGTTDYAESVKG ID. SEQ. No. 9 TINPAKTTDYAESVKG ID. SEQ. No. 10 TINPAGQTDYAE SVKG ID. SEQ. No. 11 TINPAGTTDYAEYVKG ID. SEQ. No. 12 DINPAKTTDYAESVKG ID. SEQ. No. 13 DINPAGQTDYAESVKG ID. SEQ. No. 14 DINPAGTTDYAEYVKG ID. SEQ. No. 15 DSYGY ID. SEQ. No. 16 RFMISEYSMH ID. SEQ. No. 17 TINPAGTTDYAESVKG ID. SEQ. No. 18 DGYGY ID. SEQ. No. 19 EVQLVESGGGLVQPGGSLRLSCAASRFMISEYSMHWV RQAP GKGLEWVS TINPAGTTDYAE SVKGRF TISRDNA KNTLYLQMNSLRAEDTAVYYCDGYGYRGQGTLVTVSS ID. SEQ. N °: 20 MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGF LFGWFIKSSNEATNITPKHNMKAFLDELKAENIKKFL YNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELA HYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPP PGYENVSDIVPPFSAFS QGMP P E D F GD LVYVNYARTE FKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGA KGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNIL NLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHP IGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGF TGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDR YVILGGHRDSWVFGGIDPQSGAAWHEIVRSFGTLKK EGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQE RGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKEL KSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSG
Petition 870190117813, of 11/14/2019, p. 124/156
120/133
NDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSV YETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIV LPFDCRDYAWLRKYADKIYSISMKHPQEMKTYSVSF DSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMND QLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGE SFPGIYDALFDIES KVD P S KAWGEVKRQIYVAAF QST AAAETLSEVA ID. SEQ. N °: 21 EVQLVESGGGLVQPGGSLRLSCAASRFMISEYHMHWVRQAPGKGLEWVSDINPAGTTDYAESVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCDSYGYRGQGTLVTVSS ID. SEQ. N °: 22 EVQLVESGGGLVQPGGSLRLSCAASRFMISEYHMHWV RQAP GKGLEWVS TINPAGTTDYAE SVKGRF TISRDNA KNTLYLQMNSLRAEDTAVYYCDSYGYRGQGTLVTVSS ID. SEQ. N °: 23 EVQLVESGGGLVQPGGSLRLSCAASRFMISEYSMHWV RQAP GKGLEWVS TINPAKTTDYAE SVKGRF TISRDNA KNTLYLQMNSLRAEDTAVYYCDSYGYRGQGTLVTVSS ID. SEQ. N °: 24 EVQLVESGGGLVQPGGSLRLSCAASRFMISPYSMHWV RQAP GKGLEWVS TINPAGTTDYAE SVKGRF TISRDNA KNTLYLQMNSLRAEDTAVYYCDGYGYRGQGTLVTVSS ID. SEQ. N °: 25 EVQLVESGGGLVQPGGSLRLSCAASRFMISEYSMHWV RQAP GKGLEWVS TINPAGQTDYAE SVKGRF TISRDNA KNTLYLQMNSLRAEDTAVYYCDGYGYRGQGTLVTVSS ID. SEQ. N °: 26 EVQLVESGGGLVQPGGSLRLSCAASRFMISEYSMHWVRQAPGKGLEWVSTINPAGTTDYAEYVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCDGYGYRGQGTLVTVSS ID. SEQ. N °: 27 EVQLVESGGGLVQPGGSLRLSCAASRFMISEYHMHWVRQAPGKGLEWVSDINPAKTTDYAESVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCDSYGYRGQGTLVTVSS ID. SEQ. N °: 28 EVQLVESGGGLVQPGGSLRLSCAASRFMISPYHMHWVRQAPGKGLEWVSDINPAGTTDYAESVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCDSYGYRGQGTLVTVSS ID. SEQ. N °: 29 EVQLVESGGGLVQPGGSLRLSCAASRFMISEYHMHWVRQAPGKGLEWVSDINPAGQTDYAESVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCDSYGYRGQGTLVTVSS ID. SEQ. N °: 30 EVQLVESGGGLVQPGGSLRLSCAASRFMISEYHMHWVRQAPGKGLEWVSDINPAGTTDYAEYVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCDSYGYRGQGTLVTVSS ID. SEQ. N °: 31 EVQLVESGGGLVQPGGSLTLSCAASRFMISEYHMHWVRQAPGKGLEWVSDINPAGTTDYAESVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCDSYGYRGQGTQVTVSS ID. SEQ. N °: 32 EVQLVESGGGLVQPGGSLTLSCAASRFMISEYHMHWV RQAP GKGLEWVS TINPAGTTDYAE SVKGRF TISRDNA KNTLYLQMNSLKPEDTAVYYCDSYGYRGQGTQVTVSS
Petition 870190117813, of 11/14/2019, p. 125/156
121/133
Table 9: Sequences of the CD3 binding domain.
IP. SEQ. N °: description AA string 34 Anti-CD3, clone 2B2 EVQLVESGGGLVQPGGSLKLSCAASGF TFNKYAINWVRQAP GKGLEWVARIRSK YNNYAT YYAD QVKD RF TIS RD D T A S KN YLQMNNLKTEDTAVYYCVRHANFGNSY ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC AS S T S GAVT GNYP NWVQQKP GQAP RGL IGGTKFLVPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCTLWYSNRWVFGGG TKLTVL 35 Anti-CD3, clone 9F2 EVQLVESGGGLVQPGGSLKLSCAASGF EFNKYAMNWVRQAP GKGLEWVARIRSK YNKYATYYAD SVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSY ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GS F S S GAVT GNYP NWVQQKP GQAP RGL IGGTKFLAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYDNRWVFGGG TKLTVL 36 Anti-CD3, clone 5A2 EVQLVESGGGLVQPGGSLKLSCAASGF TFNKYAMNWVRQAP GKGLEWVARIRSK YNNYATYYAD SVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSH ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GS S T S GYVT GNYP NWVQQKP GQAP RGL IGGTSFLAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYSNRWIFGGG TKLTVL 37 Anti-CD3, clone 6A2 EVQLVESGGGLVQPGGSLKLSCAASGF MFNKYAMNWVRQAP GKGLEWVARIRSK SNNYATYYAD SVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSY ISYWATWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GS F S S GAVT GNYP NWVQQKP GQAP RGL IGGTKLLAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYSNSWVFGGG TKLTVL
Petition 870190117813, of 11/14/2019, p. 126/156
122/133
38 Anti-CD3, clone 2D2 EVQLVESGGGLVQPGGSLKLSCAASGF TFNTYAMNWVRQAP GKGLEWVARIRSK YNNYATYYKD SVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSP ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC S T GS gaws GNYP NWVQQKP GQAP RGL IGGTEFLAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 39 Anti-CD3, clone 3F2 EVQLVESGGGLVQPGGSLKLSCAASGF TYNKYAMNWVRQAP GKGLEWVARIRSK YNNYATYYAD EVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSP ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GS KGAVT S S GNYP NWVQQKP GQAP RGL IGGTKELAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCTLWYSNRWVFGGG TKLTVL 40 Anti-CD3, clone 1A2 EVQLVESGGGLVQPGGSLKLSCAASGN TFNKYAMNWVRQAP GKGLEWVARIRSK YNNYE TYYAD SVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHTNFGNSY ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GS S T S GAVT GYYP NWVQQKP GQAP RGL IGGTYFLAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 41 Anti-CD3, clone 1C2 EVQLVESGGGLVQPGGSLKLSCAASGF TFNNYAMNWVRQAP GKGLEWVARIRSK YNNYATYYADAVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSQ ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC S GS TGAVTD GNYPNWVQQKP GQAP RGL IGGIKFLAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 42 Anti-CD3, clone 2E4 EVQLVESGGGLVQPGGSLKLSCAASGF TFNKYAVNWVRQAP GKGLEWVARIRSK YNNYATYYAD SVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSY
Petition 870190117813, of 11/14/2019, p. 127/156
123/133
ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GE S T GAVT S GNYP NWVQQKP GQAP RGL IGGTKILAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLW 43 Anti-CD3, clone 10E4 EVQLVESGGGLVQPGGSLKLSCAASGF TFNKYPMNWVRQAP GKGLEWVARIRSK YNNYATYYAD SVKD RF TISRDD SKNTA YLQMNNLKNEDTAVYYCVRHGNFNNSY ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC S GS TGAVTKGNYPNWVQQKP GQAP RGL IGGTKMLAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCALWYSNRWVFGGG TKLTVL 44 Anti-CD3, clone 2H2 EVQLVESGGGLVQPGGSLKLSCAASGF TFNGYAMNWVRQAP GKGLEWVARIRSK YNNYATYYAD EVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSP ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC S T GS gaws GNYP NWVQQKP GQAP RGL IGGTEFLAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 45 Anti-CD3, clone 2A4 EVQLVESGGGLVQPGGSLKLSCAASGN TFNKYAMNWVRQAP GKGLEWVARIRSK YNNYATYYAD SVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGDSY ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GSSTGAVTHGNYPNWVQQKPGQAPRGL IGGTKVLAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 46 Anti-CD3, clone 10B2 EVQLVESGGGLVQPGGSLKLSCAASGF TFNNYAMNWVRQAP GKGLEWVARIRS G YNNYATYYAD SVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSY ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GSYTGAVTSGNYPNWVQQKPGQAPRGL IGGTKFNAPGTPARFSGSLLGGKAALT
Petition 870190117813, of 11/14/2019, p. 128/156
124/133
LSGVQPEDEAEYYCVLWYANRWVFGGGTKLTVL 47 Anti-CD3, clone 1G4 EVQLVESGGGLVQPGGSLKLSCAASGF EFNKYAMNWVRQAP GKGLEWVARIRSK YNNYE TYYAD SVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSL ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GS S S GAVT GNYPNWVQQKP GQAP RGL IGGTKFGAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 48 anti-CD3 wt EVQLVESGGGLVQPGGSLKLSCAASGF TFNKYAMNWVRQAP GKGLEWVARIRSK YNNYATYYAD SVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSY ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GS S T S GAVT GNYP NWVQQKP GQAP RGL IGGTKFLAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 49 anti-CD3 wt HC CDR1 GFTFNKYAMN 50 anti-CD3 wt HC CDR2 RIRSKYNNYATYYAD SVK 51 anti-CD3 wt HC CDR3 HGNFGNSYISYWAY 53 anti-CD3 wt LC CDR1 GSSTGAVTSGNYPN 54 anti-CD3 wt LC CDR2 GTKFLAP 55 anti-CD3 wt LC CDR3 VLWYSNRWV 56 HC CDR1 variant 1 GNTFNKYAMN 57 HC CDR1 variant 2 GFEFNKYAMN 58 HC CDR1 variant 3 GFMFNKYAMN 59 HC CDR1 variant 4 GFTYNKYAMN 60 HC CDR1 variant 5 GFTFNNYAMN 61 HC CDR1 variant 6 GFTFNGYAMN 62 HC CDR1 variant 7 GFTFNTYAMN 63 HC CDR1 variant 8 GFTFNEYAMN 64 HC CDR1 variant 9 GFTFNKYPMN 65 HC CDR1 variant 10 GFTFNKYAVN 66 HC CDR1 variant 11 GFTFNKYAIN 67 HC CDR1 variant 12 GFTFNKYALN 68 HC CDR2 variant 1 RIRS GYNNYATYYAD SVK 69 HC CDR2 variant 2 RIRSKSNNYATYYAD SVK 70 HC CDR2 variant 3 RIRSKYNKYATYYAD SVK
Petition 870190117813, of 11/14/2019, p. 129/156
125/133
71 HC CDR2 variant 4 RIRSKYNNYE TYYAD SVK 72 HC CDR2 variant 5 RIRSKYNNYATEYADSVK 73 HC CDR2 variant 6 RIRSKYNNYATYYKD SVK 74 HC CDR2 variant 7 RIRSKYNNYATYYADEVK 75 HC CDR2 variant 8 RIRSKYNNYATYYADAVK 76 HC CDR2 variant 9 RIRSKYNNYATYYADQVK 77 HC CDR2 variant 10 RIRSKYNNYATYYADDVK 78 HC CDR3 variant 1 HANFGNSYISYWAY 79 HC CDR3 variant 2 HTNFGNSYISYWAY 80 HC CDR3 variant 3 HGNFNNSYISYWAY 81 HC CDR3 variant 4 HGNFGDSYISYWAY 82 HC CDR3 variant 5 HGNFGNSHISYWAY 83 HC CDR3 variant 6 HGNFGNSPISYWAY 84 HC CDR3 variant 7 HGNFGNSQISYWAY 85 HC CDR3 variant 8 HGNFGNSLISYWAY 86 HC CDR3 variant 9 HGNFGNSGISYWAY 87 HC CDR3 variant 10 HGNFGNSYISYWAT 88 LC CDR1 variant 1 ASSTGAVTSGNYPN 89 LC CDR1 variant 2 GESTGAVTSGNYPN 90 LC CDR1 variant 3 GSYTGAVTSGNYPN 91 LC CDR1 variant 4 GSSFGAVTSGNYPN 92 LC CDR1 variant 5 GSSKGAVTSGNYPN 93 LC CDR1 variant 6 GSSSGAVTSGNYPN 94 LC CDR1 variant 7 GSSTGYVTSGNYPN 95 LC CDR1 variant 8 GSSTGAWSGNYPN 96 LC CDR1 variant 9 GSSTGAVTDGNYPN 97 LC CDR1 variant 10 GSSTGAVTKGNYPN 98 LC CDR1 variant 11 GSSTGAVTHGNYPN 99 LC CDR1 variant 12 GSSTGAVTVGNYPN 100 LC CDR1 variant 13 GSSTGAVTSGYYPN 101 LC CDR2 variant 1 GIKFLAP 102 LC CDR2 variant 2 GTEFLAP 103 LC CDR2 variant 3 GTYFLAP 104 LC CDR2 variant 4 GTSFLAP 105 LC CDR2 variant 5 GTNFLAP 106 LC CDR2 variant 6 GTKLLAP 107 LC CDR2 variant 7 GTKELAP 108 LC CDR2 variant 8 GTKILAP 109 LC CDR2 variant 9 GTKMLAP 110 LC CDR2 variant 10 GTKVLAP 111 LC CDR2 variant 11 GTKFNAP 112 LC CDR2 variant 12 GTKFGAP 113 LC CDR2 variant 13 GTKFLVP
Petition 870190117813, of 11/14/2019, p. 130/156
126/133
114 LC CDR3 variant 1 TLWYSNRWV 115 LC CDR3 variant 2 ALWYSNRWV 116 LC CDR3 variant 3 VLWYDNRWV 117 LC CDR3 variant 4 VLWYANRWV 118 LC CDR3 variant 5 VLWYSNSWV 119 LC CDR3 variant 6 VLWYSNRWI 120 LC CDR3 variant 7 VLWYSNRWA 121 Anti-CD3, clone 2G5 EVQLVESGGGLVQPGGSLKLSCAASGF TFNKYALNWVRQAP GKGLEWVARIRSK YNNYAT And YAD SVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSP ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GS S S T GAVT GNYP NWVQQKP GQAP RGL IGGTNFLAPGTPERFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYSNRWAFGGG TKLTVL 122 Anti-CD3, clone 8A5 EVQLVESGGGLVQPGGSLKLSCAASGF TFNEYAMNWVRQAPGKGLEWVARIRSK YNNYATYYAD DVKD RF TISRDD SKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSG ISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTC GSSTGAVTVGNYPNWVQQKPGQAPRGL IGGTEFLAPGTPARFSGSLLGGKAALT LSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL
Table 10: Sequences of the HSA binding domain.
IP. SEQ. N °: description AA string 123 Anti-HSA sdAb clone 6C EVQLVESGGGLVQPGNSLRLSCAASGFTFSRFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS 124 Anti-HSA sdAb clone 7A EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGADTLYADSLKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSKSSQGTLVTVSS 125 Anti-HSA sdAb clone 7G EVQLVESGGGLVQPGNSLRLSCAASGFTYSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSKSSQGTLVTVSS
Petition 870190117813, of 11/14/2019, p. 131/156
127/133
126 Anti-HSA sdAb clone 8H EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGTDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS 127 Anti-HSA sdAb clone 9A EVQLVESGGGLVQPGNSLRLSCAASGFTFSRFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS 128 Anti-HSA sdAb clone 10G EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSS 129 anti-HSA wt EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS 130 anti-HSA CDR1 wt GFTFSSFGMS 131 anti-HSA CDR2 wt SISGSGSDTLYADSVK 132 anti-HSACDR3 wt GGSLSR 133 CDR1 variant 1 GFTFSRFGMS 134 CDR1 variant 2 GFTFSKFGMS 135 CDR1 variant 3 GFTYSSFGMS 136 CDR2 variant 1 SISGSGADTLYADSLK 137 CDR2 variant 2 SISGSGTDTLYADSVK 138 CDR2 variant 3 SIS GS GRD TLYAD SVK 139 CDR2 variant 4 SISGSGSDTLYAESVK 140 CDR2 variant 5 SISGSGTDTLYAESVK 141 CDR2 variant 6 SIS GS GRD TLYAE SVK 142 CDR3 variant 1 GGSLSK 143 CDR3 variant 2 GGSLSV 144 Anti-HSA sdAb clone 6CE EVQLVESGGGLVQPGNSLRLSCAASGFTFSRFGMSWVRQAPGKGLEWVSSISGSGSDTLYAESVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS 145 Anti-HSA sdAb clone 8HE EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGTDTLYAESVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS 146 Anti-HSA sdAb clone 10GE EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAESVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSS
Table 11: Sequences of the targeted specific protein
Petition 870190117813, of 11/14/2019, p. 132/156
128/133 to the PSMA.
ID. SEQ.N °: Number —C Construction Sequence 147 C00324 PSMA TriTACHigh affinity CD3 EVQLVESGGGLVQPGGSLTLSCAASRFM ISEYSMHWVRQAPGKGLEWVSTINPAGT TDYAESVKGRFTISRDNAKNTLYLQMNS LKPEDTAVYYCDGYGYRGQGTQVTVSSG GGGSGGGSEVQLVESGGGLVQPGNSLRL SCAASGFTFSKFGMSWVRQAPGKGLEWV SSISGSGRD T Lyad SVKGRF TISRDNAK TTLYLQMNSLRPEDTAVYYCTIGGSLSV SSQGTLVTVSSGGGGSGGGSEVQLVESG GGLVQPGGSLKLSCAASGFTFNKYAINW VRQAP GKGLEWVARIRSKYNNYATYYAD QVKdRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHANFGNSYISYWAYWGQGTL VTVSSGGGGSGGGGSGGGGSQTWTQEP SLTVSPGGTVTLTCASSTGAVTSGNYPN WVQQKP GQAP RGLIGGTKF LVP GTPARF SGSLLGGKAALTLSGVQPEDEAEYYCTL WYSNRWVFGGGTKLTVLHHHHHH 148 C00339 PSMA TriTACCD3 medium affinity EVQLVESGGGLVQPGGSLTLSCAASRFM ISEYSMHWVRQAPGKGLEWVSTINPAGT TDYAESVKGRFTISRDNAKNTLYLQMNS LKPEDTAVYYCDGYGYRGQGTQVTVSSG GGGSGGGSEVQLVESGGGLVQPGNSLRL SCAASGFTFSKFGMSWVRQAPGKGLEWV SSISGSGRD T Lyad SVKGRF TISRDNAK TTLYLQMNSLRPEDTAVYYCTIGGSLSV SSQGTLVTVSSGGGGSGGGSEVQLVESG GGLVQPGGSLKLSCAASGFTFNNYAMNW VRQAP GKGLEWVARIRS GYNNYATYYAD SVKdRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTL VTVSSGGGGSGGGGSGGGGSQTWTQEP SLTVSPGGTVTLTCGSYTGAVTSGNYPN WVQQKP GQAP RGLIGGTKFNAP GTPARF SGSLLGGKAALTLSGVQPEDEAEYYCVL WYANRWVFGGGTKLTVLHHHHHH
Petition 870190117813, of 11/14/2019, p. 133/156
129/133
ID. SEQ.N °: Number —C Construction Sequence 149 C00325 PSMA TriTACCD3 low affinity EVQLVESGGGLVQPGGSLTLSCAASRFM ISEYSMHWVRQAPGKGLEWVSTINPAGT TDYAESVKGRFTISRDNAKNTLYLQMNS LKPEDTAVYYCDGYGYRGQGTQVTVSSG GGGSGGGSEVQLVESGGGLVQPGNSLRL SCAASGFTFSKFGMSWVRQAPGKGLEWV SSISGSGRD T Lyad SVKGRF TISRDNAK TTLYLQMNSLRPEDTAVYYCTIGGSLSV SSQGTLVTVSSGGGGSGGGSEVQLVESG GGLVQPGGSLKLSCAASGFEFNKYAMNW VRQAP GKGLEWVARIRSKYNNYE TYYAD SVKdRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSLISYWAYWGQGTL VTVSSGGGGSGGGGSGGGGSQTWTQEP SLTVSPGGTVTLTCGSSSGAVTSGNYPN WVQQKP GQAP RGLIGGTKF GAP GTPARF SGSLLGGKAALTLSGVQPEDEAEYYCVL WYSNRWVFGGGTKLTVLHHHHHH 150 C00236 ToolPSMA TriTAC EVQLVESGGGLVQPGGSLTLSCAASRFM ISEYSMHWVRQAPGKGLEWVSTINPAGT TDYAESVKGRFTISRDNAKNTLYLQMNS LKPEDTAVYYCDGYGYRGQGTQVTVSSG GGGSGGGSEVQLVESGGGLVQPGNSLRL SCAASGFTFSSFGMSWVRQAPGKGLEWV SSISGSGSD T Lyad SVKGRF TISRDNAK TTLYLQMNSLRPEDTAVYYCTIGGSLSR SSQGTLVTVSSGGGGSGGGSEVQLVESG GGLVQPGGSLKLSCAASGFTFNKYAMNW VRQAP GKGLEWVARIRSKYNNYATYYAD SVKdRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTL VTVSSGGGGSGGGGSGGGGSQTWTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPN WVQQKP GQAP RGLIGGTKF LAP GTPARF SGSLLGGKAALTLSGVQPEDEAEYYCVL WYSNRWVFGGGTKLTVLHHHHHH
Petition 870190117813, of 11/14/2019, p. 134/156
130/133
ID. SEQ.N °: Number —C Construction Sequence 151 C00362 PSMA p8 TriTAC EVQLVESGGGLVQPGGSLRLSCAASRFM ISEYSMHWVRQAPGKGLEWVSTINPAGT TDYAESVKGRFTISRDNAKNTLYLQMNS LRAEDTAVYYCDGYGYRGQGTLVTVSSG GGGSGGGSEVQLVESGGGLVQPGNSLRL SCAASGFTFSKFGMSWVRQAPGKGLEWV SSISGSGRD T Lyad SVKGRF TISRDNAK TTLYLQMNSLRPEDTAVYYCTIGGSLSV SSQGTLVTVSSGGGGSGGGSEVQLVESG GGLVQPGGSLKLSCAASGFTFNKYAINW VRQAP GKGLEWVARIRSKYNNYATYYAD QVKdRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHANFGNSYISYWAYWGQGTL VTVSSGGGGSGGGGSGGGGSQTWTQEP SLTVSPGGTVTLTCASSTGAVTSGNYPN WVQQKP GQAP RGLIGGTKF LVP GTPARF SGSLLGGKAALTLSGVQPEDEAEYYCTL WYSNRWVFGGGTKLTVLHHHHHH 152 C00363 PSMA HDSTriTAC C363 EVQLVESGGGLVQPGGSLTLSCAASRFM ISEYHMHWVRQAPGKGLEWVSDINPAGT TDYAESVKGRFTISRDNAKNTLYLQMNS LKPEDTAVYYCDSYGYRGQGTQVTVSSG GGGSGGGSEVQLVESGGGLVQPGNSLRL SCAASGFTFSKFGMSWVRQAPGKGLEWV SSISGSGRD T Lyad SVKGRF TISRDNAK TTLYLQMNSLRPEDTAVYYCTIGGSLSV SSQGTLVTVSSGGGGSGGGSEVQLVESG GGLVQPGGSLKLSCAASGFTFNKYAINW VRQAP GKGLEWVARIRSKYNNYATYYAD QVKdRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHANFGNSYISYWAYWGQGTL VTVSSGGGGSGGGGSGGGGSQTWTQEP SLTVSPGGTVTLTCASSTGAVTSGNYPN WVQQKP GQAP RGLIGGTKF LVP GTPARF SGSLLGGKAALTLSGVQPEDEAEYYCTL WYSNRWVFGGGTKLTVLHHHHHH
Petition 870190117813, of 11/14/2019, p. 135/156
131/133
ID. SEQ.N °: Number —C Construction Sequence 153 C00364 PSMA HTSTriTAC C364 EVQLVESGGGLVQPGGSLTLSCAASRFM ISEYHMHWVRQAPGKGLEWVSTINPAGT TDYAESVKGRFTISRDNAKNTLYLQMNS LKPEDTAVYYCDSYGYRGQGTQVTVSSG GGGSGGGSEVQLVESGGGLVQPGNSLRL SCAASGFTFSKFGMSWVRQAPGKGLEWV SSISGSGRD T Lyad SVKGRF TISRDNAK TTLYLQMNSLRPEDTAVYYCTIGGSLSV SSQGTLVTVSSGGGGSGGGSEVQLVESG GGLVQPGGSLKLSCAASGFTFNKYAINW VRQAP GKGLEWVARIRSKYNNYATYYAD QVKdRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHANFGNSYISYWAYWGQGTL VTVSSGGGGSGGGGSGGGGSQTWTQEP SLTVSPGGTVTLTCASSTGAVTSGNYPN WVQQKP GQAP RGLIGGTKF LVP GTPARF SGSLLGGKAALTLSGVQPEDEAEYYCTL WYSNRWVFGGGTKLTVLHHHHHH 154 C00298 PSMA BiTE QVQLVESGGGLVKPGESLRLSCAASGFT FSDYYMYWVRQAPGKGLEWVAIISDGGY YTYYSDIIKGRFTISRDNAKNSLYLQMN SLKAEDTAVYYCARGFPLLRHGAMDYWG QGTLVTVSSGGGGSGGGGSGGGGSDIQM TQSPSSLSASVGDRVTITCKASQNVDTN VAWYQQKPGQAPKSLIYSASYRYSDVPS RFSGSASGTDFTLTISSVQSEDFATYYC qqydsypytfgggtkleiksggggsevq LVESGGGLVQPGGSLKLSCAASGFTFNK YAMNWVRQAP GKGLEWVARIRSKYNNYA TYYADSVKdRFTISRDDSKNTAYLQMNN LKTEDTAVYYCVRHGNFGNSYISYWAYW GQGTLVTVSSGGGGSGGGGSGGGGSQTV VTQEPSLTVSPGGTVTLTCGSSTGAVTS GNYPNWVQQKP GQAP RGLIGGTKF LAP G TPARFSGSLLGGKAALTLSGVQPEDEAE YYCVLWYSNRWVFGGGTKLTVLHHHHHH
Petition 870190117813, of 11/14/2019, p. 136/156
132/133
ID. SEQ.N °: Number —C Construction Sequence 155 C00131 EGFR TriTAC QVKLEESGGGSVQTGGSLRLTCAASGRT S RS RE YGMGWF RQAP GKE FVS GISWRGD STGYADSVKGRFTISRDNAKNTVDLQMN SLKPEDTAIYYCAAAAGSAWYGTLYEYD YWGQGTQVTVSSGGGGSGGGSEVQLVES GGGLVQPGNSLRLSCAASGFTFSSFGMS WVRQAPGKGLEWVSSISGSGSDTLYADS VKGRFTISRDNAKTTLYLQMNSLRPEDT AVYYCTIGGSLSRSSQGTLVTVSSGGGG SGGGSEVQLVESGGGLVQPGGSLKLSCA ASGFTFNKYAMNWVRQAPGKGLEWVARI RS KYNNYATYYAD _D S V K DS RD RF TIS KN TAYLQMNNLKTEDTAVYYCVRHGNFGNS YISYWAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTWTQEPSLTVSPGGTVTLTCG SST GAVT S GNYP NWVQQKP GQAP RGLIG GTKFLAPGTPARFSGSLLGGKAALTLSG VQPEDEAEYYCVLWYSNRWVFGGGTKLT VLHHHHHH 156 C00410 PSMA Z2 TriTAC EVQLVESGGGLVQPGGSLTLSCAASRFM ISEYHMHWVRQAPGKGLEWVSTINPAGT TDYAESVKGRFTISRDNAKNTLYLQMNS LRAEDTAVYYCDSYGYRGQGTLVTVSSG GGGSGGGSEVQLVESGGGLVQPGNSLRL SCAASGFTFSKFGMSWVRQAPGKGLEWV SSISGSGRD T Lyad SVKGRF TISRDNAK TTLYLQMNSLRPEDTAVYYCTIGGSLSV SSQGTLVTVSSGGGGSGGGSEVQLVESG GGLVQPGGSLKLSCAASGFTFNKYAINW VRQAP GKGLEWVARIRSKYNNYATYYAD QVKdRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHANFGNSYISYWAYWGQGTL VTVSSGGGGSGGGGSGGGGSQTWTQEP SLTVSPGGTVTLTCASSTGAVTSGNYPN WVQQKP GQAP RGLIGGTKF LVP GTPARF SGSLLGGKAALTLSGVQPEDEAEYYCTL WYSNRWVFGGGTKLTVLHHHHHH
Table 12: Exemplary framework sequences.
ID. INSEQ. N °: description Sequence 165 Framework (fl) EVQLVESGGGLVQPGGSLTLSCAAS
Petition 870190117813, of 11/14/2019, p. 137/156
133/133
16 6 Framework (f2) WVRQAP GKGLEWVS 167 Framework (f3) RFTISRDNAKNTLYLQMNSLRAEDTAVYYC 168 Framework (f4) DGYGYRGQGTLVTVSS
Petition 870190117813, of 11/14/2019, p. 138/156

权利要求:
Claims (16)
[1]
1. Prostate-specific membrane antigen-binding protein, characterized by comprising
regions determinants in complementarity CDR1, CDR2 and CDR3, in what (The) The sequence in amino acids in CDR1 is how presented in RFMISX1YX2MH (SEQ ID. N °: D;(B) The sequence in amino acids in CDR2 is how presented in X3INPAX4 X ₅ TDYAEX ₆ VKG (ID. SEQ. N °: 2) ; and (ç) The sequence in amino acids in CDR3 is how
presented in DX YGY (SEQ ID. N °: 3).
[2]
2. Protein binding to the prostate-specific membrane antigen according to claim 1, characterized by the fact that said protein comprises the following formula:
f1-rl-f2-r2-f3-r3-f4 where, ri is the ID. SEQ. No.: 1; r2 is the ID. SEQ. No.: 2; and r3 is the ID. SEQ. No.: 3; and where fi, Í2, fs and Í4 are structural residues selected so that said protein is at least eighty percent identical to the amino acid sequence shown in the ID. SEQ. N °: 4.
3. Protein in connection to membrane antigen prostate specific, according with claim 2, characterized by fact that Xi is proline. 4. Protein in connection to membrane antigen prostate specific, according with claim 2, characterized by fact that X2 is histidine. 5. Protein in connection to membrane antigen
prostate-specific according to claim 2, characterized by the fact that X3 is aspartic acid.
Petition 870190117804, of 11/14/2019, p. 8/24
2/16
6. Prostate-specific membrane antigen-binding protein according to claim 2, characterized by the fact that X4 is lysine.
7. Prostate-specific membrane antigen-binding protein according to claim 2, characterized by the fact that X5 is glutamine.
8. Prostate-specific membrane antigen-binding protein according to claim 2, characterized by the fact that Xg is tyrosine.
9. Prostate-specific membrane antigen-binding protein according to claim 2, characterized by the fact that X it's serine.
10. Prostate-specific membrane antigen-binding protein according to any of claims 1 to 9, characterized in that the binding protein has a greater affinity for a human prostate-specific membrane antigen than that of a binding protein that has the sequence shown as ID. SEQ. N °: 4.
11. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 9, characterized by the fact that Xi is proline.
12. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 9, characterized by the fact that X5 is glutamine.
13. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 9, characterized by the fact that Xg is
Petition 870190117804, of 11/14/2019, p. 9/24
[3]
3/16 tyrosine.
14. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 9, characterized by the fact that X4 is lysine and X it's serine.
15. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 9, characterized in that X2 is histidine, X3 is aspartic acid, X4 is lysine and X it's serine.
16. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 9, characterized in that Xi is proline, X2 is histidine, X3 is aspartic acid and X it's serine.
17. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 9, characterized in that X2 is histidine, X3 is aspartic acid, X5 is glutamine and X it's serine.
18. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 9, characterized in that X2 is histidine, X3 is aspartic acid, Xg is tyrosine and X it's serine.
19. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 9, characterized in that X2 is histidine and X it's serine.
20. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 9, characterized in that X2 is histidine, X3 is aspartic acid and X it's serine.
21. Membrane antigen-binding protein
Petition 870190117804, of 11/14/2019, p. 10/24
[4]
Prostate-specific 4/16 according to any of claims 11 to 20, characterized in that the binding protein has a greater affinity for a human prostate-specific membrane antigen than that of a binding protein which has the string shown in the ID. SEQ. N °: 4.
22. Prostate-specific membrane antigen-binding protein according to any of claims 19 to 21, characterized in that the binding protein still has a greater affinity for a Cynomolgus prostate-specific membrane antigen than that of a binding protein that has the sequence shown in the ID. SEQ. N °: 4.
23. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 22, characterized in that rl comprises the ID. SEQ. No. 5, ID. SEQ. No. 6 or ID. SEQ. N °: 7.
24. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 23, characterized by the fact that r2 comprises the ID. SEQ. No. 8, ID. SEQ. No. 9, ID. SEQ. No. 10, ID. SEQ. No. 11, ID. SEQ. No. 12, ID. SEQ. N °: 13 or ID. SEQ. N °: 14.
25. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 24, characterized in that r3 comprises the ID. SEQ. N °: 15.
26. Prostate-specific membrane antigen-binding protein characterized by the fact that
Petition 870190117804, of 11/14/2019, p. 11/24
[5]
5/16 comprises CDR1, CDR2 and CDR3, comprising the sequence shown as ID. SEQ. No.: 4, in which one or more amino acid residues selected from amino acid positions 31, 33, 50, 55, 56, 62 and 97 are replaced.
27. Prostate-specific membrane antigen-binding protein according to claim 26, characterized in that it comprises one or more additional substitutions at amino acid positions other than positions 31, 33, 50, 55, 56, 62 and 97.
28. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitution in position
31.
29. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitution at position 33.
30. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitution at position 50.
31. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitution at position 55.
32. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitution at position 56.
33. Membrane antigen-binding protein
Petition 870190117804, of 11/14/2019, p. 12/24
[6]
Prostate-specific 6/16 according to claim 26 or 27, characterized in that it comprises substitution in position 62.
34. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitution at position 97.
35. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitutions at amino acid positions 55 and 97.
36. Prostate-specific membrane antigen binding protein according to any of claims 28 to 35, characterized in that the binding protein has a greater affinity for human prostate-specific membrane antigen than that of a binding protein that has the sequence shown in the ID. SEQ. N °: 4.
37. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitutions at amino acid positions 33 and 97.
38. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitutions at amino acid positions 33, 50 and 97.
39. Prostate-specific membrane antigen binding protein according to claim 37 or 38, characterized in that the binding protein has a greater affinity for membrane antigen
Petition 870190117804, of 11/14/2019, p. 13/24
[7]
7/16 human prostate specific than that of a binding protein that has the sequence shown as ID. SEQ. N °: 4.
40. Prostate-specific membrane antigen binding protein according to claim 37 or 38, characterized by the fact that the binding protein still has a greater affinity for Cynomolgus prostate specific membrane antigen than that of a binding protein that has the sequence shown in the ID. SEQ. N °: 4.
41. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitutions at amino acid positions 31, 33, 50 and 97.
42. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitutions at amino acid positions 33, 50, 55 and 97.
43. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitutions at amino acid positions 33, 50, 56 and 97.
44. Prostate-specific membrane antigen-binding protein according to claim 26 or 27, characterized in that it comprises substitutions at amino acid positions 33, 50, 62 and 97.
45. Prostate-specific membrane antigen-binding protein, characterized by comprising a CDR1, CDR2 and CDR3, where CDR1 comprises the sequence as shown is the ID. SEQ. N °: 16.
Petition 870190117804, of 11/14/2019, p. 14/24
[8]
8/16
46. Prostate-specific membrane antigen-binding protein, characterized by comprising a CDR1, CDR2 and CDR3, where CDR2 comprises the sequence as shown in ID. SEQ. N °: 17.
47. Prostate-specific membrane antigen-binding protein, characterized by comprising a CDR1, CDR2 and CDR3, where CDR3 comprises the sequence as shown in ID. SEQ. N °: 18.
48. Prostate-specific membrane antigen-binding protein, characterized by comprising a sequence that is at least 80% identical to the sequence shown in ID. SEQ. N °: 4.
49. Prostate-specific membrane antigen-binding protein, characterized by comprising a CDR1, CDR2 and CDR3, in which CDR1 has at least 80% identity for the ID. SEQ. N °: 16, CDR2 has at least 85% identity for the ID. SEQ. N °: 17, and CDR3 has at least 80% identity for the ID. SEQ. N °: 18.
50. Prostate-specific membrane antigen-binding protein, characterized by comprising a CDR1, CDR2 and CDR3, where CDR1 comprises the sequence shown in ID. SEQ. No. 16, CDR2 comprises the sequence shown in the ID. SEQ. N °: 17, and CDR3 comprises the sequence shown in the ID. SEQ. N °: 18.
51. Prostate specific membrane antigen binding protein according to any one of claims 1 to 50, characterized in that said binding protein binds to one or both of the human prostate specific membrane antigen and Cynomolgus prostate specific membrane antigen.
Petition 870190117804, of 11/14/2019, p. 15/24
[9]
9/16
52. Prostate-specific membrane antigen-binding protein according to any of claims 1 to 51, characterized in that said binding protein binds a human prostate-specific membrane antigen and human-specific membrane antigen Cynomolgus prostate with comparable binding affinities.
53. Prostate-specific membrane antigen-binding protein according to any one of claims 1 to 51, characterized in that said binding protein binds to a human prostate-specific membrane antigen with a greater binding affinity than Cynomolgus prostate specific membrane antigen.
54. Polynucleotide characterized by the fact that it encodes a PSMA-binding protein as defined in any one of claims 1 to 53.
55. Vector characterized by the fact that it comprises the polynucleotide as defined in claim 54.
56. Host cell characterized by being transformed with the vector as defined in claim 55.
57. Pharmaceutical composition characterized by comprising (i) a PSMA-binding protein as defined in any one of claims 1 to 53, the polynucleotide as defined in claim 54, the vector as defined in claim 55 or the host cell as defined in claim 56, and (ii) a pharmaceutically acceptable carrier.
58. Process characterized by being used for production
Petition 870190117804, of 11/14/2019, p. 16/24
[10]
10/16 of a PSMA-binding protein as defined in any one of claims 1 to 53, said process comprising culturing a host transformed or transfected with a vector comprising a nucleic acid sequence encoding a protein binding to albumin-PSMA as defined in any one of claims 1 to 53 under conditions that allow expression of the PSMA-binding protein and recovery and purification of the protein produced from the culture.
59. Method characterized by being used for the treatment or improvement of a proliferative disease, a tumor disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host disease or a host-versus-graft disease, which comprises the administration of
connection to PSMA according defined in Any of them of claims 1 to 53, the one . individual what 2 of it needs • 60. Method, according The claim 59, characterized by fact of that the individual is human. 61. Method, according The claim 60, characterized by fact of that method still understands the
administration of an agent in combination with the PSMA-binding protein as defined in any one of claims 1 to 53.
62. Multispecific binding protein, characterized in that it comprises the PSMA binding protein as defined in any one of claims 1, 26 or 45 to 50.
63. Antibody characterized by comprising the protein
Petition 870190117804, of 11/14/2019, p. 17/24
[11]
11/16 binding to PSMA as defined in any one of claims 1, 26 or 45 to -50.
64. Multispecific antibody, bispecific antibody, sdAb, variable heavy domain, peptide or linker, characterized in that it comprises the PSMA-binding protein as defined in any one of claims 1, 26 or 45 to 50.
65. An antibody characterized in that it comprises the PSMA-binding protein as defined in any one of claims 1, 26 or 45 to 50, wherein said antibody is a single domain antibody.
66. Single domain antibody, as defined in claim 64, characterized in that said antibody is derived from a variable region of the IgG heavy chain.
67. Multispecific binding protein or antibody, characterized in that it comprises the PSMA binding protein as defined in any one of claims 1, 26 and 45 to 50 and a CD3 binding domain.
68. Method, characterized by being used for the treatment or improvement of a proliferative disease, a tumor disease, an inflammatory disease, an immune disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host disease or a host-versus-graft disease, which comprises administering the multispecific antibody as defined in any of claims 64 to 68, to an individual who needs it.
69. Method, characterized by being used to treat or ameliorate a condition of the prostate, which
Petition 870190117804, of 11/14/2019, p. 18/24
[12]
12/16 comprises administering the multispecific antibody as defined in any one of claims 64 to 68, to an individual who needs it.
70. The method, characterized in that it is used to treat or ameliorate a condition of the prostate, which comprises administering the PSMA-binding protein as defined in any of claims 1 to 53, to an individual who needs it.
71. Prostate-specific membrane antigen-binding protein according to claim 1, characterized in that it comprises any combination of the following:
(i), where Xi is proline;
(ii), where X2 is histidine;
(iii), where X3 is aspartic acid;
(iv) where X4 is lysine;
(v), where X5 is glutamine;
(vi), where Xg is tyrosine; and (vii), in which X it's serine.
72. Prostate-specific membrane antigen-binding protein according to claim 71, characterized in that the binding protein has a greater affinity for a human prostate-specific membrane antigen than that of a binding protein which has the string shown as ID. SEQ. N °: 4.
73. Prostate-specific membrane antigen-binding protein according to claim 1, characterized in that it comprises any combination of the following:
(i), where Xi is proline; where X5 is glutamine;
Petition 870190117804, of 11/14/2019, p. 19/24
[13]
13/16 (ii), where Xg is tyrosine; where X4 is lysine and X it is serine;
(iii), where X ₂ is histidine, X3 is aspartic acid, X4 is lysine and X it is serine;
(iv), where Xi is proline, X ₂ is histidine, X3 is aspartic acid and X it is serine;
(v), where X ₂ is histidine, X3 is aspartic acid, X5 is glutamine and X it is serine;
(vi), where X ₂ is histidine, X3 is aspartic acid, X4 is lysine and X it is serine;
(vii), where Xi is proline, X ₂ is histidine, X3 is aspartic acid and X it is serine;
(viii), where X ₂ is histidine, X3 is aspartic acid, X5 is glutamine and X it is serine;
(ix), where X ₂ is histidine, X3 is aspartic acid, Xg is tyrosine and X it is serine; and (x), where X ₂ is histidine, X3 is aspartic acid and X it's serine.
74. Prostate-specific membrane antigen-binding protein according to claim 73, characterized in that the binding protein has a greater affinity for a human prostate-specific membrane antigen than that of a binding protein that has the string shown in the ID. SEQ. N °: 4.
75. Prostate-specific membrane antigen binding protein according to claim 74, characterized in that the binding protein still has a greater affinity for a Cynomolgus prostate-specific membrane antigen than that of a protein connection that has the sequence shown in the
Petition 870190117804, of 11/14/2019, p. 20/24
[14]
14/16
ID. SEQ. N °: 4.
76. Prostate-specific membrane antigen-binding protein according to claim 26, characterized in that it comprises any combination of the following:
(i) replacement in position 31;
(ii) replacement in position 50;
(iii) replacement in position 55; replacement in position 56;
(iv) replacement in position 62;
(v) replacement in position 97;
(vi) substitutions in positions 55 and 97;
(vii) substitutions in positions 33 and 97;
(viii) substitutions in positions 33, 50 and 97;
(ix) substitutions in positions 31, 33, 50 and 97;
(x) substitutions in positions 33, 50, 55 and 97;
(xi) substitutions in positions 33, 50, 56 and 97; and (xiii) substitutions in positions 33, 50, 62 and 97.
77. Prostate-specific membrane antigen-binding protein according to claim 76, characterized in that the binding protein has a greater affinity for human prostate-specific membrane antigen than that of a binding protein that has the sequence shown in the ID. SEQ. N °: 4.
78. Prostate-specific membrane antigen-binding protein according to claim 77, characterized by the fact that the binding protein still has a greater affinity for Cynomolgus prostate-specific membrane antigen than that of a connection that has the sequence shown in
Petition 870190117804, of 11/14/2019, p. 21/24
[15]
15/16
ID. SEQ. N °: 4.
79. Method of treatment or improvement of prostate cancer, characterized by the fact that ara comprising the administration of the PSMA-binding protein it comprises
determining regions of complementarity CDR1 , CDR2 and CDR3, where:(a) the sequence of amino acids from CDR1 is how presented in RFMISX1YX2MH(b) the sequence of (SEQ ID. NO:amino acids from D;CDR2 is how presented in X3INPAX4X5TDYAEX6VKG (SEQ ID. NO. : 2) ; and (c) the sequence of amino acids from CDR3 is how displayed in DX YGY (ID. SEQ. N °: 3), to a individual
you need it.
80. Antibody comprising the PSMA-binding protein, as defined in claim 1, characterized in that said antibody is a single domain antibody.
81. An antibody comprising the PSMA-binding protein according to claim 80, characterized in that said single domain antibody is part of a triespecific antibody.
82. Antibody comprising the PSMA-binding protein, as defined in claim 26, characterized by the fact that said antibody is a single domain antibody.
83. An antibody comprising the PSMA-binding protein according to claim 82, characterized in that said single domain antibody is part of a triespecific antibody.
84. Antibody comprising the protein binding to
Petition 870190117804, of 11/14/2019, p. 22/24
[16]
16/16
PSMA, as defined in claim 49, characterized by the fact that said antibody is a single domain antibody.
85. An antibody comprising the PSMA-binding protein according to claim 84, characterized in that said single domain antibody is part of a triespecific antibody.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112019010604A2|2019-12-17|prostate-specific membrane antigen binding protein

---

AU2019202283B2|2020-11-26|Trispecific binding proteins and methods of use

---

US10066016B2|2018-09-04|Single chain variable fragment CD3 binding proteins

---

US10844134B2|2020-11-24|PSMA targeting trispecific proteins and methods of use

---

US20190031749A1|2019-01-31|Single domain serum albumin binding protein

---

JP5513114B2|2014-06-04|Human anti-folate receptor alpha antibodies and antibody fragments for radioimmunotherapy of ovarian cancer

---

KR20150042828A|2015-04-21|Methods of treating a tauopathy

---

BR112020025443A2|2021-03-16|IL-11 ANTIBODIES

---

BRPI0809351A2|2014-09-02|ANTI CD166 HUMAN ANTIBODY CONNECTING HUMAN TUMOR CELLS

---

US20110189093A1|2011-08-04|Prostate specific membrane antigen antibodies and antigen binding fragments

---

US20200231672A1|2020-07-23|Single chain variable fragment cd3 binding proteins

---

AU2018261720A1|2019-11-07|Compositions and methods related to xCT antibodies

---

ES2831651T3|2021-06-09|Use of antibodies and antagonists directed against Lrg1 in a treatment

---

US10421808B2|2019-09-24|Bak binding proteins

---

CN114025802A|2022-02-08|Use of bispecific antigen binding molecules that bind PSMA and CD3 in combination with 4-1BB co-stimulation

同族专利:

---

公开号 | 公开日

---

JP2020501532A|2020-01-23|

---

JP2021061842A|2021-04-22|

---

IL266800D0|2019-08-29|

---

EP3544997A1|2019-10-02|

---

US20210100902A1|2021-04-08|

---

CN110198955A|2019-09-03|

---

WO2018098354A1|2018-05-31|

---

EP3544997A4|2020-07-01|

---

JP6812551B2|2021-01-13|

---

US20180161428A1|2018-06-14|

---

KR102275008B1|2021-07-13|

---

KR20190085542A|2019-07-18|

---

AU2017363300A1|2019-06-20|

---

EA201991168A1|2019-12-30|

---

KR20210087108A|2021-07-09|

---

US10849973B2|2020-12-01|

---

CA3044659A1|2018-05-31|

---

MX2019006043A|2019-09-26|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

FR901228A|1943-01-16|1945-07-20|Deutsche Edelstahlwerke Ag|Ring gap magnet system|

---

US4816567A|1983-04-08|1989-03-28|Genentech, Inc.|Recombinant immunoglobin preparations|

---

US5225539A|1986-03-27|1993-07-06|Medical Research Council|Recombinant altered antibodies and methods of making altered antibodies|

---

US6548640B1|1986-03-27|2003-04-15|Btg International Limited|Altered antibodies|

---

GB8607679D0|1986-03-27|1986-04-30|Winter G P|Recombinant dna product|

---

US6534055B1|1988-11-23|2003-03-18|Genetics Institute, Inc.|Methods for selectively stimulating proliferation of T cells|

---

US6905680B2|1988-11-23|2005-06-14|Genetics Institute, Inc.|Methods of treating HIV infected subjects|

---

US5530101A|1988-12-28|1996-06-25|Protein Design Labs, Inc.|Humanized immunoglobulins|

---

US5703055A|1989-03-21|1997-12-30|Wisconsin Alumni Research Foundation|Generation of antibodies through lipid mediated DNA delivery|

---

US5399346A|1989-06-14|1995-03-21|The United States Of America As Represented By The Department Of Health And Human Services|Gene therapy|

---

US5585362A|1989-08-22|1996-12-17|The Regents Of The University Of Michigan|Adenovirus vectors for gene therapy|

---

US5859205A|1989-12-21|1999-01-12|Celltech Limited|Humanised antibodies|

---

GB8928874D0|1989-12-21|1990-02-28|Celltech Ltd|Humanised antibodies|

---

US5061620A|1990-03-30|1991-10-29|Systemix, Inc.|Human hematopoietic stem cell|

---

EP0519596B1|1991-05-17|2005-02-23|Merck & Co. Inc.|A method for reducing the immunogenicity of antibody variable domains|

---

US5199942A|1991-06-07|1993-04-06|Immunex Corporation|Method for improving autologous transplantation|

---

DE69233254T2|1991-06-14|2004-09-16|Genentech, Inc., South San Francisco|Humanized Heregulin antibody|

---

ES2136092T3|1991-09-23|1999-11-16|Medical Res Council|PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.|

---

AU2764792A|1991-10-04|1993-05-03|Iit Research Institute|Conversion of plastic waste to useful oils|

---

GB9125768D0|1991-12-04|1992-02-05|Hale Geoffrey|Therapeutic method|

---

US5766886A|1991-12-13|1998-06-16|Xoma Corporation|Modified antibody variable domains|

---

US5858358A|1992-04-07|1999-01-12|The United States Of America As Represented By The Secretary Of The Navy|Methods for selectively stimulating proliferation of T cells|

---

US6005079A|1992-08-21|1999-12-21|Vrije Universiteit Brussels|Immunoglobulins devoid of light chains|

---

CA2142331C|1992-08-21|2010-02-02|Cecile Casterman|Immunoglobulins devoid of light chains|

---

US5350674A|1992-09-04|1994-09-27|Becton, Dickinson And Company|Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof|

---

US5639641A|1992-09-09|1997-06-17|Immunogen Inc.|Resurfacing of rodent antibodies|

---

US6352694B1|1994-06-03|2002-03-05|Genetics Institute, Inc.|Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells|

---

US7175843B2|1994-06-03|2007-02-13|Genetics Institute, Llc|Methods for selectively stimulating proliferation of T cells|

---

US5731168A|1995-03-01|1998-03-24|Genentech, Inc.|Method for making heteromultimeric polypeptides|

---

US6692964B1|1995-05-04|2004-02-17|The United States Of America As Represented By The Secretary Of The Navy|Methods for transfecting T cells|

---

US7067318B2|1995-06-07|2006-06-27|The Regents Of The University Of Michigan|Methods for transfecting T cells|

---

US5773292A|1995-06-05|1998-06-30|Cornell University|Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood|

---

US6136311A|1996-05-06|2000-10-24|Cornell Research Foundation, Inc.|Treatment and diagnosis of cancer|

---

US6107090A|1996-05-06|2000-08-22|Cornell Research Foundation, Inc.|Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains|

---

US6670453B2|1997-10-27|2003-12-30|Unilever Patent Holdings B.V.|Multivalent antigen-binding proteins|

---

BR9907241A|1998-01-26|2000-10-17|Unilever Nv|Expression library, process for preparing the same, using an unimmunized source of nucleic acid sequences, and, processes for preparing antibody fragments and, for preparing an antibody|

---

HU9900956A2|1998-04-09|2002-04-29|Aventis Pharma Deutschland Gmbh.|Single-chain multiple antigen-binding molecules, their preparation and use|

---

EP1144616B2|1999-01-19|2009-01-14|Unilever Plc|Method for producing antibody fragments|

---

US6326193B1|1999-11-05|2001-12-04|Cambria Biosciences, Llc|Insect control agent|

---

US20060228364A1|1999-12-24|2006-10-12|Genentech, Inc.|Serum albumin binding peptides for tumor targeting|

---

US6867041B2|2000-02-24|2005-03-15|Xcyte Therapies, Inc.|Simultaneous stimulation and concentration of cells|

---

KR20030032922A|2000-02-24|2003-04-26|싸이트 테라피스 인코포레이티드|Simultaneous stimulation and concentration of cells|

---

US7572631B2|2000-02-24|2009-08-11|Invitrogen Corporation|Activation and expansion of T cells|

---

US6797514B2|2000-02-24|2004-09-28|Xcyte Therapies, Inc.|Simultaneous stimulation and concentration of cells|

---

US20030190598A1|2000-05-26|2003-10-09|Jasmid Tanha|Single-domain antigen-binding antibody fragments derived from llama antibodies|

---

AU7547401A|2000-06-12|2001-12-24|Akkadix Corp|Materials and methods for the control of nematodes|

---

CN1294148C|2001-04-11|2007-01-10|中国科学院遗传与发育生物学研究所|Single-stranded cyctic trispecific antibody|

---

GB0110029D0|2001-04-24|2001-06-13|Grosveld Frank|Transgenic animal|

---

CN1195779C|2001-05-24|2005-04-06|中国科学院遗传与发育生物学研究所|Double-specificity antibody resisting human ovary cancer and human CD3|

---

US7666414B2|2001-06-01|2010-02-23|Cornell Research Foundation, Inc.|Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen|

---

US9321832B2|2002-06-28|2016-04-26|Domantis Limited|Ligand|

---

CN1678634A|2002-06-28|2005-10-05|多曼蒂斯有限公司|Immunoglobulin single variable antigen combination area and its opposite constituent|

---

WO2003025020A1|2001-09-13|2003-03-27|Institute For Antibodies Co., Ltd.|Method of constructing camel antibody library|

---

US20050215472A1|2001-10-23|2005-09-29|Psma Development Company, Llc|PSMA formulations and uses thereof|

---

JP5355839B2|2001-10-23|2013-11-27|ピーエスエムエーデベロプメントカンパニー，エル．エル．シー．|PSMA antibodies and protein multimers|

---

JP2005289809A|2001-10-24|2005-10-20|Vlaams Interuniversitair Inst Voor Biotechnologie Vzw |Mutant heavy-chain antibody|

---

JP2005518789A|2002-01-28|2005-06-30|メダレックス， インク．|Human monoclonal antibody against prostate specific membrane antigen |

---

JP4511363B2|2002-11-07|2010-07-28|エラスムスユニフェルシテイトロッテルダム|FRET probe and method for detecting interacting molecules|

---

EP2390268B1|2002-11-08|2017-11-01|Ablynx N.V.|Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor|

---

EP2267032A3|2002-11-08|2011-11-09|Ablynx N.V.|Method of administering therapeutic polypeptides, and polypeptides therefor|

---

US9320792B2|2002-11-08|2016-04-26|Ablynx N.V.|Pulmonary administration of immunoglobulin single variable domains and constructs thereof|

---

PT2316852E|2002-11-08|2014-06-23|Ablynx Nv|Stabilized single domain antibodies|

---

GB0228210D0|2002-12-03|2003-01-08|Babraham Inst|Single chain antibodies|

---

CA2523716C|2003-05-31|2014-11-25|Micromet Ag|Human anti-human cd3 binding molecules|

---

CA2531118C|2003-07-01|2013-01-08|Immunomedics, Inc.|Multivalent carriers of bi-specific antibodies|

---

CA2536238C|2003-08-18|2015-04-07|Medimmune, Inc.|Humanization of antibodies|

---

EP1660534A2|2003-08-22|2006-05-31|MedImmune, Inc.|Humanization of antibodies|

---

CN100376599C|2004-04-01|2008-03-26|北京安波特基因工程技术有限公司|Recombining single chained three specific antibodies of anti CCA, anti CD 3, anti CD 28 through genetic engineering|

---

US8921528B2|2004-06-01|2014-12-30|Domantis Limited|Bispecific fusion antibodies with enhanced serum half-life|

---

EP1786918A4|2004-07-17|2009-02-11|Imclone Systems Inc|Novel tetravalent bispecific antibody|

---

EP1634603A1|2004-08-26|2006-03-15|Eberhard-Karls-Universität Tübingen Universitätsklinikum|Treatment of transformed or infected biologic Cells|

---

US20080069772A1|2004-08-26|2008-03-20|Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum|Treatment of transformed or infected biological cells|

---

FR2879605B1|2004-12-16|2008-10-17|Centre Nat Rech Scient Cnrse|PRODUCTION OF ANTIBODY FORMATS AND IMMUNOLOGICAL APPLICATIONS OF THESE FORMATS|

---

SI1752471T1|2005-01-05|2009-04-30|F Star Biotech Forsch & Entw|Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions|

---

US7833979B2|2005-04-22|2010-11-16|Amgen Inc.|Toxin peptide therapeutic agents|

---

US20060252096A1|2005-04-26|2006-11-09|Glycofi, Inc.|Single chain antibody with cleavable linker|

---

PT2949668T|2005-05-18|2019-10-24|Ablynx Nv|Improved nanobodies tm against tumor necrosis factor-alpha|

---

US20070269422A1|2006-05-17|2007-11-22|Ablynx N.V.|Serum albumin binding proteins with long half-lives|

---

DK2444424T3|2005-05-20|2018-12-03|Ablynx Nv|IMPROVED NANOL BODIES FOR TREATING AGGREGATED MEDICINAL DISORDERS|

---

EP1726650A1|2005-05-27|2006-11-29|Universitätsklinikum Freiburg|Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen|

---

NZ597168A|2005-08-19|2013-07-26|Abbott Lab|Dual variable domain immunoglobin and uses thereof|

---

ES2856451T3|2005-10-11|2021-09-27|Amgen Res Munich Gmbh|Compositions comprising specific antibodies for different species, and uses thereof|

---

WO2007062466A1|2005-11-29|2007-06-07|The University Of Sydney|Demibodies: dimerisation-activated therapeutic agents|

---

WO2007115230A2|2006-03-30|2007-10-11|University Of Medicine And Dentistry Of New Jersey|A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells|

---

JP2010500876A|2006-08-18|2010-01-14|アブリンクスエン．ヴェー．|Amino acid sequence directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signaling|

---

CN101646689A|2006-09-08|2010-02-10|埃博灵克斯股份有限公司|Serum albumin binding proteins with long half-lives|

---

US20100166734A1|2006-12-20|2010-07-01|Edward Dolk|Oral delivery of polypeptides|

---

TR201816277T4|2007-04-03|2018-11-21|Amgen Res Munich Gmbh|Cross-species-specific binding domain.|

---

KR101264473B1|2007-05-24|2013-05-29|아블린쓰 엔.브이.|Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders|

---

EP2014680A1|2007-07-10|2009-01-14|Friedrich-Alexander-Universität Erlangen-Nürnberg|Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives|

---

US20090304719A1|2007-08-22|2009-12-10|Patrick Daugherty|Activatable binding polypeptides and methods of identification and use thereof|

---

EP2195342A1|2007-09-07|2010-06-16|Ablynx N.V.|Binding molecules with multiple binding sites, compositions comprising the same and uses thereof|

---

CN104004088B|2007-09-26|2017-11-07|Ucb医药有限公司|dual specificity antibody fusions|

---

JP5809557B2|2008-06-05|2015-11-11|アブリンクス エン．ヴェー．|Amino acid sequences directed against viral envelope proteins and polypeptides containing them for the treatment of viral diseases|

---

US20100122358A1|2008-06-06|2010-05-13|Crescendo Biologics Limited|H-Chain-only antibodies|

---

US8444976B2|2008-07-02|2013-05-21|Argen-X B.V.|Antigen binding polypeptides|

---

AU2009266873A1|2008-07-02|2010-01-07|Emergent Product Development Seattle, Llc|TGF-beta antagonist multi-target binding proteins|

---

EP3375790A1|2008-10-01|2018-09-19|Amgen Research GmbH|Cross-species-specific single domain bispecific single chain antibody|

---

CN102171248B|2008-10-01|2015-07-15|安进研发（慕尼黑）股份有限公司|Cross-species-specific PSMAxCD3 bispecific single chain antibody|

---

PT2352763E|2008-10-01|2016-06-02|Amgen Res Gmbh|Bispecific single chain antibodies with specificity for high molecular weight target antigens|

---

US9327022B2|2008-10-14|2016-05-03|National Research Council Of Canada|BSA-specific antibodies|

---

US20100189727A1|2008-12-08|2010-07-29|Tegopharm Corporation|Masking Ligands For Reversible Inhibition Of Multivalent Compounds|

---

EP2210902A1|2009-01-14|2010-07-28|TcL Pharma|Recombinant monovalent antibodies|

---

SG10201402960SA|2009-03-05|2014-08-28|Abbvie Inc|IL-17 Binding Proteins|

---

US20110195494A1|2009-10-02|2011-08-11|Boehringer Ingelheim International Gmbh|Dll4-binging molecules|

---

WO2011051327A2|2009-10-30|2011-05-05|Novartis Ag|Small antibody-like single chain proteins|

---

JP6184695B2|2009-12-04|2017-08-23|ジェネンテック， インコーポレイテッド|Multispecific antibodies, antibody analogs, compositions and methods|

---

EP2332994A1|2009-12-09|2011-06-15|Friedrich-Alexander-Universität Erlangen-Nürnberg|Trispecific therapeutics against acute myeloid leukaemia|

---

EA022984B1|2009-12-29|2016-04-29|Эмерджент Продакт Дивелопмент Сиэтл, Ллс|Ron binding constructs and methods of use thereof|

---

GB2476681B|2010-01-04|2012-04-04|Argen X Bv|Humanized camelid VH, VK and VL immunoglobulin domains|

---

WO2011119484A1|2010-03-23|2011-09-29|Iogenetics, Llc|Bioinformatic processes for determination of peptide binding|

---

US8937164B2|2010-03-26|2015-01-20|Ablynx N.V.|Biological materials related to CXCR7|

---

US9556273B2|2010-03-29|2017-01-31|Vib Vzw|Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages|

---

WO2012025525A1|2010-08-24|2012-03-01|Roche Glycart Ag|Activatable bispecific antibodies|

---

WO2012025530A1|2010-08-24|2012-03-01|F. Hoffmann-La Roche Ag|Bispecific antibodies comprising a disulfide stabilized - fv fragment|

---

EP2621953B1|2010-09-30|2017-04-05|Ablynx N.V.|Biological materials related to c-met|

---

EP2640750A1|2010-11-16|2013-09-25|Boehringer Ingelheim International GmbH|Agents and methods for treating diseases that correlate with bcma expression|

---

CN106039306A|2011-03-30|2016-10-26|埃博灵克斯股份有限公司|Methods of treating immune disorders with single domain antibodies against TNF-alpha|

---

EP2694549B1|2011-04-08|2018-08-15|The United States of America, as represented by The Secretary, Department of Health and Human Services|Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer|

---

WO2012158818A2|2011-05-16|2012-11-22|Fabion Pharmaceuticals, Inc.|Multi-specific fab fusion proteins and methods of use|

---

EA201400108A1|2011-07-06|2014-05-30|Генмаб Б.В.|OPTIONS OF POLYPEPTIDES AND THEIR APPLICATIONS|

---

US20150158934A1|2011-09-09|2015-06-11|Ucl Business Plc|Broadly neutralizing vhh against hiv-1|

---

EP2758436B1|2011-09-23|2019-06-12|Universität Stuttgart|Serum half-life extension using immunoglobulin binding domains|

---

TWI679212B|2011-11-15|2019-12-11|美商安進股份有限公司|Binding molecules for e3 of bcma and cd3|

---

EA033947B1|2012-01-13|2019-12-12|Юлиус-Максимилианс-Универзитет Вюрцбург|Set of polypeptides for identifying and/or eliminating cells, use thereof, nucleic acid molecule encoding one of the polypeptides of the set, set of nucleic acids encoding the set of polypeptides, pharmaceutical composition comprising these sets|

---

WO2013110531A1|2012-01-23|2013-08-01|Ablynx Nv|Sequences directed against hepatocyte growth factor and polypeptides comprising the same for the treatment of cancers and/or tumors|

---

ES2812849T3|2012-02-24|2021-03-18|Abbvie Stemcentrx Llc|Anti-DLL3 antibodies and procedures for using them|

---

GB201203442D0|2012-02-28|2012-04-11|Univ Birmingham|Immunotherapeutic molecules and uses|

---

ES2680151T3|2012-03-01|2018-09-04|Amgen Research Gmbh|Long-term polypeptide binding molecules|

---

MX2014011781A|2012-03-30|2014-11-26|Bayer Healthcare Llc|Protease-regulated antibodies.|

---

RU2673153C2|2012-04-20|2018-11-22|АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи|Polypeptides binding to cd3|

---

WO2013192546A1|2012-06-22|2013-12-27|Cytomx Therapeutics, Inc.|Activatable antibodies having non-binding steric moieties and mehtods of using the same|

---

US20140004121A1|2012-06-27|2014-01-02|Amgen Inc.|Anti-mesothelin binding proteins|

---

CN112587658A|2012-07-18|2021-04-02|博笛生物科技有限公司|Targeted immunotherapy for cancer|

---

US10040870B2|2012-08-31|2018-08-07|Argenx Bvba|Highly diverse combinatorial antibody libraries|

---

KR101963231B1|2012-09-11|2019-03-28|삼성전자주식회사|Protein complex for preparing bispecific antibodies and method using thereof|

---

JOP20200236A1|2012-09-21|2017-06-16|Regeneron Pharma|Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof|

---

KR20160056938A|2013-09-24|2016-05-20|유니버시티 오브 워싱턴 스로우 잇츠 센터 포 커머셜라이제이션|Desmoglein 2 Binding Proteins and Uses Therefor|

---

CA2885761C|2012-09-27|2021-09-21|The United States Of America, As Represented By The Secretary, Department Of Health And Human Services|Mesothelin antibodies and methods for eliciting potent antitumor activity|

---

JO3519B1|2013-01-25|2020-07-05|Amgen Inc|Antibody constructs for CDH19 and CD3|

---

ES2681948T3|2013-03-05|2018-09-17|Baylor College Of Medicine|Coupling cells for immunotherapy|

---

WO2014160030A2|2013-03-13|2014-10-02|Health Research, Inc.|Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen|

---

WO2014151910A1|2013-03-15|2014-09-25|Amgen Inc.|Heterodimeric bispecific antibodies|

---

US20140302037A1|2013-03-15|2014-10-09|Amgen Inc.|BISPECIFIC-Fc MOLECULES|

---

AR095596A1|2013-03-15|2015-10-28|Amgen Res Gmbh|UNIQUE CHAIN UNION MOLECULES UNDERSTANDING N-TERMINAL ABP|

---

RU2020123264A|2013-07-25|2020-10-14|Сайтомкс Терапьютикс, Инк.|MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION|

---

US20160251440A1|2013-09-26|2016-09-01|Ablynx N.V.|Bispecific nanobodies|

---

JP6706578B2|2013-12-30|2020-06-10|エピムアブ バイオセラピューティクス インコーポレイテッド|Tandem Fab immunoglobulins and uses thereof|

---

ES2747749T3|2014-04-02|2020-03-11|Hoffmann La Roche|Multispecific antibodies|

---

KR102355609B1|2014-05-29|2022-01-27|마크로제닉스, 인크.|Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof|

---

GB201412659D0|2014-07-16|2014-08-27|Ucb Biopharma Sprl|Molecules|

---

AR101669A1|2014-07-31|2017-01-04|Amgen Res Gmbh|ANTIBODY CONSTRUCTS FOR CDH19 AND CD3|

---

WO2016016415A1|2014-07-31|2016-02-04|Amgen Research Gmbh|Bispecific single chain antibody construct with enhanced tissue distribution|

---

ME03724B|2014-09-05|2021-01-20|Janssen Pharmaceutica Nv|Cd123 binding agents and uses thereof|

---

CN109842529B|2014-09-05|2021-10-26|华为技术有限公司|Method, device and network system for configuring service|

---

WO2016046778A2|2014-09-25|2016-03-31|Amgen Inc|Protease-activatable bispecific proteins|

---

JP2017531430A|2014-10-07|2017-10-26|セレクティスＣｅｌｌｅｃｔｉｓ|Method for modulating the activity of immune cells induced by CAR|

---

KR20170084327A|2014-11-26|2017-07-19|젠코어 인코포레이티드|Heterodimeric antibodies that bind cd3 and cd38|

---

WO2016105450A2|2014-12-22|2016-06-30|Xencor, Inc.|Trispecific antibodies|

---

EA038407B1|2015-02-05|2021-08-24|Янссен Вэксинс Энд Превеншн Б.В.|Binding molecules directed against influenza hemagglutinin and uses thereof|

---

EP3256495A4|2015-02-11|2018-09-19|Aptevo Research and Development LLC|Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins|

---

MA41951A|2015-04-22|2018-02-28|Agbiome Inc|INSECTICIDE GENES AND METHODS OF USE|

---

WO2016179003A1|2015-05-01|2016-11-10|Genentech, Inc.|Masked anti-cd3 antibodies and methods of use|

---

US10526597B2|2015-05-21|2020-01-07|Full Spectrum Genetics, Inc.|Method of improving characteristics of proteins|

---

WO2016187594A1|2015-05-21|2016-11-24|Harpoon Therapeutics, Inc.|Trispecific binding proteins and methods of use|

---

EP3303595A2|2015-06-03|2018-04-11|Agbiome, Inc.|Pesticidal genes and methods of use|

---

CA2986604A1|2015-06-26|2016-12-29|University Of Southern California|Masking chimeric antigen receptor t cells for tumor-specific activation|

---

TW201708256A|2015-07-31|2017-03-01|安美基研究（慕尼黑）公司|Antibody constructs for MSLN and CD3|

---

US20180230193A1|2015-08-07|2018-08-16|Andreas Loew|Treatment of cancer using chimeric cd3 receptor proteins|

---

WO2017025698A1|2015-08-11|2017-02-16|Queen Mary University Of London|Bispecific, cleavable antibodies|

---

CN106519037B|2015-09-11|2019-07-23|科济生物医药（上海）有限公司|Activable Chimerical receptor|

---

EP3370743A4|2015-11-05|2019-04-24|City of Hope|Methods for preparing cells for adoptive t cell therapy|

---

ES2873846T3|2015-11-19|2021-11-04|Revitope Ltd|Functional Antibody Fragment Complementation for a Two-Component System for Targeted Elimination of Unwanted Cells|

---

WO2017136549A1|2016-02-03|2017-08-10|Youhealth Biotech, Limited|Compounds for treating eye disorders or diseases|

---

EP3426689A4|2016-03-08|2020-01-15|Maverick Therapeutics, Inc.|Inducible binding proteins and methods of use|

---

BR112018073761A2|2016-05-20|2019-02-26|Harpoon Therapeutics, Inc.|single chain variable fragment cd3 binding proteins|

---

AU2017268460A1|2016-05-20|2018-12-13|Harpoon Therapeutics, Inc.|Single domain serum albumin binding protein|

---

US20190309092A1|2016-07-21|2019-10-10|Development Center For Biotechnology|Modified antigen-binding fab fragments and antigen-binding molecules comprising the same|

---

US20190225702A1|2016-10-14|2019-07-25|Harpoon Therapeutics, Inc.|Innate immune cell trispecific binding proteins and methods of use|

---

KR20190087539A|2016-11-23|2019-07-24|하푼 테라퓨틱스, 인크.|PSMA-targeted triple specific proteins and methods of use|

---

MX2019006043A|2016-11-23|2019-09-26|Harpoon Therapeutics Inc|Prostate specific membrane antigen binding protein.|

---

WO2018136725A1|2017-01-19|2018-07-26|Harpoon Therapeutics, Inc.|Innate immune cell inducible binding proteins and methods of use|

---

US20200148771A1|2017-02-28|2020-05-14|Harpoon Therapeutics, Inc.|Inducible monovalent antigen binding protein|

---

WO2018160671A1|2017-02-28|2018-09-07|Harpoon Therapeutics, Inc.|Targeted checkpoint inhibitors and methods of use|

---

WO2018165619A1|2017-03-09|2018-09-13|Cytomx Therapeutics, Inc.|Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof|

---

WO2018204717A1|2017-05-03|2018-11-08|Harpoon Therapeutics, Inc.|Compositions and methods for adoptive cell therapies|

---

US10543271B2|2017-05-12|2020-01-28|Harpoon Therapeutics, Inc.|Mesothelin binding proteins|

---

US10730954B2|2017-05-12|2020-08-04|Harpoon Therapeutics, Inc.|MSLN targeting trispecific proteins and methods of use|

---

CN111465612A|2017-10-13|2020-07-28|哈普恩治疗公司|B cell maturation antigen binding proteins|

---

JP2020537644A|2017-10-13|2020-12-24|ハープーン セラピューティクス，インク．|Trispecific protein and usage|

---

US20210284728A1|2018-05-14|2021-09-16|Harpoon Therapeutics, Inc.|Dual binding moiety|

---

WO2019222282A1|2018-05-14|2019-11-21|Harpoon Therapeutics, Inc.|Conditionally activated binding protein comprising a sterically occluded target binding domain|

---

SG11202011330PA|2018-05-14|2020-12-30|Harpoon Therapeutics Inc|Binding moiety for conditional activation of immunoglobulin molecules|

---

US20210355219A1|2018-09-21|2021-11-18|Harpoon Therapeutics, Inc.|Conditionally activated target-binding molecules|

---

WO2020061482A1|2018-09-21|2020-03-26|Harpoon Therapeutics, Inc.|Egfr binding proteins and methods of use|

---

US20220054544A1|2018-09-21|2022-02-24|Harpoon Therapeutics, Inc.|Conditionally active receptors|

---

CA3114038A1|2018-09-25|2020-04-02|Harpoon Therapeutics, Inc.|Dll3 binding proteins and methods of use|WO2016187594A1|2015-05-21|2016-11-24|Harpoon Therapeutics, Inc.|Trispecific binding proteins and methods of use|

---

BR112018073761A2|2016-05-20|2019-02-26|Harpoon Therapeutics, Inc.|single chain variable fragment cd3 binding proteins|

---

MX2019006043A|2016-11-23|2019-09-26|Harpoon Therapeutics Inc|Prostate specific membrane antigen binding protein.|

---

KR20190087539A|2016-11-23|2019-07-24|하푼 테라퓨틱스, 인크.|PSMA-targeted triple specific proteins and methods of use|

---

US10730954B2|2017-05-12|2020-08-04|Harpoon Therapeutics, Inc.|MSLN targeting trispecific proteins and methods of use|

---

US10543271B2|2017-05-12|2020-01-28|Harpoon Therapeutics, Inc.|Mesothelin binding proteins|

---

JP2020537644A|2017-10-13|2020-12-24|ハープーン セラピューティクス，インク．|Trispecific protein and usage|

---

CN111465612A|2017-10-13|2020-07-28|哈普恩治疗公司|B cell maturation antigen binding proteins|

---

WO2020061482A1|2018-09-21|2020-03-26|Harpoon Therapeutics, Inc.|Egfr binding proteins and methods of use|

---

CA3114038A1|2018-09-25|2020-04-02|Harpoon Therapeutics, Inc.|Dll3 binding proteins and methods of use|

---

US11180563B2|2020-02-21|2021-11-23|Harpoon Therapeutics, Inc.|FLT3 binding proteins and methods of use|

---

WO2021202376A1|2020-03-30|2021-10-07|The United States Of America, As Represented By The Secretary, Department Of Health And Human Services|Method for blocking uptake of prostate-specific membrane antigen -targeted radionuclides by exocrine organs|

---

WO2022008646A1|2020-07-08|2022-01-13|LAVA Therapeutics N.V.|Antibodies that bind psma and gamma-delta t cell receptors|

法律状态:
2021-10-13| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201662426086P| true| 2016-11-23|2016-11-23|

---

PCT/US2017/063121|WO2018098354A1|2016-11-23|2017-11-22|Prostate specific membrane antigen binding protein|

---